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Summary
Copy number variations (CNVs), as one type of genetic variation in which a large
sequence of nucleotides is repeated in tandem multiple times to a variable extent
among different individuals of one population, have gained much attention with
regard to human phenotypic diversity. Recent efforts to map human structural
variation have shown that CNVs affect a significantly larger proportion of the human
genome than single nucleotide polymorphisms (SNPs). This gave rise to the idea of
CNVs playing an important role in explaining some of the large proportion of the
phenotypic variance in a population that is due to genetic factors and that could
not yet be explained by common SNPs. Current data from SNP genotyping arrays
were found to be useful not only for the genome-wide genotyping of SNPs, but also
for the detection of CNVs. However, due to the mostly still inadequate accuracy
of CNV detection and the rareness of provided methods for association testing, to
design a genome-wide CNV association study can be a challenge.
This thesis explored four strategies for the genome-wide association analyses of
raw CNV data being derived from the Affymetrix Genome-Wide Human SNP Array
6.0. Initially, the two most commonly used strategic approaches are presented and
applied to real data examples for the phenotypes early-onset extreme obesity and
childhood attention - deficit / hyperactivity disorder (ADHD). On the one hand,
raw intensity values reflecting individual copy numbers are directly tested for an
association with the risk of disease, without providing or making use of any infor-
mation about CNV genotypes. On the other hand, genome-wide CNV analyses are
performed as a two-step procedure in first calling individual CNV genotypes and
then using these to test for CNV - phenotype associations. Secondly, two extensions
of the standard strategies are introduced, which both form its own strategy with a
special focus on the intention to overcome problems and weaknesses of the respective
widely used strategy. In this sense, one proposed strategy accounts for the fact that
thousands of array-provided CNV marker are located in genomic regions without
underlying copy number variability, and thus suggests to test only a pre-selected set
of relevant and informative intensity values for associations in order to relax the mul-
tiple testing issue. Furthermore, the second proposed strategy addresses the known
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inaccuracy of CNV calling in especially common CNV regions that is often caused to
some extent by the high CNV population frequency and the consequent inadequacy
of estimating CNV genotypes relative to sample’s mean or median hybridization
intensity values. Instead, the use of intensity reference values being estimated in a
Gaussian mixture model framework, called MCMR, is investigated in application to
data examples for the HapMap and replicate samples as well as to the previously
analysed obesity data set. The latter obesity sample has been analysed in use of
all four genome-wide CNV analyses strategies which allowed a comparison on the
strategy’s applicability and performance.
The four strategies were observed to greatly vary in terms of computing efforts
and genetic results. Whereas one of the two standard strategies was successful in the
identification of rare CNVs at the PARK2 locus being genome-wide statistitically
significantly associated with ADHD in children, none of these two strategies detected
any CNV - obesity association. Contrarily, alternative MCMR reference intensity
values showed improved reliability of CNV calls compared to standard calling in
terms of stability, reproducibility and false positive rates. As a consequence, a novel
common CNV for early-onset extreme obesity on chromosome 11q11 was identified
in application of the proposed analyses strategies. Moreover, a common deletion at
chromosome 10q11.22, which was previously reported to be associated with body
mass index (BMI), was also replicated in use of one the proposed strategies.
The results suggest that the choice of the genome-wide CNV association analyses
strategy may greatly influence genetic results. The presented strategic investigations
presented here give an overview on aspects to consider when planning a genome-
wide CNV analyses pipeline, but do not allow general recommendations towards an
optimal design.
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Zusammenfassung
Kopienzahl Variationen (CNVs), als eine Art von genetischer Variation, bei der
eine große Sequenz von Nukleotiden im Tandem mehrfach wiederholt ist mit ei-
nem variablen Umfang zwischen verschiedenen Individuen einer Population, haben
viel Aufmerksamkeit hinsichtlich menschlicher pha¨notypischer Vielfalt gewonnen.
Ju¨ngste Bemu¨hungen die menschliche strukturelle Variation abzubilden haben ge-
zeigt, dass CNVs im Vergleich zu Einzelnukleotid Polymorphismen (SNPs) einen
signifikant gro¨ßeren Anteil des menschlichen Genoms beeinflussen. Dies fu¨hrte zu
der Idee, dass CNVs eine wichtige Rolle spielen ko¨nnten in der Aufkla¨rung eines
Teils der pha¨notypischen Varianz in einer Population, die auf genetischen Faktoren
beruht und die bisher zum Großteil durch ha¨ufige SNPs noch nicht erkla¨rt werden
konnte. Aktuelle Daten von SNP Genotypisierungs-Arrays erwiesen sich nicht nur als
nu¨tzlich fu¨r die genomweite Genotypisierung von SNPs, sondern auch zum Nachweis
von CNVs. Allerdings kann, aufgrund der meist noch unzureichenden Genauigkeit
des CNV Nachweises und der Seltenheit der bereitgestellten Methoden zum Testen
von Assoziationen, das Planen der genauen Gestaltung einer genomweiten CNV
Assoziations-Studie eine Herausforderung sein.
Diese Dissertation untersucht vier Strategien fu¨r genomweite Assoziations - Aus-
wertungen von CNV Rohdaten, welche von dem Affymetrix 6.0 Array gewonnen wur-
den. Zuna¨chst werden die beiden am ha¨ufigsten verwendeten strategischen Ansa¨tze
vorgestellt und auf reale Daten Beispiele fu¨r die Pha¨notypen fru¨hmanifeste extreme
Adipositas und kindliche Aufmerksamkeits-Defizit / Hyperaktivita¨ts-Sto¨rung (AD-
HS) angewendet. Auf der einen Seite werden Intensita¨ts-Rohdaten, welche die indi-
viduelle Kopienzahl widerspiegeln, direkt auf eine Assoziation mit dem Krankheits-
Risiko getestet, ohne die Bereitstellung oder die Nutzung von Informationen u¨ber
CNV Genotypen. Auf der anderen Seite werden genomweite CNV Analysen als Zwei-
Schritt-Verfahren durchgefu¨hrt, in denen zuna¨chst individuelle CNV Genotypen er-
kannt und anschließend auf CNV - Pha¨notyp Assoziationen getestet werden. Zum
Zweiten werden zwei Erweiterungen der Standard-Strategien eingefu¨hrt, die beide ei-
gensta¨ndige Strategien darstellen, welche sich besonders auf die Absicht fokussieren
Probleme und Schwa¨chen der jeweiligen weit verbreiteten Strategie zu u¨berwinden.
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In diesem Sinne befasst sich eine der vorgeschlagenen Strategien damit, dass Tausen-
de der auf dem Array bereitgestellten CNV Marker in genomischen Regionen ohne
zugrunde liegende Kopienzahl Variabilita¨t lokalisiert sind, und empfiehlt deshalb nur
eine vorab ausgewa¨hlte Menge von relevanten und informativen Intensita¨ts-Werten
auf Assoziationen zu testen, wodurch das Problem des multiplen Testens aufge-
lockert wird. Des weiteren beru¨cksichtigt die zweite vorgeschlagene Strategie die
bekannte Ungenauigkeit in der CNV Bestimmung fu¨r insbesondere Regionen mit
ha¨ufigen CNVs, welche oft zu einem gewissen Grad durch die hohe Populations-
Ha¨ufigkeit der CNVs verursacht wird sowie durch die daraus resultierende Un-
angemessenheit des Scha¨tzens von CNV Genotypen unter Beru¨cksichtigung von
Gruppen-Mittelwert oder Gruppen-Median der Hybridisierungs-Intensita¨ts-Werte.
Stattdessen wird die Verwendung von Intensita¨ts-Referenz-Werten, welche im Rah-
men eines Gaußschen Mischverteilungsmodell gescha¨tzt und als MCMR bezeichnet
werden, untersucht im Hinblick auf Anwendungen an Beispieldaten von HapMap-
und Replikat-Probanden sowie auch auf den zuvor bereits analysierten Adiposi-
tas Datensatz. Dieser Adipositas Datensatz wurde mittels aller vier Strategien zur
genomweiten CNV Auswertung analysiert, wodurch ein Vergleich aller Strategien
hinsichtlich ihrer Anwendbarkeit und Leistungsfa¨higkeit ermo¨glicht wurde.
Fu¨r die vier Strategien wurde ein stark unterschiedlich ausgepra¨gter Rechenauf-
wand und stark variierende genetische Ergebnissen beobachtet. Wa¨hrend eine der
beiden Standard-Strategien seltene CNVs in einem Teilbereich des PARK2 Gens als
genomweit signifikant assoziiert mit ADHS bei Kindern identifizieren konnte, ent-
deckte keine dieser beiden Strategien auch nur eine CNV - Adipositas Assoziation.
Im Gegensatz dazu konnte fu¨r alternative MCMR Referenz-Intensita¨ts-Werte eine
verbesserte Verla¨sslichkeit der gescha¨tzten CNVs im Vergleich zur Standard Detekti-
on in Bezug auf Stabilita¨ts-, Reproduzierbarkeits- und Falsch-Positiv-Raten gezeigt
werden. Als Konsequenz daraus wurde in Anwendung der vorgeschlagenen Analyse-
Strategien ein ha¨ufiger CNV auf Chromosom 11q11 erstmals als mutmaßlich kausale
Variante fu¨r fru¨hmanifeste extreme Adipositas identifiziert. Daru¨ber hinaus wurde
auch eine ha¨ufige Deletion auf Chromosom 10q11.22, fu¨r die zuvor bereits eine As-
soziation mit dem Ko¨rper-Masse-Index (BMI) berichtet wurde, unter Verwendung
einer der beiden vorgeschlagenen Strategien repliziert.
Die Resultate deuten an, dass die Strategie-Wahl zur genomweiten CNV Assoziati-
ons - Auswertung die genetischen Ergebnisse stark beeinflusst. Die hier vorgestellten
Untersuchungen der Strategien geben einen U¨berblick u¨ber Aspekte, die bei der Pla-
nung einer genomweiten CNV Analyse-Pipeline zu beru¨cksichtigen sind, sie lassen
allerdings keine allgemeinen Empfehlungen bezu¨glich eines optimalen Designs zu.
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1 Introduction
One of the central current goals in human biology is to better understand the ge-
netic contribution to human phenotypes. On the one hand, the study of human
genetics is impossible without technological methods providing knowledge of the
human genome sequence. On the other hand, partial or even complete information
about thousands of individual human genome sequences is worthless without the
availability of appropriate statistical methods to classify and evaluate the observed
genetic variation.
Recent efforts to map human genetic variation led to the discovery of 38 mil-
lion single nucleotide polymorphisms (SNPs), 1.4 million short insertion or deletion
variants (InDels) and 14 thousand large deletions (Consortium et al., 2012). On
average, the genome of each human individual was estimated to differ from the ge-
nomic sequence of any other randomly selected human individual in at least 3.7
million SNPs, 350 InDels and 750 large deletions. Thus, with an assumed human
genome size of three GB, the genomes of any two non-related people are different
at about one in 800 DNA bases and they are less than 99.9 percent the same. To
evaluate whether this is a small or a large proportion of variation, one has to keep in
mind that the human genome is, on average, only approximately 98.7 percent iden-
tical to corresponding sequences in the genome of our closest living relatives, the
chimpanzees (The-Chimpanzee-Sequencing and Analysis-Consortium, 2005; Pru¨fer
et al., 2012).
A catalog of genetic differences and similarities in human beings provides a foun-
dation for the study of human genetics. The information is used to screen variants
discovered in genomic data from individuals with genetic disorders, cancers or spe-
cific phenotypic characteristics. Of special interest are genetic variants with poten-
tial functional consequences, such as sequence differences in protein coding regions
(i.e. exons of genes) that lead to differences in the encoded protein sequence (Consor-
tium et al., 2010a) or those with high evolutionary conservation (Consortium et al.,
2012). Each human individual was estimated to typically harbour 10 000 − 11 000
non-synonymous sites (Consortium et al., 2010a) among which 2 500 are at con-
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served positions (Consortium et al., 2012). All this variation in DNA and especially
its complex combinations offer the potential of being disease causal variants.
For 20 years, family-based linkage studies and small-scale candidate gene studies
were successful in the identification of genetic variants leading to monogenic diseases,
i.e. to disorders that are caused by mutations in a single gene (also called Mendelian
diseases), such as the Huntington’s disease (Hardy and Singleton, 2009). In the past
few years, genome-wide association studies (GWASs), which investigate more than
a million of SNPs in thousands of individuals, have identified hundreds of genetic
variants that are robustly associated with complex diseases, such as type 2 diabetes
(Hardy and Singleton, 2009). By use of commercial SNP chips, GWASs address the
’common disease - common variant’ hypothesis in analysing allelic variants that are
present in more than one to five percent of the population. However, most common
associated variants were found to have moderate effects (relative risks of 1.1− 1.5)
and were shown to account for only a small proportion of the trait’s phenotypic
variance that is due to genetic differences (heritability) (Manolio et al., 2009).
Several potential sources of the ’missing heritability’ have been proposed, includ-
ing i) a yet undetected much larger number of variants with smaller effects, ii) a
lesser number of rare variants with possibly much larger effects that are almost un-
detectable by use of existing SNP chips, iii) structural variants other than SNPs
that are only poorly captured by existing SNP chips, iv) gene-gene interactions
with low power for being detected, and v) currently neglected environmental factors
(Manolio et al., 2009). One specific type of structural variants are copy number
variants, (CNVs) which are genomic regions of at least one kilo base (kb) being
present in variable numbers across several individuals. CNVs account for a major
proportion of human genetic polymorphisms (Redon et al., 2006). Although their
role in genetic susceptibility to a variety of human diseases has been predicted to
be important, they have not been explicitly examined in most GWASs in the past.
With the development of improved methods for CNV detection, this particular type
of genetic variation has gained increasing attention throughout the last years.
Several CNVs were found to be associated with many different human diseases,
such as autism, schizophrenia, Crohn’s disease or psoriasis (Manolio et al., 2009).
As with SNPs, disease associated CNVs were so far detected to include rare variants
with large association effect sizes as well as a variety of common variants with mod-
erate effects. Due to the strong linkage disequilibrium between SNPs and common
CNVs, a large study accounting for several thousand individuals recently concluded
that the contribution to human phenotypic variation of most common simple CNVs,
those that can be well typed by use of existing SNP chips, was already indirectly
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detected in form of phenotypic associations with nearby SNPs (Consortium et al.,
2010b). Further large-scale association studies directly addressing the remaining
23% of common CNVs that are of complex, multi-allelic type and that are thus
complicated to be classified using SNP chip technology, are still required to com-
prehensively evaluate the entire phenotypic contribution of common CNVs (Conrad
et al., 2010). However, there is a broad consensus on low frequency and rare CNVs
as well as any other type of rare variants being promising candidates to explain a
large proportion of the ’missing heritability’ (Manolio et al., 2009; Conrad et al.,
2010).
Due to the widespread availability of SNP chips, as a consequence of GWASs be-
coming increasingly popular, a special interest on using SNP platform data for CNV
analyses has been developed during the past years (Cooper et al., 2008). Currently,
high-density SNP arrays have become a convenient tool for the study of CNVs. How-
ever, there is still no consensus on the best method for the detection and analysis
of such structural variants (Koike et al., 2011; Dellinger et al., 2010).
In this thesis, several approaches for the genome-wide association analysis of CNVs
are presented from a statistical point of view. Rather than exploring the variety of
genotyping technology, the focus is primarily on the investigation of raw CNV data
being derived from the Affymetrix 6.0 SNP genotyping array. Key issues, such as
how to account for the uncertainty of CNV genotype calling or which statistical
testing methods to choose in the association testing step, are not restricted to any
specific genotyping platform. Instead, the major challenges in evaluating the impact
of CNVs on phenotype variation are consistently present over different technical
methods. Each presented strategy may easily be adapted to variously derived raw
CNV data.
Chapter 2 provides a biological overview of CNVs as one particular type of struc-
tural variants. Basic characteristics and classifications of CNVs that are essential in
understanding the specific challenges in their analyses, are briefly explained.
Chapter 3 describes in detail existing methods for genome-wide association anal-
yses of raw CNV data. This overview addresses the variety of available technical
methods, algorithms and software tools for the detection of CNVs as well as statis-
tical aspects of association testing. Two main existing strategies are shown in detail
and their applicability is illustrated on real data for the phenotypes obesity and
ADHD. Parts of the obtained genetic results were published in Jarick et al. (2012).
Chapter 4 introduces two new statistical strategies for the genome-wide associ-
ation analysis of raw CNV data. Both proposed strategies involve extensions and
modifications of certain parts of the two presented existing strategies into two new
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test designs. Key aspects of the two proposed strategies are shortly outlined and
compared against each other. In addition to this more general overview, a detailed
presentation of both proposed strategies is given in the following two chapters.
Chapter 5 concentrates on the first proposed CNV analyses strategy, which has
a special focus on the selection of genomic marker probe sets being tested for an
association with the trait of interest. One of the most striking differences between
the genome-wide analysis of CNVs and other genomic variants, such as SNPs or
short tandem repeats (STRs), is that the locations in which individuals have gained
or lost copies of genetic material are a priori unknown. Current genotyping plat-
forms provide SNP probe sets that are designed to reflect the presence or absence
of the two SNP marker alleles and (additional) CNV probe sets that are selected
for their linear response to copy number changes. The corresponding genome-wide
analysis of SNPs is a straight-forward procedure, which includes the assignment of
genotype classes AA, AB or BB to each recruited individual and the subsequent as-
sociation testing at each available genetic marker. Contrarily, any CNV association
testing has to additionally address the question of how and with which precision
the quantitative continuous measurements produced by genotyping platforms can
be transferred into precise DNA copy numbers. Bypassing the genotype calling step
and instead directly testing the CNV intensity measurements, does not sufficiently
solve this problem. Instead a new problem arises, since not even the existence of
CNVs is ensured for any probe sets that might be found to be statistically signif-
icantly associated with phenotypic characteristics. Consequently, the introduced
strategy involves to restrict association testing on those probe sets with a certain
minimal copy number variability. The consideration of this aspect was first pro-
posed by Ionita-Laza et al. (2008). As a first application of the suggested method, a
genome-wide CNV association analysis for the binary trait obesity was performed,
which was published in Jarick et al. (2011).
Chapter 6 presents the second alternative to standard genome-wide CNV associa-
tion analyses strategies. The classical two-step procedure is extended by an extensive
modeling of the probe-wise copy number neutral intensity measurements prior to the
estimation of underlying CNV genotypes and subsequent association testing. The
performance of the proposed approach was investigated in comparison to existing
methods by application to publicly available HapMap and replicate data. It will be
demonstrated that the precision of CNV calling and thus the validity of association
testing can be greatly improved by use of sophisticated reference models in terms
of stability and reproducibility rates as well as with respect to the percentage of
false positive or Mendelian inconsistent CNV calls. Finally, the obesity data set
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was re-analysed in application of the second proposed strategy, whereby the CNV-
obesity association results can be compared across all four considered strategies.
Being aware of the limitations resulting from real data studies, not allowing to make
general conclusions about statistical power or type 1 error, this example impressively
demonstrates how the choice of the CNV analysis strategy may relevantly change
genetic results.
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2 Copy Number Variations -
Biological Background
Every two humans are genetically different from each other. Genome sequencing of
an individual human revealed that a minimum of 0.5 percent variation exists between
two haploid genomes, that is to say, only 99.5 percent similarity exists between
the two chromosomal copies inherited from each parent (Levy et al., 2007). Due
to mutational events, even monozygotic twins have infrequent genetic differences
(Bruder et al., 2008).
In the early 1960s, before the availability of sequencing technology, the first ob-
served differences in our genetic architecture, such as aneuploidies, rearrangements,
heteromorphisms or fragile sites, were large enough to be identified using a micro-
scope (Feuk et al., 2006a). In contrast to these microscopic structural variants, which
are at least three mega base pairs (Mb) in size, submicroscopic structural variants
have gained increasing attention in the course of the ongoing technological devel-
opment. To date, the diversity of genetic variations is classified according to size,
structural type and their frequency of occurrence in a population. Accordingly, the
spectrum of genetic variants ranges from simple point mutations or more frequent
single nucleotide polymorphisms (SNPs) to various repetitive elements of varying
size, such as short tandem repeats (STRs), micro- or minisatellites, and of varying
structure including insertions, duplications, deletions, inversions or translocations.
An overview of human genetic variation is given in Table 2.1 below.
A copy number variation (CNV) is defined as ”a segment of DNA that is one kilo
base pairs (kb) or larger and is present at a variable copy number in comparison
with a reference genome” (Levy et al., 2007). Furthermore, ”a CNV can be simple
in structure, such as tandem duplication, or may involve complex gains or losses
of homologous sequences at multiple sites in the genome” (Redon et al., 2006).
CNVs can be classified according to whether they appear in a deleted or duplicated
manner, with respect to the number of occurring alleles, that is whether they are bi-,
tri-, or multi-allelic, or with regard to their simple or complex structure. Notably,
classes of CNVs include insertions, deletions and duplications but not the copy
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Table 2.1: Human genetic variation. The table is adapted from Feuk et al. (2006b)
and partly updated by recent frequency estimates.
Variation Type Definition Frequency (if known) in
the human genome
single nucleotide
polymorphism
(SNP)
Single base pair (bp) variation
found in > 1% of chromosomes
in a given population.
∼ 38 million SNPs in the
human population
(Consortium et al., 2012)
Insertion/Deletion
variant (InDel)
Deletion or insertion of a DNA
segment, including small poly-
morphic changes and large chro-
mosomal aberrations.
InDels > 1 kb in size are called
CNVs.
∼ 1.4 million bi-allelic In-
Dels in the human genome
(Consortium et al., 2012)
Microsatellite or
short tandem
repeat (SRT)
Sequences containing variable
numbers of 1 − 6 bp repeats to-
taling < 200 bp in length.
> 1 million microsatellites
in the human genome,
∼ 3% of the sequence
Minisatellite and
variable numbers
of tandem repeats
(VNTRs)
Polymorphic sequence contain-
ing 20− 50 copies of 6− 100 bp
repeats.
∼ 150 000 minisatellites, of
which ∼ 20% are polymor-
phic
Multisite variant
(MSV)
Single nucleotide variant with
complex characteristics due to
CNV or gene conversion.
The number of MSVs was
unknown in 2006.
Intermediate-sized
structural variant
(ISV)
Gain or loss of a DNA sequence
> 8 kb in size also including in-
version breakpoints.
297 ISVs were identified us-
ing a fosmid library from a
single genome.
copy number vari-
ation (CNV);
copy number poly-
morphism (CNP);
large-scale CNV
(LCV)
Copy number change > 1 kb.
If the frequency is > 1%, it is
called a CNP.
LCVs are CNVs ∼ 50 kb in size
or greater.
∼ 14 000 large deletions
(> 500 bp) in the human
genome
(Consortium et al., 2012)
Inversion Rearrangement causing a seg-
ment of DNA to be present in re-
verse orientation.
Estimates of microscopi-
cally detectable inversion
frequencies are 0.12− 0.7%
(pericentric) and 0.1−0.5%
(paracentric)
Translocation Rearrangement in which a DNA
fragment is attached to a differ-
ent chromosome.
1/500 is heterozygous for
a reciprocal translocation
and 1/1 000 for Robertso-
nian translocations
Unbalanced
rearrangements
Rearrangements which lead to a
net gain or loss of DNA are re-
ferred to as unbalanced.
Unbalanced rearrange-
ments occur in ∼ 1/1 500
live births.
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number neutral translocations or inversions. Individual CNV states are commonly
categorized into relative losses or gains. In many cases, the reference genome is
assumed to equal the most common genome which harbours exactly two copies of
the respective DNA segment - one on each of the two homologous chromosomes. In
this case, relative losses can be homozygous or hemizygous deletions with a total
of one or none copies of the DNA segment left, respectively. Analogously, relative
gains include the presence of a total unphased number of three, four, five or more
copies of the respective DNA segment. A graphical representation of exemplary
CNV classes with regard to the CNV copy number is given in Figure 2.1 below.
Figure 2.1: Schematic representation of CNV classes based on individual copy num-
ber states.
A CNV that is neither inherited from the mother nor from the father is called
to appear de novo. Simple CNVs are segments which are deleted or duplicated
in tandem. Examples for simple bi-allelic de novo or inherited CNVs are given in
Figure 2.2 below.
Figure 2.2: Schematic representation of simple bi-allelic CNV inheritance classes.
Losses and gains in offspring are defined relative to parental genomes.
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In addition to simple CNVs, those that appear at multiple sites in the genome or
with a variety of present copies are called complex CNVs. Figure 2.3 illustrates an
example of a multi-allelic inherited CNV as well as of a complex de novo CNV.
Figure 2.3: Exemplary schematic representation of an inherited multi-allelic CNV
(A) and of an inherited complex CNV (B), respectively.
In particular, ”a CNV that occurs in more than 1% of the population” (Feuk et al.,
2006a) is referred to as a copy number polymorphism (CNP). CNVs that do not
affect germline cells, which instead occur in the form of somatic alterations, are more
precisely denoted as copy number alterations or copy number aberrations (CNAs).
Closely related to CNVs, those duplications reaching fixation in the population are
then visible in the genome as segmental duplications (SDs). SDs ”are defined as
duplicated genomic regions of > 1 kb with 90% or greater sequence identity among
the duplicates” (Kim et al., 2008).
Concerning the mechanism of copy number changes, CNVs can arise both meiot-
ically and somatically, as shown by the findings that monozygotic twins can display
different DNA copy number variation profiles (Bruder et al., 2008). Moreover, CNV
copy numbers can vary across different organs and tissues from the same individual
(Piotrowski et al., 2008). In general, there are two mechanisms that cause changes
in structure of chromosomes: homologous recombination and non-homologous re-
combination (Lin et al., 2011). There are at least two main mechanisms for changes
in CNV copy number: non-allelic homologous recombination and microhomology-
mediated events (Lin et al., 2011). Homologous recombination is the basis of many
DNA repair processes. When a damaged sequence is repaired by use of a homologous
sequence at the same chromosomal position on the sister chromatid or on the homol-
ogous chromosome, there will be no structural changes. Contrarily, repair processes
utilizing homologous sequences in different chromosomal positions, which are called
non-allelic homologous recombination, can change the chromosome structure.
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3 Overview of Methods for the
Genome-Wide Association Analysis
of Raw CNV Data
This chapter is an introduction to the methodical aspects of genome-wide copy num-
ber variation analyses. Currently, most CNV analyses consist of a discovery and of
an association testing step. In the subsequent paragraphs, an introduction to recent
developments concerning both steps will be given, with a special focus on the analy-
sis of case-control and family-based samples that were previously genotyped with the
Affymetrix Genome-Wide Human SNP array 6.0. Two main existing strategies for
the genome-wide association analysis of array-derived CNV data will be presented
and their application will be illustrated on real data examples for the phenotypes
obesity and attention - deficit / hyperactivity disorder (ADHD).
3.1 Technology for CNV Discovery
With regard to the detection of individual copy number variations, there is a variety
of methods that assay the genome at either a genome-wide or at a targeted level,
with varying degrees of resolution. An overview of those approaches that potentially
had the greatest impact on recent CNV discoveries (Feuk et al., 2006a) is given in
Table 3.1.
3.1.1 Microarray Technology for CNV Discovery
Besides quantitative, primarily PCR-based assays, array-based analyses are the sec-
ond main approach for identifying CNVs (Feuk et al., 2006a). Two-channel array-
based comparative genome hybridization (aCGH) and SNP genotyping arrays are
the two major types of data that serve as the source of CNV discovery using microar-
rays. Table 3.2 lists the most important, currently available microarray platforms
for genome-wide CNV detection.
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Table 3.1: Technical methods for the detection of CNVs in the human genome.
Adapted from (Feuk et al., 2006a).
Method CNVs,
1− 50 kb
CNVs,
> 50 kb
Genome-wide scans
Karyotyping No Yes
(> 3 Mb)
Clone-based array comparative genome
hybridization (aCGH)
No Yes
(> 50 kb)
Oligonucleotide-based array comparative
genome hybridization (aCGH)
Yes
(> 35 kb)
Yes
(> 35 kb)
SNP array Yes Yes
Sequence-assembly comparison Yes Yes
Clone paired-end sequencing (fosmid) Yes
(deletions > 8 kb;
insertions <40 kb)
Yes
(deletions > 8 kb)
Targeted scans
Microsatellite genotyping Yes
(deletions)
Yes
(deletions)
Multiplex amplifiable probe hybridization
(MAPH)
Yes Yes
Multiplex ligation-dependent probe ampli-
fication (MLPA)
Yes Yes
Quantitative multiplex PCR of short fluo-
rescent fragments (QMPSF)
Yes Yes
Real-time quantitative polymerase chain
reaction (qPCR)
Yes Yes
fluorescence in situ hybridization (FISH),
including metaphase, interphase and fibre
FISH
Yes Yes
Southern blotting Yes Yes
Concerning array-based comparative genome hybridization (aCGH) approaches,
labelled fragments from a genome of interest are competitively hybridized with a sec-
ond differentially labelled genome to arrays that are spotted with cloned DNA frag-
ments. The array can be spotted with different DNA sources. Genomic clones, for
example bacterial artificial chromosome (BAC) clones, PCR fragments or oligonu-
cleotides can all be used as array targets. After hybridization, determination of
the fluorescence ratio reveals differences in copy number between the test and the
reference DNA sample. The first reported application of CGH technology was in
1992 to investigate copy number differences between cancer cells and healthy cells
at the chromosome level (Shen and Wu, 2009). In 1997, the first microarray CHG
technology was developed with substantially improved resolution as a result of us-
ing cloned genomic DNA as probes in a microarray format, which contain sequence
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Table 3.2: Major commercial microarray platforms and their current products.
Adapted from (Shen and Wu, 2009).
Plat-
form
Type
Com-
pany Array platform
Median
probe
spacing
(resolu-
tion)
Probe
set
number
Oligo-
nucleo-
tide
probe
type
aCGH
Agilent Technologies, Santa Clara, CA
4× 44K CGH array 43 kb 43.000+ 60-mer
8× 60 K CGH array 41.4 kb 55.000+ 60-mer
2× 105 K CGH array 21.7 kb 99.000+ 60-mer
4× 180 K CGH array 13 kb 170.000+ 60-mer
244 K CGH array 8.9 kb 236.000+ 60-mer
2× 400 K CGH array 5.3 kb 411.000+ 60-mer
1 Million CGH array 2.1 kb 963.000+ 60-mer
NimbleGen, Madison, WI
HG18 CGH 4×72 K WG Tiling
v2.0 40 kb 72 000
50- to
75-mer
385K WG Tiling, single array 6.27 kb 385 000 / array
50- to
75-mer
385 K WG Tiling, 4-set array 1.57 kb 385 000 / array
50- to
75-mer
385 K WG Tiling, 8-set array 713 bp 385 000 / array
50- to
75-mer
SNP genotyping platform including CN probes
Affymetrix, Santa Clara, CA
Genome-Wide Human SNP
Array 6.0 0.7 kb
906 600
+946 000
(SNP+CN) 25-mer
Illumina, San Diego, CA
HumanCNV370-Quad DNA
analysis BeadChip 4.9 kb
320 000
+60 000
(SNP+CN) 50-mer
Human610-Quad DNA
analysis BeadChip 2.7 kb
550 000
+60 000
(SNP+CN) 50-mer
Human1M-Duo BeadChip 1.5 kb
1.1×106 SNP +
CN probe sets
targeting exons 50-mer
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information that permit their specific localization in the human genome. Due to its
extensive coverage of the genome, aCGH with BACs is particularly popular (Feuk
et al., 2006a). Compared to the use of BACs, aCGH comprising long oligonucleotides
(60− 100 bp) with increasing smaller inter-probe spacing can improve the detection
resolution, which starts from 50 kb when using BACs and ranges from 30 to 50 kb
for most available oligonucleotide arrays (Feuk et al., 2006a).
SNP arrays were explicitly developed to genotype germline encoded single nu-
cleotide polymorphisms. In addition to information about SNP genotypes, current
SNP genotyping platforms also provide copy number information in form of hy-
bridization intensity signals that are obtained from spotted oligonucleotides on the
SNP arrays. SNP microarrays are a specific type of oligonucleotide arrays, in which
the SNP array probes are explicitly designed to indicate the alternative alleles of
SNPs. For a test sample, the measured strengths of hybridization to each probe
directly reflects the content of nucleic acid in each sample, and can thus be used as
a measure of DNA copy number. In contrast to CGH arrays, genotyping arrays do
not use a specific control sample. Instead, changes in copy number are detected by
comparing individual hybridization intensities with averaged sample hybridization
intensities being probe-wise derived from a group of selected control subjects.
3.1.2 Affymetrix Genome-Wide Human SNP Array 6.0
One of the currently most popular genotyping arrays for genomic profiling is the
Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix 6.0), which combines
SNP probes for SNP genotyping with additional CNV probes that are specifically
designed for the detection of DNA copy number changes.
In particular, the hybrid array Affymetrix 6.0 contains 909 622 SNP probe sets and
additional 945 826 non-polymorphic probe sets for CNV analyses. The latter copy
number probes are sequential oligonucleotide probes that do not depend upon the
presence of SNPs. Both, SNP and non-polymorphic sites are represented by clusters
of identical oligomers of 25 nucleotides immobilized at a specific location on the
microarray. Each such cluster of oligomers is commonly referred to as a probe (Chai
et al., 2010). Since for most SNPs only two alleles are observed, the examination
of a specific SNP is based on several pairs of SNP probes, which differ in just one
nucleotide at the position of the SNP locus. Probes targeting the same SNP or non-
polymorphic site are commonly referred to as probe sets (Chai et al., 2010). Among
the non-polymorphic probe sets, 744 000 probe sets are evenly spaced along the
chromosome, and the remaining 202 000 probe sets target 5 677 known CNV regions
reported in the Toronto Database of Genomic Variants (DGV) (Affymetrix, 2009). A
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Table 3.3: Basic summary of the content of the Affymetrix Genome-Wide Hu-
man SNP Array 6.0 according to the current Affymetrix annotation
files ’GenomeWideSNP 6.na25.annot.csv’ and ’GenomeWideSNP 6.cn.
na25.annot.csv’ (www.affymetrix.com).
Chr
#
SNP
probe
sets
median
SNP
probe
dis-
tance
[bp]
mean
SNP
probe
dis-
tance
[bp]
# CN
probe
sets
median
CN
probe
dis-
tance
[bp]
mean
CN
probe
dis-
tance
[bp]
# CN
probe
sets in
known
CNV
re-
gions
total #
probe
sets
(SNP
& CN)
median
probe
dis-
tance
(SNP
& CN)
[bp]
mean
probe
dis-
tance
(SNP
& CN)
[bp]
NA* 1 224 - - 20 - - - 1 244 - -
1 71 444 1 306 3 452 73 055 2 166 3 358 18 370 144 499 689 1 698
2 74 103 1 391 3 275 77 799 2 296 3 095 22 942 151 902 722 1 585
3 60 838 1 356 3 276 65 499 2 210 3 019 18 321 126 337 699 1 565
4 56 134 1 429 3 405 62 799 2 209 3 021 15 865 118 933 705 1 595
5 56 569 1 329 3 191 57 764 2 263 3 103 13 719 114 333 702 1 567
6 56 400 1 288 3 026 55 040 2 143 3 078 13 504 111 440 665 1 520
7 47 144 1 395 3 366 52 674 2 011 2 989 18 249 99 818 662 1 577
8 48 753 1 154 2 998 48 287 2 166 3 004 15 609 97 040 643 1 495
9 41 521 1 083 3 376 39 515 1 883 3 522 12 819 81 036 577 1 718
10 48 284 1 151 2 800 44 047 2 153 3 047 13 727 92 331 627 1 453
11 44 624 1 241 3 009 43 671 2 128 3 049 13 369 88 295 655 1 508
12 42 670 1 309 3 100 43 539 2 210 3 013 11 504 86 209 681 1 522
13 34 362 1 199 2 799 30 948 2 423 3 084 9 293 65 310 662 1 461
14 28 160 1 305 3 092 28 179 2 360 3 108 8 270 56 339 724 1 555
15 26 120 1 257 3 135 26 690 2 171 3 048 8 813 52 810 687 1 540
16 27 772 1 042 3 193 25 557 2 056 3 450 10 264 53 329 626 1 653
17 20 693 1 615 3 800 25 331 1 990 3 080 9 231 46 024 763 1 695
18 26 620 1 214 2 859 24 890 2 344 3 032 6 487 51 510 665 1 466
19 11 912 2 156 5 338 17 943 1 764 3 528 8 174 29 855 802 2 120
20 22 891 1 187 2 725 20 161 2 165 3 071 5 385 43 052 647 1 438
21 12 606 1 130 2 933 12 181 1 951 3 026 4 425 24 787 589 1 487
22 11 546 1 229 3 043 12 454 1 453 2 798 5 925 24 000 559 1 452
X 36 865 1 679 4 199 49 200 2 183 3 120 14 772 86 065 816 1 784
Y 257 36 643 95 254 8 583 944 6 355 2 479 8 840 912 6 170
MT 110 102 144 0 - − 0 110 102 144
Total 909 622 1 297 3 262 945 826 2 154 3 144 281 516 1 855 448 681 1 604
* NA = not available.
detailed characteristic reflecting the content of the Affymetrix 6.0 microarray is given
in Table 3.3. In summary, due to the availability of non-polymorphic copy number
probes in addition to SNP probes, the Affymetrix 6.0 array provides approximately
doubled resolution (median probe distance = 681 bp) for CNV detection compared
to the exclusive presence of SNP probes (median probe distance = 1 297 bp).
3.2 Software for CNV Discovery
To date, several methods for CNV detection based on genome-wide SNP array data
are available. Reflecting just a fractional amount of available tools, Table 3.4 sum-
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marizes those tools for the identification of CNVs that are currently most widely
used.
Table 3.4: Summary of widely used software for detecting CNVs from SNP array
data. Adapted from (Winchester et al., 2009).
Software Platform
Related
Publication Details
Birdsuite
(Birdseye &
Canary) Affymetrix
Korn et al. (2008),
McCarroll et al. (2008)
Combined tool set for genotyp-
ing of SNPs and known CNPs,
integrated in the Genotyping
console (GTC) 3.0
CNAT Affymetrix
Huang et al. (2004),
Affymetrix (2007)
’Copy Number Analysis Tool’
for proprietary-run in Genotyp-
ing Console (GTC) 3.0
CNVPartition
1.2.1 Illumina Illumina (2010) Proprietary-run in BeadStudio
dChip SNP
Affymetrix or
Illumina Li et al. (2008)
HMM based stand alone soft-
ware
GADA &
GADA-JRN
Affymetrix or
Illumina
Pique-Regi et al. (2008)
&
Pique-Regi et al. (2009)
’Genome Alteration Detection
Algorithm’ uses sparse Bayesian
Learning
HMMSeg Multiple Day et al. (2007)
HMM application tool for any
genomic data
ITALICS Affymetrix Rigaill et al. (2008)
R package ’Iterative and Alter-
native normaLIsation and Copy
number calling for Affymetrix
SNP arrays’
Nexus Biodiscov-
ery, CBS Multiple Olshen et al. (2004)
Commercial ’Circular Binary
Segmentation’ detection tool
PennCNV
Illumina or
Affymetrix Wang et al. (2007)
Guided HMM application, Perl
script based
QuantiSNP
Illumina or
Affymetrix Colella et al. (2007)
Guided HMM application, com-
mand line based
SCIMM and
SCIMM-Search Illumina Cooper et al. (2008)
’SNP Conditional Mixture Mod-
elling’ algorithm implemented in
R
TriTyper Illumina Franke et al. (2008)
Identify and genotype SNPs
with null allele
The wide range of presently available analysis tools for CNV detection varies in
terms of the algorithm used for CNV genotype calling, in the extent to which com-
ponents for pre- and post-processing of the data are provided and in the applicability
across genotyping platforms. The two most prominent commercial SNP array ven-
dors, Affymetrix and Illumina, provide specially designed proprietary software for
complete CNV detection analyses, the Genotyping Console and the BeadStudio.
Due to limitations on CNV analyses using proprietary software, a variety of al-
ternative tools were developed. One group of CNV detection tools, such as dChip,
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HMMSeg, PennCNV or QuantiSNP, are based on hidden Markov models (HMMs)
by assuming that observed intensity values are directly related to the unobserved
copy number states via locus-specific emission distributions. Furthermore, copy
number states of neighboring loci are assumed to be similarly characterized, i.e. to
depend on each other.
Moreover, a variety of methods that were originally developed for CNV analyses
based on aCGH data have been adapted to the use with SNP array data. For
instance GADA, which can be applied to SNP array data, is a modification of
the Circular Binary Segmentation (CBS) algorithm (Olshen et al., 2004), originally
designed for aCGH data. The main idea of the segmentation algorithm was to
convert noisy intensity values into regions of similar copy number by continuously
dividing a region into segments until each segment is differently composed and can
clearly be distinguished from neighboring sections.
Alternative approaches for CNV detection from SNP array data involve condi-
tional mixture models. In the SCIMM tool, the observation that copy number losses
appear to have unique signal-intensity clusters is explicitly used for the identification
of deletions.
Furthermore, ITALICS is based on separating probe sets with abnormal intensities
from copy number neutral probe sets. Iteratively, copy number states are estimated
for each probe set, and multiple linear regression is used to estimate the non-linear
effects on the copy number.
Finally, TriTyper combines CNV prediction and SNP genotyping by use of a
maximum likelihood estimation in order to detect deletions. More precisely, SNP
genotyping clusters are modeled in a way to additionally incorporate an extra, so
called null allele, and deviations from Hardy-Weinberg equilibrium (HWE) are used
as an indicator for the presence or absence of this null allele, which is assumed to
reflect deleterious events.
In addition to the core step of calculating individual copy number states, any CNV
discovery analysis also consists of several further steps, which are schematically
represented in Figure 3.1. The detection of CNVs from SNP array data usually
starts with pre-processing of the typically noisy raw output data from microarray
experiments. At first, hybridization intensity signals of each individual array are
extracted and summarized across probe sets. Afterwards, quantile normalization
was shown to perform favorably in removing those variation between arrays, which
is of potential non-biological origin (Bolstad et al., 2003). The final step in data pre-
processing is to calculate individual continuous raw copy numbers per probe sets,
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which are subsequently categorized into discrete copy number states in the following
CNV genotype calling step. At the end of a CNV detection pipeline, spurious CNV
calls, such as for instance singletons or those that cover large gaps between probe
sets, are removed in the course of quality control (QC).
Figure 3.1: Schematic representation of essential steps in CNV detection from SNP
array data.
Several recent publications (Dellinger et al., 2010; Koike et al., 2011; Winchester
et al., 2009; Zhang et al., 2011) have addressed the question to what extent accuracy
of CNV identification depends on the detection program in use and the respective
applied parameters. Consistently, programs based on Hidden Markov models, such
as PennCNV, QuantiSNP or Birdsuite, were shown to have a better detection per-
formance than other programs with regard to several criteria: Compared to others,
HMM-based tools yielded higher reproducibility rates across multiple different ar-
rays of the same individual as well as lower Mendelian inconsistency rates in trio
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data (Koike et al., 2011). The recovery rates, i.e. the ability to call CNVs that were
previously identified by paired-end sequencing of whole-genome fosmid clones or by
aCGH and additional validation procedures, were higher for HMM-based tools, and
also positive predictive values of qPCR validated rare CNVs were shown to be higher
in comparison to those of alternative tools (Zhang et al., 2011). In simulation stud-
ies, QuantiSNP outperformed other methods based on ROC curve residuals over
most considered data sets (Dellinger et al., 2010).
In general, comparative analyses of different CNV detection tools demonstrated
that there is currently no faultless software available for CNV identification and
that academically developed tools seem to be more sensitive and to detect more
events than proprietary algorithms (Winchester et al., 2009). Two previous studies
measured the similarity of CNVs, being detected in use of each program, as the pair-
wise sensitivity between programs: The mean observed similarity of detected CNVs
across different tools equaled approximately 40% (Koike et al., 2011; Winchester
et al., 2009) with a range of 0 to 100% when considering CNVs of only one individ-
ual (Winchester et al., 2009) and a range of 4 to 75% for CNVs that were identified in
publicly available data from a total of 270 individuals in the International HapMap
Project [http://hapmap.ncbi.nlm.nih.gov/] (Koike et al., 2011).
One striking difficulty when judging the quality of CNV detection algorithms is
the lack of a gold standard which could be used for the calculation of validity mea-
sures like sensitivity or specificity. Theoretically, such a gold standard would reflect
the biological presence of CNVs in the genome of certain specified individual for
which genetic marker information is, at best, publicly available. In fact, SNP array
data for 270 individuals of different ancestry, who were analysed in the context of
the International HapMap Project, is accessible to the public (e.g. via download
from affymetrix.com/support/technical/sample data/genomewide snp6 data.affx in
case of Affymetrix 6.0 data). However, there is currently no consensus on the set
of truly underlying CNVs of those HapMap individuals. Up to now, several techni-
cal methods for genotyping of CNVs, such as paired-end sequencing (Korbel et al.,
2007; Kidd et al., 2008), by use of Mendelian inconsistent SNP genotypes (Conrad
et al., 2006), tiling arrays (Redon et al., 2006; Conrad et al., 2010), aCGH (Perry
et al., 2008) and massively parallel sequencing (Park et al., 2010), were applied to
all HapMap persons or to a subset of selected HapMap individuals, respectively.
Depending on the resolution of the respective technological procedure, several dif-
ferently composed CNV sets have been published by now. When considering the
set of CNVs that were detected for one particular individual (NA15510) in three
different studies (Kidd et al., 2008; Korbel et al., 2007; Redon et al., 2006), only
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43 CNV events were found in all three studies out of a total of 174, 352 and 11
CNVs being reported in each single study, respectively (Winchester et al., 2009).
Consequently, sensitivity of CNV identification software can either be presented rel-
ative to a certain CNV detection study, or it can alternatively be given in the form
of a range being calculated with respect to results of several studies. Two recent
publications, both focussing on a comparison of CNV detection tools, consistently
report a mean sensitivity of approximately 15%, with a range from 0.1% to 54%,
when all CNV detection algorithms where considered with respect to several other
experimental results (Winchester et al., 2009; Koike et al., 2011).
3.3 Association Analyses of CNV Data
Structural variants, such as CNVs, can have an influence on phenotypes (Feuk et al.,
2006a). For example, CNVs can modify drug response. Furthermore, CNVs that
encompass or overlap a disease-associated gene can predispose to or cause disease
in the current or in the next generation. Deletions, duplications or insertions of
dosage-sensitive genes lead to reduced or increased gene expression, which can cause
diseases. Dosage-insensitive genes can also cause disease, for instance in case that a
deletion unmasks a recessive mutation on the homologous chromosome. Addition-
ally, insertions or CNV start and end points can disrupt gene structure or can lead
to formations of new transcripts through gene fusion or exon shuffling. In the prox-
imity of dosage-sensitive genes, CNVs can alter gene expression through positive
or negative effects. A deletion of important regulatory elements can, for instance,
down-regulate gene expression, or a deletion of a functional element could unmask
a functional polymorphism within an effector with consequences for gene function.
Additionally, as susceptibility alleles in combination with several other genetic fac-
tors, CNVs can affect complex phenotypes or a complex disease state (Feuk et al.,
2006a).
The first empirical evidence that CNVs can be associated with human phenotypes,
came from the observation that sporadic cases of autosomal dominant diseases, like
the Charcot-Marie-Tooth disease type 1A (CMT1A) or hereditary neuropathy with
liability to pressure palsy (HNPP), result from de novo CNV events (Inoue and Lup-
ski, 2002; Lupski, 2007). Diseases that are caused exclusively by genome structural
changes are referred to as ’genomic disorders’ (Lupski, 2007). Until very recently,
the impact of structural genetic variation was thought to be limited to rare ge-
nomic disorders (Ionita-Laza et al., 2009). However, it is now known that CNVs
are not exclusively present in patients with sporadic diseases, but that there exists
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also widespread common structural variation among unaffected individuals (Conrad
et al., 2010). Consequently, the question of whether CNVs influence more common
complex human diseases has been addressed and positively answered in several stud-
ies, for instance for asthma (Brasch-Andersen et al., 2004) or schizophrenia (Walsh
et al., 2008).
3.3.1 Strategies for Genome-Wide Association Testing of CNV
Data
As depicted in Figure 3.2, two main strategical approaches can be applied for CNV
association analyses (Ionita-Laza et al., 2009): approach S1 and approach S2. A
brief summary of the main principles of both approaches is additionally presented
Figure 3.2: Schematic representation of the two main approaches for CNV associa-
tion analyses.
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in Table 3.5. In the following section, approach S1 and S2 will be embedded as key
issues into complete analyses strategies.
Approach S1 : One methodology aims to avoid the problems that are connected
with accuracy in CNV genotype calling. Instead, raw copy number values, which are
assumed to reflect the true unknown copy number states, are directly provided for
statistical testing. According to the study design, classical statistical methods for
continuously distributed data, such as the parametric t-test or the non-parametric
Mann-Whitney U test for case-control designs, can be applied. Moreover, methods
from SNP association testing can be adapted to the more general scenario of raw
signal data when family-based designs are considered. Notably, the approach S1 is
limited in the sense of biological interpretation and prognostic relevance.
Approach S2 : The second methodology is composed as a two-step procedure.
Firstly, CNV genotypes are inferred and afterwards these are incorporated in clas-
sical tests of association, which are well explored in the course of previous and
ongoing widely-used association analyses accounting for phenotype-association ef-
fects of SNPs. Consequently, the performance of the approach S2 depends on the
ability to genotype CNVs. Currently, there is no consensus about whether and how
to incorporate the uncertainty of CNV genotype calling in the analysis. Moreover,
due to the discretisation of continuous CNV copy numbers into CNV copy number
classes, substantial information and statistical power may be get lost (Ionita-Laza
et al., 2009). Finally, when considering CNVs that harbour more than 2 alleles, the
standard association tests provided from SNP association studies are not directly
applicable and have to be extended to the multi-allelic scenarios instead.
Table 3.5: Two main approaches for genome-wide statistical association testing of
CNV data.
Genome-wide
Statistical Testing
Approach S1
Genome-wide
Statistical Testing
Approach S2
Statistical testing is
based on ...
individual raw copy
number values for each
available CNV probe set.
individual CNVs.
Statistical tests are
performed at ...
any available CNV
probe set.
any genomic region of-
fering at least one CNV.
The number of tests
performed equals the ...
number of available
CNV probe sets.
number (sub-) CNV re-
gions.
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Concerning approach S2, several overlapping individual CNVs with similar but
not equal start and end points are often assumed to differ mainly due to technical
inaccuracy of the genotyping platform, and are thus transformed into CNVs of
exactly the same length and location. Consequently, in this situation it suffices to
perform statistical association testing at the CNV level and not at the marker level
as it is done when applying approach S1 (see Table 3.5).
3.3.2 Case-Control Association Testing with CNV Data
One of the most simple and commonly used approaches for genetic association anal-
yses is the case-control design, which incorporates one group of unrelated affected
probands and another group of unrelated unaffected individuals. One apparent prob-
lem in genetic case-control association studies is to distinguish association findings
that are based on true biological effects from those that are caused by the underlying
structure of the population from which cases and controls were selected.
Depending on the selected methodology for association testing, parametric (for
example the t-test) or alternatively non-parametric statistical tests (for example
the χ2 test, the trend test or the Mann-Whitney test) to test for differences in the
frequencies of the different copy number classes or for differences in the distributions
of continuous raw copy number signals between both groups are applied to the case-
control setting.
3.3.3 Family-Based Association Testing with CNV Data
Approaches in which classical genetic association testing is performed within fami-
lies offer protection from population stratification effects, but this typically comes
at the cost of reduced power relative to case-control scenarios. However, simulations
showed that the differences between case-control designs and trio designs are gener-
ally small in terms of statistical power when the number of trios is assumed to equal
the number of cases and likewise the number of controls. Contrarily, with respect
to unbalanced case-control scenarios accounting for considerably more controls than
cases (i.e. ratio > 3), the number of trios needed to achieve comparable statistical
power is substantially increased relative to the number of unrelated cases (McGinnis
et al., 2002). On the other hand, trio designs were shown to be more powerful than
case-control scenarios when the disease under study is rare (i.e. disease prevalence
≈ 0.1%) (Laird and Lange, 2006).
In particular, association testing of CNVs with disease can also in family data be
performed on the basis of integers that reflect the individual biological copy numbers
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or alternatively on the basis of continuous measurements that approximate the true
CNV states. The classical Family-Based Association Test (FBAT) from the SNP
analysis setting, has recently been generalized for the application to continuously
distributed CNV data (Ionita-Laza et al., 2008).
Compared to case-control studies, family-based designs additionally offer the
chance to determine the inheritance status of childish CNVs and to subsequently
test for potential relationships with the disease status. However, the assignment
of the underlying heritability is frequently problematic, since allelic copy numbers
cannot always unambiguously be defined on the basis of the estimated diploid copy
numbers. For example, a copy number state of two, i. e. a total number of two
copies, could either represent a 1/1 or a 2/0 genotype. Alternatively, CNV data can
be regarded as a quantitative trait, which allows the heritability of all types of CNV
to be adequately demonstrated (Locke et al., 2006).
3.4 Two Existing Strategies for the Genome-Wide
Analysis of Raw CNV Data
Mainly driven by the respective approach for genome-wide association testing, a
distinction is made between two main strategies for the whole genome-wide asso-
ciation analysis of raw CNV data. For simplicity, the two existing strategies will
be referred to as strategy S1 and S2 in the following. Both complete strategies are
shown graphically in Figure 3.3.
Most parts of both strategies were already explained in the previous chapters. In
order to complete a genome-wide CNV analysis strategy, a third validation step is
usually added to the first two steps of CNV detection and CNV association testing.
Due to the previously mentioned technological uncertainties, both strategies, S1
and S2, typically end up with validation experiments and corresponding follow-
up analyses accounting for at least those genomic regions with initially observed
statistically significant association test results. That is, individual copy number
states of interesting (i.e. statistically significant) findings need to be re-determined
in the present sample by use of an alternative technological method and subsequently
association tests have to be re-evaluated based on the obtained validated CNVs.
In CNV analyses, a distinction is often made between focussing on rare or on
common CNVs that appear with a certain frequency (for example > 5%) in a pop-
ulation (McCarroll and Altshuler, 2007). Due to their sparseness, rare CNVs are
commonly suggested to be grouped, based on pre-specified criteria, before being
tested. Additionally, permutation procedures are explicitly recommended to test for
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association of rare CNVs with disease. In order to illustrate the influence of CNV
frequency on the design of the genome-wide analysis strategy, real data examples
with a special focus on common as well as on rare CNVs will be presented in the
following sections.
Figure 3.3: Schematic representation of the two main existing strategies for the
genome-wide association analysis of raw CNV data.
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3.5 Application of Strategy S1 to the Phenotype
Obesity
With the dramatical growth of common obesity among adults as well as with the
parallel less extreme growth among children, the interest in explaining the origins of
the complex trait obesity has increased drastically in the last years. Apart from the
obvious impact of environmental factors, common obesity undoubtedly has a large
underlying genetic component (Walley et al., 2009). There are several classical twin
studies in obesity that have revealed average heritability estimates of 40−75% (Maes
et al., 1997) for weight (Stunkard et al., 1986a,b) and for BMI (body mass index)
(Turula et al., 1990; Wardle et al., 2008) in both adults and children. Consequently,
approximately half of the inter-individual difference in body weight was shown to
be explicitly caused by genetic variability.
Nevertheless, in several recent large scale meta-analyses, which incorporated up to
∼ 250 000 individuals, only a small proportion of genetic variants that are causal for
common obesity could be detected so far (Willer et al., 2009; Speliotes et al., 2010).
In sum, by examining associations between BMI and SNPs, such large population-
based studies revealed a total of 42 variants at independent genetic loci that were
estimated to collectively account for only 1.45% of the variance in BMI, which
corresponds to approximately 2− 4% of the genetic BMI variance.
On the one hand, the residual variance in BMI with genetic cause may potentially
be explained by a variety of further SNPs with even more little effect sizes, which
might be detected in samples with considerably greater sample size. On the other
hand, rare single base variants with comparably great association effects, which are
undetectable in application of the mostly used SNP genotyping arrays, are assumed
to make up a large proportion of the still unexplained genetic variability of complex
traits, such as obesity (Manolio et al., 2009). Finally, structural genetic variants of
type other than SNPs or single point mutations, as for instance CNVs, are another
potential source of causal genetic variants (Manolio et al., 2009).
In this chapter, application of strategy S1 to genome-wide raw CNV data of a
family-based obesity sample will be presented. The question whether specific com-
mon CNVs that are detectable by use of SNP arrays might be a genetic cause for the
trait obesity will be further addressed in later parts of this thesis. In the following
chapter, application of strategy S2 to the phenotype obesity will be presented. More-
over, in chapters 5.2 and 6.3, the proposed strategies PS1 and PS2 will additionally
be applied to the same data set. Finally, advantages, disadvantages and limitations
of each implemented CNV analyses strategy will be comparably discussed in detail.
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3.5.1 Data Set
The family-based obesity sample was made up of 424 trios, each one consisting of
one obese child or adolescent and both biological parents. According to a German
reference population (Hebebrand et al., 1994), the measured BMI (in kg/m2) of
each offspring was above the 90th age- and sex-specific percentile. Most of the
index cases (93.6%) were extremely obese with a BMI percentile ≥ 97th. Details on
phenotypical characteristics of the obesity trio sample can be found in Jarick et al.
(2011) (Supplementary Table S1).
For follow-up analyses, an independent case-control sample comprising 453 obese
children or adolescents and 435 normal weight or lean adult controls was adducted.
All obese subjects (cases) of the case-control sample had a BMI above the 90th age-
and sex-specific percentile. 92.5% cases of the case-control sample were extremely
obese with a BMI percentile ≥ 97th. Phenotypical characteristics of the case-control
sample can be found in detail in Jarick et al. (2011) (Supplementary Table S1).
For all 1 272 individuals of the obesity trio sample as well as for all 888 individuals
of the case-control sample, genotyping was performed on the Affymetrix Genome-
Wide Human SNP Array 6.0 by the ATLAS Biolabs GmbH (Berlin, Germany).
Besides∼ 900 000 SNP probe sets (∼ 870 000 autosomal), this SNP genotyping array
additionally contains ∼ 940 000 non-polymorphic probe sets (∼ 890 000 autosomal)
for copy number analyses. More details on the Affymetrix 6.0 chip can be found
in chapter 3.1.2. The genotyping procedure was exactly identical for each three
members of any trio, i.e. their DNA material was pipetted to the same micro-plate
and their hybridization intensity levels were assigned within the same batch.
3.5.2 Methods
Data pre-processing
Corresponding to strategy S1 (see Figure 3.3), statistical association testing was
based on the fluorescence hybridization intensities at the autosomal non - polymor-
phic copy number (CN) probe sets that are a measure of copy number variance.
For each individual and each probe set, raw intensity values were extracted from the
individual ’.CEL’ files by use of the R-package ’affxparser’ (Bengtsson et al., 2008a).
Afterwards, the FBAT approach was genome-wide applied to the family-based obe-
sity sample, that is to each of the 888 023 autosomal CN probe sets, in order to test
the locus-specific CNV characteristics for an association with obesity.
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Association testing
Since the offspring’s genotyping procedure was identical to those of the parents,
inter-familial differences in hybridization intensity measurements should solely be
derived from CNV inheritance or from de novo CNV events, but not from tech-
nical artefacts. Applied to a binary trait, the FBAT is equivalent to a score test
with a test statistic equaling the standardized sum of within-family components (see
chapter 5.1.2.1 for a detailed description). Hence, a normalization of raw intensity
values prior to the association testing is dispensable here. Consequently, the raw hy-
bridization intensity measurements were directly tested without being transformed
into raw copy number measurements (see chapter 6.1.1). The latter makes use of the
fact that the FBAT approach is invariant under linear transformation (see chapter
5.1.2.1).
To account for multiple comparisons in testing multiple hypotheses (n = 888 023),
the empirical Bayes method of local false discovery rates (lfdr) as proposed by Efron
et al. (2001) was applied. The lfdr approach is motivated by the tail area false
discovery rate (FDR), which was introduced by Benjamini and Hochberg (1995) in a
frequentist framework. When a collection of hypotheses is tested simultaneously, the
FDR equals the expected proportion of erroneously rejected null hypotheses among
all rejected null hypotheses using a given rejection rule (Benjamini and Hochberg,
1995). Closely connected to a local version of the FDR, the lfdr is defined as the
posteriori probability that a single null hypothesis is true given the observed value
of the respective test statistic (Efron et al., 2001; Efron, 2004, 2007a,b).
In more detail, the lfdr method is based on a Bayesian two-class model that divides
all test cases into two classes, ’null’ or ’non-null’, corresponding to whether or not
they are generated according to the null hypothesis and with prior probabilities
p0 and p1 = 1 − p0, and with associated test statistic densities f0 and f1. The
test statistic density f can then be written as a mixture density f = p0f0 + p1f1.
According to the Bayes theorem, the lfdr for an observed test statistic value z is
given as the posteriori probability lfdr(z) = P(’null’|z) = p0f0(z)/f(z).
Using the ’locfdr’ R package (Efron et al., 2011), lfdr estimates were obtained
on the basis of empirical non-parametric estimates using central matching for the
null distribution density fˆ0, the mixture density fˆ and the factor pˆ0. Thus, the
applied lfdr methodology especially accounts for the fact that the null sub-density
f0 might differ from the theoretical null distribution. The natural choice for f0
would be the standard N (0, 1) density in the underlying FBAT context with test
statistics
√
FBATk, k = 1, . . . , 888 023 (CNV FBAT z-values, cf. equation (5.4) in
chapter 5.1.2.1). However, a deviation from the theoretical null distribution can
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be caused by several reasons that are listed by Efron (2004, 2007a,b): (1) failed
assumptions on the test statistic, (2) unobserved covariates, (3) correlation across
probes and genes, (4) a large proportion of genuine but uninterestingly small ef-
fects. As shown by Efron (2004, 2007a,b), in all these situations the application of
the inappropriate theoretical null results in misclassified FDR and lfdr estimates.
Of note, Efron (2007a) emphasized that even if the theoretical null is singularly
appropriate for each probe-wise test situation, correlation across probes can lead
to an effectively deviated null distribution f0 compared to the theoretical N (0, 1).
Moreover, Efron (2004) point out that the popular permutation methods, which
provide a way of avoiding assumptions on an underlying correlation stucture and
asymptotic approximations (like normality), do not automatically resolve the ques-
tion of an appropriate null hypothesis f0. As shown by Efron (2004), unobserved
covariates such as personal characteristics of the analysed study patients (i.e. age,
gender or geographical location) are likely to widen or narrow the empirical f0, and
this effect is not detectable in permutationally derived null hypothesis. Efron (2004)
point out that a permutation null distribution will not reveal correlation effects of
hidden covariates, but will closely match the theoretical null distribution, irrespec-
tive of whether or not there are unobserved covariates or other factors influencing
the theoretical null distribution. Finally, results of each inference method, FDR,
lfdr, Bonferroni, family-wise error rate (FWER), are doubtful if the null hypothesis
is not chosen appropriately. Efron (2004) strongly argues to prefer the empirical
null hypothesis in observational studies.
Evaluation of statistically significant results, CNV calling and follow-up analyses
As stated by Ionita-Laza et al. (2008), it is challenging to evaluate whether sta-
tistically significant association test results are caused by underlying CNV - trait
associations or rather by hybridization intensity differences depending on probe-
specificity and signal-to-noise properties of the platform, when the CNV FBAT
methodology was applied genome-wide without an a priori selection of markers.
To address this concern, the HMM CNV detection algorithm implemented in the
Affymetrix Genotyping Console (GTC) 3.0 was employed on the raw intensity data.
For each of the 1 272 individuals of the family-based obesity sample, CNV calls were
estimated by comparing individual signal intensities against a reference sample. Due
to computational constraints, the reference sample size was limited to 106 parental
pairs of the obesity trio sample. In order to minimize the potential effect of the
choice of the reference sample on the CNV calling results, two differently composed
reference samples, each comprising 106 parental pairs, were used. One reference
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sample (ref1) was a random collection, whereas the other one (ref2) was based on
those parental pairs with the lowest mean BMI standard deviation scores out of all
non-obese parental pairs. Phenotypical details on both reference samples can be
found in Jarick et al. (2011) (Supplementary Table S1).
For probe sets with statistically significant CNV FBAT results, follow-up anal-
yses were performed in the case-control sample. Significance of CNV FBATs was
determined with respect to a lfdr level of 0.2, which was proposed to be a sensible
threshold by Efron (2004). To address potential plate effects, quantile normaliza-
tion (Bolstad et al., 2003) was applied to the raw intensity signals of the case-control
sample. Subsequently, logistic regression with predictors normalized intensities, sex
and age was used to test the CN probe sets for an association with obesity.
3.5.3 Results
For the Affymetrix 6.0 chip, a total of 888 023 CN probe sets are available for
copy number analysis. Genome-wide CNV FBAT results for the analysis of 424
obesity trios are summarized in form of a Manhattan plot, which is depicted in
Figure 3.4. Non of the tested probe sets reached genome-wide significance at a
relevant significance level when correction for multiple testing would be performed
in a Bonferroni manner (minimal CNV FBAT p-value = 1.06×10−4). However, due
to correlations across probes, a Bonferroni correction, which assumes simultaneous
testing of independent hypotheses, is not appropriate for the underlying situation.
Contrarily, the lfdr method that does not require stochastic independence between
probes, yielded 23 probe sets with lfdr values below 0.20 (Figure 3.5, Table 3.6),
which is a sensible threshold as proposed by Efron (2004). As shown in Figure
3.5, the empirical null distribution, N (−0.182, 0.5762), strongly deviates from the
theoretical null, N (0, 1). However, given the genome-wide correlation structure
across probes, this is a non-surprising and well known phenomenon (Efron, 2004;
Efron et al., 2001; Eyheramendy et al., 2011).
The majority of lfdr significant probe sets (n = 13) is located in regions (human
genome version 18, hg18) without reported CNVs in the Toronto Database of Ge-
nomic Variants (DGV) (Table 3.6). For approximately half of the residual ten probe
sets (n = 4), no copy number variability was estimated in the affected offspring of
the analysed sample of 424 obesity trios. The most promising association test re-
sults, that is those with lowest CNV FBAT p-values, showed either no evidence
for CNV variability with regard to the DGV or to sample-based estimates of CNV
frequencies.
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Figure 3.4: Manhattan plot for the genome-wide CNV analysis of 424 obesity trios
accounting for 888 023 CN probe sets. For all CN probe sets, the − log10
transformed CNV FBAT p-values are shown relative to their chromoso-
mal position. 23 FBAT results with lfdr < 0.2 are circled.
Figure 3.5: Histogram and lfdr curve of CNV FBAT z-values for the genome-wide
analysis of 424 obesity trios accounting for 888 023 CN probe sets.
Panel A: Histogram. The red dashed curve depicts the standard nor-
mal distribution, the dashed blue line is pˆ0fˆ0, the empirical null density,
N (−0.182, 0.5762), and the green line is the empirically estimated mix-
ture density. The small pink bars represent estimated non-null counts.
Panel B: Lfdr curve, derived from empirical estimates of f0, f and p0
(Panel A). Observed CNV FBAT z-values are illustrated as ticks on the
horizontal line at lfdr level 0.2, those with lfdr < 0.2 are printed in red.
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Table 3.6: Results for 23 probe sets with lfdr < 0.2 across 888 023 CNV FBATs, each accounting for 424 obesity trios. (Results are
sorted by FBAT z-values. Each CN probe accounts for 25 bp.)
CN probe
set ID
Chr: Position
[hg18]
FBAT
z-value
FBAT
p-value lfdr
known
CNV
[DGV]
CNV fre-
quency in
offspring [%],
ref1 // ref2
CNV fre-
quency in
parents [%],
ref1 // ref2
logistic
regres-
sion
z-value
logistic
regres-
sion
p-value
CN 895557 21 : 44 716 718+ −3.877 0.0001 0.001 YES 0 // 0 0 // 0 1.518 0.1291
CN 1256115 7 : 41 769 452+ −3.330 0.0009 0.025 - 0 // 0 0 // 0 1.051 0.293
CN 792740 18 : 50 771 860+ −3.087 0.0020 0.075 - 0 // 0 0 // 0 0.293 0.7697
CN 1071025 4 : 20 652 044+ −3.063 0.0022 0.082 - 0 // 0 0 // 0 1.854 0.0638
CN 502773 1 : 82 317 273+ −3.055 0.0023 0.085 - 0 // 0 0 // 0 1.060 0.2893
CN 648814 14 : 105 520 700+ −3.038 0.0024 0.090 YES 0.71 // 0.71 1.65 // 2.00 -0.423 0.6722
CN 819604 2 : 153 658 655+ −2.971 0.0030 0.115 - 0 // 0 0.24 // 0.24 1.978 0.0479
CN 1325083 9 : 8 427 225+ −2.934 0.0034 0.131 - 0 // 0 0 // 0 -1.401 0.1611
CN 635265 13 : 73 536 303+ −2.920 0.0035 0.137 - 0 // 0 0 // 0 -0.339 0.7345
CN 779388 18 : 36 203 193+ −2.914 0.0036 0.140 - 0 // 0 0 // 0 0.578 0.563
CN 369358 8 : 4 784 964+ −2.912 0.0036 0.140 YES 0.24 // 0.24 0.12 // 0.12 0.229 0.8191
CN 915257 22 : 22 661 955+ −2.892 0.0038 0.150 YES 2.36 // 3.54 2 // 2.59 0.245 0.8063
CN 663949 15 : 45 351 560+ −2.886 0.0039 0.153 YES 0.24 // 0.24 0 // 0 0.456 0.6485
CN 816331 2 : 202 126 216+ −2.886 0.0039 0.153 YES 0 // 0 0.12 // 0.12 -2.401 0.0164
CN 540526 10 : 99 065 374+ −2.865 0.0042 0.163 YES 0 // 0 0.12 // 0 1.840 0.0657
CN 913545 22 : 41 296 360+ −2.859 0.0042 0.165 YES 0.71 // 1.18 1.06 // 1.30 -0.765 0.4444
CN 480122 1 : 32 876 668+ −2.853 0.0043 0.169 - 0 // 0 0.12 // 0.12 1.055 0.2916
CN 484362 1 : 25 606 827+ −2.834 0.0046 0.178 - 0.47 // 0.47 0.12 // 0.12 -1.216 0.2239
CN 678173 14 : 80 138 675+ −2.834 0.0046 0.178 - 0 // 0 0.35 // 0.24 -2.643 0.0082
CN 679595 14 : 45 136 094+ −2.804 0.0051 0.194 YES 0 // 0 0 // 0 2.563 0.0104
CN 915256 22 : 22 660 257+ −2.793 0.0052 0.199 YES 2.36 // 3.54 2 // 2.59 0.375 0.7078
CN 819097 2 : 128 655 731+ 2.886 0.0039 0.167 - 0 // 0 0 // 0 -2.386 0.0170
CN 1297053 9 : 131 449 649+ 2.966 0.0030 0.144 - 0.71 // 0.71 0.24 // 0.24 -0.990 0.3221
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Two of the 23 lfdr significant CN probe sets, CN 816331 and CN 678173, showed
an effect direction in logistic regression testing that was identical to CNV FBAT, and
additionally yielded a nominal significant logistic regression p-value at a significance
level of five percent. None of these two logistic regression test results remained
significant after correction for simultaneously testing 23 hypotheses, in neither a
Bonferroni nor a lfdr manner.
3.5.4 Discussion
Strategy S1 for the genome-wide analysis of raw CNV data was applied to a family-
based sample comprising 424 extremely obese children or adolescents and their bi-
ological parents. For association testing, the CNV FBAT methodology as proposed
by Ionita-Laza et al. (2008) was adopted. Significance was assessed via the lfdr
method that was introduced by Efron (2004). Out of 888 023 tested CN probe sets,
23 achieved genome-wide significant CNV FBAT results. However, a majority of
17 probe sets were located in genomic regions without evidence for copy number
variability, neither with respect to previous reports nor to estimates based on the
present sample. The logistic regression framework was applied to a case-control
sample of 453 obese children and adolescents and 435 lean adult controls for follow-
up analyses of significant findings from the family-based sample. Two probe sets
showed nominally significant and directionally consistent test results. None of the
latter probe sets reached statistical significance after correction for multiple testing.
On the one hand, strategy S1 is easy to implement with regard to the fact that
raw hybridization intensity measurements can directly be tested for an association.
Since each available array probe set is incorporated into the association testing
step without any prior pre-selection, the most complex, work intensive and time
consuming part of strategy S1 is the data pre-processing step.
On the other hand, the interpretation of association test results obtained from
strategy S1 might be challenging due to the fact that biological plausibility is not
necessarily a priori provided. To address this issue in the analysed obesity data
set, underlying copy number variability of significantly associated probe sets was
assessed with respect to sample based estimates and to estimates from a publicly
available catalog of structural variants in healthy control samples (DGV). Out of
23 CN probe sets with significant CNV FBATs, a minority of six (= 26%) probe
sets is located in genomic regions that were reported to be copy number variable
in the DGV, and that were additionally estimated to be covered by individual,
postentially disease causing CNVs in the analysed family-based obesity sample. Of
note, the estimated sample copy number variability did not exceed 3.54% for any
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of the six probe sets. For the other 17 probe sets, for which a lack of copy number
variability was observed, there is no obvious reason to believe that the association
test result reached significance due to the presence of underlying CNV association
effects. Instead, significance may rather be caused by technical fluctuations for the
latter probe sets. These doubts could be resolved in use of altervative technical
approaches aiming to validate array based CNV calls or by follow-up analyses in
independent obesity samples as it was done here. However, none of the findings could
be strengthened by follow-up analyses in an independent case-control obesity sample.
Consequently, in application of strategy S1 there is no hint for any association of
CNVs with obesity.
It turned out that one of the main advantages of strategy S1, its easy, computa-
tionally simple and fast implementation at a genome-wide level without the necessity
of previous knowledge on structure, genomic location or even existence of CNVs, si-
multaneously offers the potential for being one of its greatest weaknesses. Generally
speaking, the effective impact of this aspect on genetic results might depend on the
quality of raw genotyping data and primarily on those of pre-processed raw copy
number data. In more detail, the better appropriate the assignment of individuals
to genotyping plates and the more comparable the genotyping pipeline was trans-
posed across batches, the lower is the risk of any bias due to technical concerns.
Moreover, data pre-processing, such as normalization procedures, may additionally
minimize potentially spurious results. However, particularly the CNV FBAT ap-
proach was designed as a robust approach against any such confounding. Keeping
in mind that each three members of any considered obesity trio were pipetted to the
same micro-plate, the normalization step was thus skipped here.
Another disadvantage of testing probe-specific raw copy number measurements
for an association with the trait of interest without knowledge on underling CNVs is
that follow-up analyses are canonically performed for significantly discovered probe
sets. However, any potentially associated CNV is known to be described by a set
of several consecutive array probes with highly correlated characteristics. Conse-
quently, a higher power might be achieved in replication attempts that additionally
account for surrounding probes of initial findings. However, in application of CNV
analyses strategy S1 no knowledge is provided on how to appropriately extent the
follow-up probe set clique concerning this issue. This lack of information might be
addressed by a rudimentary CNV calling step, aiming to detect sample-specific CNV
breakpoints, as it is proposed in the modified CNV analyses strategy PS2.
Finally, there is no way out of getting to know the true underling CNV geno-
types of positive findings by validating the association signal independently by use
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of a different technology. Otherwise, no insight can be provided into the biological
mechanisms of how the identified CNV influences the disease of interest. The pre-
sented application of strategy S1 was finished without technical validation because
of having found no positive CNV association effects.
3.6 Application of Strategy S2 to the Phenotype
Obesity
In the following chapter, the application of strategy S2 will be demonstrated ex-
emplarily to genome-wide raw CNV data of a family-based obesity sample. For
this purpose, the same data set of 424 obesity trios, which has been analysed by
use of strategy S1 in the previous chapter, will be re-analysed here. Subsequently,
statistical results and genetic conclusions of strategy S2 for the phenotype obesity
will be compared to those of strategy S1. Finally, strengths and weaknesses of the
genome-wide CNV analyses strategy S2 will be discussed in comparison to adequate
characteristics of strategy S1.
3.6.1 Data Set and Methods
Data set
Available genotype data for a family-based sample consisting of 424 nuclear fam-
ilies, each comprising one obese child or adolescent and both biological parents,
has been analysed here. All families were previously recruited and phenotypically
characterized through the Departments of Child and Adolescent Psychiatry of the
Universities of Duisburg-Essen and Marburg. Details on phenotypical characteris-
tics can be found in chapter 3.5.1 and in Jarick et al. (2011) (Supplementary Table
S1). For all 1 272 individuals, genotyping was performed on the Affymetrix 6.0 chip
by the ATLAS Biolabs GmbH in Berlin (for details see chapter 3.5.1).
CNV calling and association testing
For each of the 1 272 individuals, the CNV detection step was performed in appli-
cation of the PennCNV software (Wang et al., 2007) by using default parameters.
In the course of quality control (QC) for the CNV calling procedure, each CNV call
that did not cover more than 20 informative consecutive probe sets was discarded
from subsequent statistical analyses. As shown in later chapters, the CNV detection
threshold of 20 probe sets per CNV call is the optimal threshold for Affymetrix 6.0
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data with regard to CNV’s stability and reproducibility rates. The remaining CNVs
were tested for an association with the binary trait obesity by use of the FBAT
approach with assuming an additive genetic effect model. In more detail, the coding
for the different marker genotypes was specified as 0, 1, 2, 3, 4 in concordance with
the estimated total unphased number of DNA segment copies. In order to avoid re-
dundancies, only the set of unique CNV’s start and end sites but not the whole set
of available probe sets was tested for an association with the phenotype obesity. In
more detail, overlapping CNVs were at first merged into several CNV containing re-
gions (CNVRs). Secondly, each CNVR was divided into multiple sub-CNVRs. Here,
the boundaries of each single sub-CNVR were defined to equal the breakpoints of
the maximal intervals with identical CNV configuration across all 1 272 individuals.
Thus, the composition of each single CNVR is completely specified by the set of all
CNV’s start and end sites of any individual CNV (see Figure 6.7 for details).
In order to allow each FBAT to account for a minimal number of informative
families, only sites within 244 pre-specified genomic regions that offer a CNV vari-
ability of at least five percent in both, the offspring’s and the parent’s group, were
incorporated into the association testing step. Details on how these 244 CNVRs
were specified and on their structural characteristics are given in chapters 5.2.2 and
5.2.3. As previously explained in detail, genome-wide significance of simultaneously
testing multiple hypotheses was assessed by use of the lfdr method (Efron et al.
(2001), see chapter 3.5.2).
3.6.2 Results
A total of 47 796 CNVs were detected in the 1 272 individuals, 15 863 CNVs were
observed in the offspring’s group and 31 933 CNVs in the parent’s group. Out of
all detected CNVs, 39 955 CNVs were located in 244 pre-specified CNVRs with a
minimal CNV variability of five percent, 13 455 in the offspring and 29 500 in the
parents.
For association testing, FBATs were performed at a total of 3 525 unique CNV’s
start and end sites (Figure 3.6). None of the tested sites reached statistical signifi-
cance after correction for testing multiple hypotheses (minimal p-value = 0.00071).
3.6.3 Discussion
Application of strategy S2 for the genome-wide analysis of raw CNV data, to a
family-based sample of 424 obesity trios, did not reveal any evidence for an associ-
ation of certain CNVs with the trait obesity. This is in concordance with previous
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Figure 3.6: Histogram and lfdr curve of CNV FBAT z-values for the genome-wide
analysis of 424 obesity trios at 3 525 unique CNV’s start and end sites
in 244 CNVRs. Panel A: Histogram. The red dashed curve depicts the
standard normal distribution, the dashed blue line is pˆ0fˆ0, the empiri-
cal null density, N (0.107, 1.0562), and the green line is the empirically
estimated mixture density. Panel B: Lfdr curve, derived from empirical
estimates of f0, f and p0 (Panel A). Observed CNV FBAT z-value are
illustrated as ticks on the horizontal line at lfdr level 1.
results of applying strategy S1 to the same data set. Apart from a true lack of a
CNV - obesity association, one potential cause for the negative finding might be
seen in a power constraint, which may result from the moderate size of the analysed
sample.
In contrast to strategy S1, in which statistical association testing is based on
raw copy number measurements, a computational expensive CNV detection step
is performed prior to the association testing when applying strategy S2. In the
presented example for the phenotype obesity, the academically developed software
tool ’PennCNV’ was used in the CNV identification step. Compared to alternative
software programs, this HMM based program was previously shown to perform
comparably well in detecting CNVs from SNP genotyping array data (Winchester
et al., 2009; Koike et al., 2011). As outlined in chapter 3.2, there is currently no
consensus on the optimal choice of an algorithm or software for estimating individual
CNV events with reliable accuracy. When following recent recommendations of
using a second algorithm on a single data set to increase confidence in the CNV
data (Winchester et al., 2009), the complexity and computing efforts of strategy S2
would even considerably be extended. However, in filtering CNVs by calling results
from a second CNV calling software tool it would even become less likely to list all
CNVs in a sample. Of note, no CNV tested for an association in strategy S2 can be
taken for sure without separate biological validation or replication.
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3.7 Application of Strategy S2 to the Phenotype
ADHD on rare CNVs
With a worldwide-pooled prevalence of 5.2% (Polanczyk et al., 2007), attention -
deficit / hyperactivity disorder (ADHD) represents one of the most common psy-
chiatric disorders in children and adolescents. Although twin studies on ADHD in
children and adolescents indicate a strong genetic component with heritability es-
timates around 75% (Freitag et al., 2010), neither genome-wide association studies
nor large scale meta-analyses of GWASs have so far identified potential causal SNP
variants (Hinney et al., 2011).
Conversely, genome-wide analyses of CNVs provide evidence that several CNVs
might be associated with ADHD in children and adolescents (Elia et al., 2010;
Williams et al., 2010; Lesch et al., 2011; Lionel et al., 2011). Especially large
(> 500 kb), rare (< 1% frequency) CNVs were found with an increased rate in
ADHD patients compared to healthy controls. More precisely, rare CNVs identified
in children with ADHD were found to be preferentially located in several candi-
date regions, such as in the chromosome 16p13.11 region, along the NPY and the
CHRNA7 gene (at chr 15q13.3), in metabotropic glutamate receptor genes or in
several neurodevelopmental genes, that is in genes reported as candidates in other
neuropsychiatric disorders, such as schizophrenia, Parkinson disease or autism.
With regard to the mentioned previous findings, a genome-wide CNV association
study was performed by investigating the hypothesis of ’common disease - many
rare variants’ (Mayo, 2007). Thus, contrary to the previous chapters that aimed to
identify common CNVs with association effect to the trait obesity, the focus of this
chapter will be on the genome-wide association analysis of rare CNVs with respect
to the binary trait ADHD. As in the previous chapter, genome-wide raw CNV data
will be analysed in application of strategy S2. Parts of the genetic results of this
chapter have been published in Jarick et al. (2012).
3.7.1 Data Set
GWAS discovery sample.
In the discovery step, an available case-control GWAS sample of 489 ADHD pa-
tients and 1 285 population-based controls with high quality data was considered.
All GWAS cases were previously assessed for the diagnosis ADHD according to
DSM-IV (American-Psychiatric-Association, 1994) by the Department of Child and
Adolescent Psychiatry of the University of Duisburg-Essen. The ADHD patients
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are all German minors, who were recruited and phenotypically characterized in six
psychiatric outpatient units for children and adolescents (Aachen, Cologne, Essen,
Marburg, Regensburg and Wu¨rzburg). Details on the corresponding ADHD sub-
types and basic characteristics are given in Jarick et al. (2012) (Table 1).
Additionally, the GWAS discovery sample consists of 1 285 adult controls that
were not screened for ADHD, and that were previously drawn from three German
population-based epidemiological studies in adults: (i) the Heinz Nixdorf RECALL
(Risk Factors, Evaluation of Coronary Calcification, and Lifestyle) study (Schmer-
mund et al., 2002) (n = 383), (ii) PopGen (Krawczak et al., 2006) (n = 490) and (iii)
KORA (Wichmann et al., 2005) (n = 488). The recruitment areas were Western
Germany (Essen, Bochum and Mu¨hlheim) for (i), Nothern Germany (Schleswig-
Holstein) for (ii) and Southern Germany (Augsburg) for (iii), respectively. The
percentage of male GWAS controls was considerably smaller than the percentage of
male GWAS ADHD cases (cases: 81.0% males, controls: 50.7% males). Moreover,
GWAS controls were older than GWAS ADHD cases (age range cases: 6− 18 years,
controls: 25 − 75 years). Details on phenotypical characteristics can be found in
Jarick et al. (2012), Table 1.
Genome-wide genotyping of the GWAS discovery sample was performed on the
Illumina HumanHap550v3 for the controls group and on the Illumina Human660W-
Quadv1 Bead Arrays for the cases group by (i) Illumina customer service, San
Diego, CA, USA (all PopGen controls), (ii) the Department of Genomics, Life &
Brain Center, University of Bonn, Germany (all ADHD cases and Heinz Nixdorf
RECALL study controls) and (iii) the Helmholtz Center of Munich, Germany (all
KORA controls). All subjects of both groups met our stringent pre- and post-calling
quality control (QC) criteria (for details see the following Methods section and the
Supplementary Text of Jarick et al. (2012)).
Replication sample.
For replication analyses of the findings from the GWAS discovery sample, a second
available independent ADHD case-control sample consisting of 386 young German
ADHD patients and 781 German population-based healthy young controls with high
quality data was considered. The cases of the replication sample were previously
recruited and phenotypically characterized in two outpatient clinics by and at the
Departments of Child and Adolescent Psychiatry, Psychosomatic and Psychother-
apy of the Universities of Homburg and Wu¨rzburg (Germany). In this context, an
ADHD diagnosis was determined for all patients of the replication sample. Patients
were only included here, if they were diagnosed with ADHD according to DSM-
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IV (American-Psychiatric-Association, 1994), subtypes and basic characteristics are
given in Jarick et al. (2012) (Table 1). Core descriptive statistics, such as the per-
centage of males (83.7%) or the age range (6− 19 years) were comparable to those
of the ADHD GWAS discovery sample.
In addition, a total of 1 063 controls were chosen from available data sets of two
ongoing German population-based prospective birth cohorts: (i) the influence of
Life-style factors on the Immune System and Allergies Plus environment and ge-
netics (LISAplus) study (Zutavern et al., 2006) and (ii) the German Infant study
on the influence of Nutrition Intervention Plus environment and genetics (GINI-
plus) study (Berg et al., 2010). Briefly, the two birth cohorts consist of healthy
full-term newborns, who were recruited between September 1995 and January 1999
in Munich, Wesel, Leipzig and Bad Honnef, and who were follow-up until the age
of ten. A detailed description of screening and recruitment has been provided else-
where (Zutavern et al., 2006; Berg et al., 2010). Any control probands, for whom
no questionnaire information was available (n = 111) or who were not previously
categorized as being in the normal range at the age of ten on the Strengths and
Difficulties Questionnaire on the scales for hyperactivity / inattention as well as
on the total difficulties scale (n = 118), were excluded from replication analyses (n
= 229) (for details see Jarick et al. (2012), Table 1).
For all subjects of the replication sample, ADHD cases and controls, genome-
wide genotyping data of the Affymetrix Genome-Wide Human SNP Array 5.0 was
available. Similarly to the ADHD GWAS discovery sample, all analysed subjects of
the replication sample met stringent pre- and post calling QC criteria (for details see
the following Methods section and the Supplementary Text of Jarick et al. (2012)).
3.7.2 Methods
CNV calling
Prior to any CNV analyses, a standard SNP-based QC procedure was applied to
each recruited ADHD patient (n = 504) and control subject (n = 1 361) of the
GWAS discovery sample. The cases and controls group of the GWAS discovery
sample separately passed this pre-calling QC protocol, which accounts for: i) the
genotyping quality, by claiming a SNP call rate > 97% for each individual, ii)
the exclusion of subjects with discrepant sex status with regard to X-chromosomal
heterozygosity rates, iii) the exclusion of cryptically related subjects, i.e. those with
identical-by-state (IBS) values > 1.65 and iv) population stratification. Nine ADHD
patients and 61 controls were excluded in the course of this first QC step.
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CNV detection was based on those 535 364 autosomal SNPs, which are common
to the Illumina HumanHap550v3 (controls group) and the Illumina Human660W-
Quadv1 Bead Arrays (cases group) genotyping chip. CNVs were called in applica-
tion of the PennCNV software (Wang et al., 2007) by use of default parameters.
Afterwards, samples with low CNV genotyping quality were excluded based on the
following two post-calling QC criteria: i) a high standard deviation (sd) in genome-
wide hybridization intensity levels, i.e. sd(LRR) > 0.3 or ii) an implausibly high
number of CNVs, i.e. more than 90 CNV calls. Six ADHD patients and 15 con-
trol subjects were excluded in the course of this second QC step. Moreover, CNVs
with low expected recovery rates were excluded. Following former recommendations
for the applied genotyping chips (Williams et al., 2010), the following CNVs were
excluded: i) CNVs spanning less than 15 consecutive informative SNPs, ii) CNVs
spanning known gaps of at least 200 kb in the SNP array by more than half of
their lenght, and iii) CNVs in known segmental duplications present in the March
2006 human reference genome according to the Segmental Duplication DataBase
(http://humanparalogy.gs.washington.edu/build36/build36.htm.). It is often ob-
served that large CNVs are splitted into several CNV calls in application of CNV
calling algorithms. Thus, iv) two individual adjacent CNV calls with size > 200
kb and distance smaller than half of their entire length were merged into one CNV
after appropriate visual evaluation of SNP-wise values.
Association testing
For association analyses, only rare CNV calls were investigated, that is only CNV
calls with sample frequency ≤ 1% for at least half of their length spanned regions.
At each CNV locus, the hypothesis of an increased CNV frequency in ADHD cases
compared with the CNV frequency in control subjects was tested by use of one-sided
Fisher’s exact tests. Additionally, the stratified hypotheses according to CNV type,
that is an over-representation of deletions or duplications in cases versus controls,
were tested. In order to avoid redundancies, association testing was limited to the
set of unique CNV’s start and end sites. Thus, overlapping CNVs were merged
into several CNV containing regions (CNVRs), and each CNVR was devided into
several sub-CNVRs, which are defined by the start and end positions of the involved
individual CNVs (see Figure 6.7 for details). Genome-wide significance of each tested
site was assessed via the permutation approach. That is, the genome-wide null
hypothesis of no association of any CNV with ADHD was simulated by repeatedly (n
= 100 000) permuting the individual’s affection status and simultaneously preserving
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the CNV’s correlation structure. All statistical testing analyses were performed by
use of the PLINK software (Purcell et al., 2007).
CNV validation and replication analyses
For the PARK2 locus, for which CNVs were observed to be significantly associ-
ated with ADHD, qPCR experiments (TaqMan CNV assy HS03615859 cn at chr 6:
162 696 897 ± 50 bp, HCBI36/hg 18) to validate individual CNV states were per-
formed by (i) the Department of Child and Adolescent Psychiatry of the University
of Duisburg-Essen (GWAS cases) and (ii) the Department of Genomics, Life & Brain
of the University of Bonn (HNR controls). Copy number states were determined
for each individual for whom DNA was available, that is for GWAS cases and for a
relevant subset of HNR controls (see Jarick et al. (2012) for details). Subsequently,
genome-wide association testing was repeated on the basis of qPCR validated CNVs.
Moreover, the CNVR that showed statistically significant association in the GWAS
discovery sample (at the PARK2 locus), underwent follow-up analyses in the repli-
cation sample. Compared to the GWAS discovery sample, similar pre-calling and
identical post-calling QC criteria were applied to all recruited ADHD patients (n
= 461) and to all healthy control samples (n = 834) of the replication sample. In
more detail, only individuals with i) a SNP call rate < 95% and ii) no disrepant
sex status according to X-chromosomeal heterozygosity rates were considered in the
CNV calling step (cases: n = 421, controls = 814). Based on PennCNV’s CNV call-
ing, individuals with i) sd(LRR) > 0.3 or ii) more than 90 CNV calls were excluded
from the association testing step (cases: n = 35, controls = 33). Association testing
in the replication sample was performed analogously to the GWAS discovery sample
at sites, which were defined by CNV calls of individuals from the replication sample.
3.7.3 Results
In the 489 ADHD patients and 1 285 control subjects of the GWAS discovery sample,
a total of 2 432 rare CNVs of high quality were identified (cases: n = 592, controls:
n = 1 840). On average, each ADHD patient showed 1.2 rare CNVs with an average
size of 226.3 kb (range: 9.3− 2 830.8 kb) and each control subject was estimated to
carry 1.4 rare CNVs with an average size of 186.4 kb (range: 5.6− 4 479.6 kb).
There were no sex specific differences in genome-wide CNV rates between cases
and controls (data not shown). Moreover, there was no evidence for a genome-wide
burden of rare CNVs in ADHD patients compared to control subjects (for details
see Jarick et al. (2012)).
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Figure 3.7: Manhattan plot for the genome-wide analysis of rare CNVs in 489
ADHD patients and 1 285 control subjects. Nominal one-sided p-values
of Fisher’s exact tests are presented. Genome-wide statistically signifi-
cantly associated sites are circled.
Table 3.7: CNVs at the PARK2 locus in the ADHD GWAS discovery sample.
Proband’s
ID
Proband’s
Status called CNV
CNV
call’s
state
qPCR
CNV
state
control 1 control subject chr 6: 162 379 561− 162 903 833 cn = 1 cn = 1
case 1 ADHD patient chr 6: 162 477 709− 162 724 935 cn = 1 cn = 1
control 2 control subject chr 6: 162 554 327− 162 659 755 cn = 1 DNA not available
control 3 control subject chr 6: 162 594 083− 163 001 802 cn = 3 DNA not available
case 2 ADHD patient chr 6: 162 629 938− 162 935 269 cn = 3 cn = 3
case 3 ADHD patient chr 6: 162 637 688− 162 809 965 cn = 3 cn = 3
case 4 ADHD patient chr 6: 162 644 237− 162 834 976 cn = 3 cn = 2
case 5 ADHD patient chr 6: 162 644 237− 162 834 976 cn = 3 cn = 3
case 6 ADHD patient chr 6: 162 644 237− 162 829 925 cn = 3 cn = 3
case 7 ADHD patient chr 6: 162 644 237− 162 829 925 cn = 3 cn = 3
case 8 ADHD patient chr 6: 162 644 237− 162 834 976 cn = 3 cn = 3
case 9 ADHD patient chr 6: 162 644 237− 162 829 925 cn = 3 cn = 3
case 10 ADHD patient chr 6: 162 674 596− 162 834 976 cn = 3 cn = 3
case 11 ADHD patient chr 6: 162 687 672− 162 896 029 cn = 1 cn = 1
case 12 ADHD patient chr 6: 162 687 672− 162 789 187 cn = 1 cn = 1
control 4 control subject chr 6: 162 719 107− 162 965 453 cn = 3 DNA not available
control 5 control subject chr 6: 162 740 072− 162 805 539 cn = 1 DNA not available
control 6 control subject chr 6: 162 767 020− 162 903 833 cn = 1 DNA not available
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Figure 3.8: Association test results at the PARK2 locus in the ADHD GWAS dis-
covery and replication sample. Individual CNV calls are presented in
the lower parts of panel A and B. black: heterozygous deletions, purple:
hemizygous duplications, filled: in ADHD patients, unfilled: in control
subjects. One-sided p-values of Fisher’s exact tests are depicted in the
upper parts of panel A and B. green: CNVs, blue: deletions, red: du-
plications. A) Genome-wide corrected empirical p-values are shown. B)
Nominal p-values are shown. The shaded region highlights the genomic
region with genome-wide statistically significant association test results
(i.e. p < 0.05) in the discovery sample.
Table 3.8: CNVs at the PARK2 locus in the ADHD replication sample.
Proband’s
ID
Proband’s
Status called CNV
CNV
call’s
state
qPCR
CNV
state
control a control subject chr 6: 162 636 295− 162 834 267 cn = 3 DNA not available
case a ADHD patient chr 6: 162 636 295− 162 832 504 cn = 3 DNA not available
case b ADHD patient chr 6: 162 651 333− 162 800 484 cn = 1 DNA not available
case c ADHD patient chr 6: 162 665 597− 162 745 876 cn = 3 DNA not available
case d ADHD patient chr 6: 162 710 468− 162 800 484 cn = 1 DNA not available
control b control subject chr 6: 162 816 996− 162 884 672 cn = 1 DNA not available
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Table 3.9: Association test results at the PARK2 locus in the ADHD GWAS discovery and replication sample. (red: p < 0.05)
Discovery Sample Replication Sample
sub-CNVR on chr 6
cases
DELs
//
DUPsa
controls
DELs
//
DUPsa
EMP1
CNVsb
EMP2
CNVsc
EMP1
DELsb
EMP2
DELsc
EMP1
DUPsb
EMP2
DUPsc
cases
DELs
//
DUPsa
controls
DELs
//
DUPsa
EMP1
CNVsb
EMP1
DELsb
EMP1
DUPsb
162 636 295− 162 644 236 1 // 2 2 // 1 0.2107 1.0000 0.6200 1.0000 0.1862 1.0000 0 // 1 0 // 1 0.5527 1.0000 0.5545
162 644 237− 162 651 332 1 // 8 2 // 1 7.40E-04 0.0781 0.6200 1.0000 1.40E-04 0.0075 0 // 1 0 // 1 0.5527 1.0000 0.5545
162 651 333− 162 659 755 1 // 8 2 // 1 7.40E-04 0.0781 0.6200 1.0000 1.40E-04 0.0075 1 // 1 0 // 1 0.2545 0.3300 0.5545
162 659 756− 162 665 596 1 // 8 1 // 1 1.80E-04 0.0179 0.4737 1.0000 1.40E-04 0.0075 1 // 1 0 // 1 0.2545 0.3300 0.5545
162 665 597− 162 674 595 1 // 8 1 // 1 1.80E-04 0.0179 0.4737 1.0000 1.40E-04 0.0075 1 // 2 0 // 1 0.1078 0.3300 0.2577
162 674 596− 162 687 671 1 // 9 1 // 1 5.00E-05 0.0050 0.4737 1.0000 3.00E-05 0.0019 1 // 2 0 // 1 0.1078 0.3300 0.2577
162 687 672− 162 710 467 3 // 9 1 // 1 1.00E-05 2.80E-04 0.0647 1.0000 3.00E-05 0.0019 1 // 2 0 // 1 0.1078 0.3300 0.2577
162 710 468− 162 719 106 3 // 9 1 // 1 1.00E-05 2.80E-04 0.0647 1.0000 3.00E-05 0.0019 2 // 2 0 // 1 0.0431 0.1084 0.2577
162 719 107− 162 724 935 3 // 9 1 // 2 3.00E-05 0.0026 0.0647 1.0000 2.60E-04 0.0098 2 // 2 0 // 1 0.0431 0.1084 0.2577
162 724 936− 162 740 071 2 // 9 1 // 2 1.50E-04 0.0103 0.1841 1.0000 2.60E-04 0.0098 2 // 2 0 // 1 0.0431 0.1084 0.2577
162 740 072− 162 745 876 2 // 9 2 // 2 3.00E-04 0.0219 0.3033 1.0000 2.60E-04 0.0098 2 // 2 0 // 1 0.0431 0.1084 0.2577
162 745 877− 162 767 019 2 // 9 2 // 2 3.00E-04 0.0219 0.3033 1.0000 2.60E-04 0.0098 2 // 1 0 // 1 0.1088 0.1084 0.5545
162 767 020− 162 789 187 2 // 9 3 // 2 6.80E-04 0.0697 0.4187 1.0000 2.60E-04 0.0098 2 // 1 0 // 1 0.1088 0.1084 0.5545
162 789 188− 162 800 484 1 // 9 3 // 2 1.79E-03 0.2351 1.0000 1.0000 2.60E-04 0.0098 2 // 1 0 // 1 0.1088 0.1084 0.5545
162 800 485− 162 805 539 1 // 9 3 // 2 1.79E-03 0.2351 1.0000 1.0000 2.60E-04 0.0098 0 // 1 0 // 1 0.5527 1.0000 0.5545
162 805 540− 162 809 965 1 // 9 2 // 2 8.00E-04 0.0804 0.6200 1.0000 2.60E-04 0.0098 0 // 1 0 // 1 0.5527 1.0000 0.5545
162 809 966− 162 816 995 1 // 8 2 // 2 0.0021 0.2682 0.6200 1.0000 7.40E-04 0.0388 0 // 1 0 // 1 0.5527 1.0000 0.5545
162 816 996− 162 829 925 1 // 8 2 // 2 2.13E-03 0.2682 0.6200 1.0000 7.40E-04 0.0388 0 // 1 1 // 1 0.7003 1.0000 0.5545
162 829 926− 162 832 503 1 // 5 2 // 2 0.0311 0.9983 0.6200 1.0000 0.0199 0.9375 0 // 1 1 // 1 0.7003 1.0000 0.5545
a DELs: deletions, DUPs: duplications.
b EMP1: nominal one-sided p-value of Fisher’s exact test, based on comparing the CNV frequency in cases versus controls.
c EMP1: nominal one-sided p-value of Fisher’s exact test, based on comparing the frequency of CNVs, deletions or duplications in cases versus controls.
d EMP2: genome-wide corrected empirical (based on 100 000 permutations) one-sided p-value of Fisher’s exact test, based on comparing the frequency
of CNVs, deletions or duplications in cases versus controls.
44
3.7 Application of Strategy S2 to the Phenotype ADHD on rare CNVs
Association tests were performed at 3 964 genomic CNV sites, which represented
1 083 non-overlapping CNVRs (Figure 3.7). Only one CNVR, at chr 6: 162 659 756−
162 829 925 within the PARK2 gene (called PARK2 locus in the following), showed
genome-wide statistically significant association test results (Figure 3.8, Table 3.9).
On the one hand, there was a statistically significant over-representation of CNVs,
including deletions and duplications, at the PARK2 locus in ADHD patients com-
pared to controls (minimal genome-wide corrected empirical one-sided p-value =
2.8× 10−4).
On the other hand, association tests stratified by CNV type revealed that this
association effect was mainly driven by an over-representation of duplications in
ADHD cases versus controls (minimal genome-wide corrected empirical one-sided
p-value, deletions: p = 1, duplications: p = 0.0019). In total, this locus was covered
by twelve CNVs of ADHD patients (three deletions and nine duplications) and six
CNVs of control subjects (four deletions and two duplications) (Table 3.7).
At the PARK2 locus, individual copy number states of the GWAS discovery
sample were re-evaluated by use of qPCR experiments. With the exception of one
ADHD case’s duplication, each array-based CNV call could be technically validated.
Subsequent genome-wide re-analysis did not meaningfully change association test
results (for details see Jarick et al. (2012)).
For follow-up analyses, an independent sample of 386 ADHD patients and 781
healthy control subjects was examined. The finding of an association of CNVs at
the PARK2 locus with the trait ADHD was confirmed in the replication analyses
with statistical significance (minimal nominal one-sided p-value = 0.043) (Figure
3.8, Table 3.9). At the PARK2 locus, a total of four CNVs (two deletions and
two duplications) were observed in ADHD patients compared with two CNVs (one
deletion and one duplication) in control subjects of the replication sample (Table
3.8).
3.7.4 Discussion
A statistically genome-wide significant association of CNVs, including both deletions
and duplications, at the PARK2 locus could be detected in application of strategy
S2 for the genome-wide analysis of rare CNVs to an ADHD case-control sample.
This finding was technically validated by use of qPCR and it was additionally con-
firmed by statistically significant association test results in replication analyses of
an independent ADHD case-control sample. QPCR validation experiments demon-
strated that array-derived rare CNV calls were estimated with low false negative
and low false positive rates at the PARK2 locus.
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Due to the focus on rare CNVs, strategy S1, which does not provide any possibility
to filter CNV signals based on their population frequency, is not applicable to the
data example for the trait ADHD. The main emphasis of strategy S2 is to ensure
validity of CNV calls. Concerning the ADHD data set, additional pre-processing
steps were necessary prior to CNV calling due to the fact that differing genotyping
chips were used for ADHD patients and control subjects. In this sense, the whole
analysis was limited to the intersecting set of probe sets between both SNP arrays,
and conservative quality control criteria were applied.
With additional regard to the previous application to the phenotype obesity, taken
together, strategy S2 has proven to be a flexible and versatilely usable strategy for
the genome-wide analysis of both, rare and common CNVs. Compared to strategy
S1, the additional CNV calling step might on the one hand be challenging, depending
on how comparable the initial raw data was ascertained across the study subjects,
and with regard to a lack of CNV calling tools with perfect validity. However,
based on results of the CNV detection step CNV association testing may on the
other hand be performed more focused on the respective type of CNVs being most
probably causal for the trait of interest.
At least in case of rare CNVs being called for ADHD patients and control subjects
at the PARK2 locus, it was shown that rare CNVs can be called with high validity
based on SNP genotyping data. This is in concordance with previous reports that
evaluated the performance of several software suites in the identification of CNVs
with a special focus on potential differences between different CNV types according
to their population frequency. Zhang et al. (2011) found that the recovery rates of
CNVs consistently increases with decreasing underlying CNV frequency throughout
all investigates software tools, although to differing degrees. Moreover, Zhang et al.
(2011) observed that rare CNV calls were less likely to be affected by technical biases,
such as plate effects, in comparison to common CNV calls. The latter study even
concludes that common CNV calls being derived from applying any CNV calling
software to array data are not suitable for association studies without independent
experimental genotyping. In contrast, rare CNVs are of substantial better quality.
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4 Two Proposed Strategies for
Genome-Wide CNV Association
Analyses
Genome-wide association analyses of CNVs, based on raw CNV intensity data de-
rived from SNP array experiments, involve complex analyses strategies. As touched
upon in the previous chapter, modification of any single analysis step may greatly
influence association test results. In this chapter, two new strategies for genome-
wide association analyses of raw CNV data are briefly presented. Both strategies,
PS1 and PS2, are characterized in more detail in the following two chapters.
The key aspects of the two new strategies, PS1 and PS2, are graphically illustrated
in Figure 4.1 and outlined in Table 4.1. In each of the two proposed strategies, one
single analysis step is modified relative to the standard CNV analyses strategies S1
and S2 (Table 3.5), while the remaining steps are performed in an unmodified way.
Table 4.1: Two proposed strategies for genome-wide analyses of raw CNV data.
Strategy PS1 Strategy PS2
Statistical testing is
based on ...
individual raw copy num-
ber values of CNV probe
sets being located in pre-
determined CNV regions.
individual CNVs that are
called by use of sophisti-
cated reference models.
Statistical tests are
performed at ...
CNV probe sets in pre-
determined CNV regions.
any genomic region offer-
ing at least one CNV.
The number of
tests performed
equals the ...
number of CNV probe sets
in pre-determined CNV
regions.
number CNV regions.
The proposed
strategy is different
to ..
strategy S1, in the way
that markers for statistical
testing are selected.
strategy S2, in the way
that CNVs are called.
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Figure 4.1: Schematic representation of the two proposed strategies, PS1 (blue) and
PS2 (red), for genome-wide CNV analyses.
Compared to strategy S1, strategy PS1 incorporates a refinement on the selection
of genetic markers to be tested for an association. In both strategies, S1 and PS1, as-
sociation testing is performed directly on the basis of pre-processed intensity signals
without classifying them into discrete copy number states. As illustrated in section
3.5, this procedure results in testing thousands of probe sets without biological di-
versity of copy number. This will not only artificially inflate the amount of multiple
testing, but at the same time unnecessarily increase the probability for false positive
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findings without biological plausibility. Instead, strategy PS1 restricts association
testing on those probe sets that offer a minimal copy number variability with regard
to estimates in the analysed sample or to public database entries. For the determina-
tion of relevant probe sets in copy number variable regions, a simplified CNV calling
might be performed aiming to assess the potential range of probe-specific copy num-
ber variability. Otherwise, public databases such as the Database of Genomic Vari-
ants (DGV, http://projects.tcag.ca/variation/) or the Human Genome Structural
Variation Project (http://humanparalogy.gs.washington.edu/structuralvariation/)
may be helpful in the probe set selection step. The decision of CNVs to be or not to
be called in the data set of interest should depend on the underlying hypothesis of
interest, i.e. the ’rare disease - rare variant’, the ’common disease - common variant’
or the ’common disease - many rare variants’ hypothesis (Mayo, 2007). Common
CNVs with a population frequency above five percent will likely be recognized in
public databases, which reflect CNV mapping results of several previous studies.
However, CNVs with lower frequency that may even be specific to the phenotypic
trait of interest might be missed without a sample-specific CNV identification.
Alternatively, strategy PS2 focuses on a modified procedure of the CNV genotype
calling step. In more detail, sample-specific copy number neutral reference intensity
values that are the basis of CNV calling are estimated in fitting a Gaussian mixture
model to the observed hybridization intensity data at each available informative
probe set. This approach is motivated by the observation that the widespread use
of median probe-wise reference intensity values offers the risk of potential CNV
misclassifications. It will be demonstrated that the burdensome procedure of deter-
mining sophisticated reference intensity values provides benefits in terms of stability,
reproducibility, false positive and Mendelian inconsistency rates of CNV calls. An
improved accurateness of CNV detection insures a higher reliability of subsequently
performed association tests.
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5 Strategy PS1: Association Testing
Based on Copy Number Variation
Signals
As outlined in the previous chapters, changing single parts of a CNV analysis strat-
egy may remarkable influence association test results. The design of a whole genome-
wide CNV association analysis may have an influence on both, the risk of false
positive and false negative findings.
In this chapter, we will focus on how to select array probe sets for inclusion in
association tests when genome-wide testing is based on pre-processed continuously
distributed intensity values, which are an indirect measure of individual copy num-
ber states. First, the proposed analyses strategy PS1 will be introduced by giving
a general overview of the new methodical aspects in comparison to strategy S1.
Afterwards, key aspects concerning statistical association testing will be presented
in detail for the case-control and the family-based analyses designs. Finally, the
practical application of strategy PS1 on a real data example for the trait obesity
is given. Exactly the same obesity data set that has previously been investigated
by use of the two standard strategies, S1 and S2, will be re-analysed by applying
strategy PS1 and potential benefits and disadvantages will be discussed based on
this example.
5.1 Strategy PS1
When applying strategy S2 or PS2, one of the first steps of a genome-wide CNV
analysis is the estimation of individual CNVs. Subsequently, genome-wide associ-
ation testing is based on the obtained CNV calls. Thus, the number of tests to
perform in a genome-wide analysis is given by the number of genomic regions that
contain CNV calls. Contrarily, the CNV calling step is skipped when strategy S1
or PS1 is implemented. Instead, genome-wide association testing is based on pre-
processed hybridization intensity data that have not been categorized into discrete
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copy number classes, but are positively correlated with individual CNV states. Since
in application of strategy S1 there is no CNV classification available at all for any
of the CNV markers, each available CNV probe set is tested for an association with
the phenotype of interest irrespective of whether it is biologically plausible, that is
whether or not the probe set reflects an underlying CNV.
One disadvantage of strategy S1 is that significant association test results due to
potential noisy data in genomic regions, which are in fact free of copy number vari-
ability, cannot be distinguished from significant findings in truly associated CNV
Figure 5.1: Schematic representation of the proposed CNV analyses strategy PS1.
51
5.1 Strategy PS1
regions. False positive association test results in genomic regions without CNV ap-
pearance can only be recognized as such in the final validation step. Additionally,
several association tests are performed for markers in regions where the null hy-
pothesis of no association can in fact not be rejected due to missing copy number
variability of the region. This enrichment of null markers artificially exacerbates the
multiple testing problem. Furthermore, performing the greatest possible number of
tests involves many perfectly correlated tests for probe sets in the same CNV.
As shown in Figure 5.1, the proposed CNV analysis strategy PS1 includes one
additional step in comparison to strategy S1. Prior to the association testing step,
a subset of markers is selected for association testing. In this inserted step, markers
may on the one hand be selected based on information of public CNV catalogues,
such as the DGV (Database of Genomic Variants, http://projects.tcag.ca/varia
tion/). As illustrated in Figure 5.1, sample-specific CNV information that result
from a minimalistic CNV calling step may alternatively be considered. In short, the
marker selection step aims to identify most informative probe sets for association
analyses.
Let information for a total of p probe sets be available for CNV analyses from
array experiments in a sample that comprises n individuals. Let r denote the number
of CNV containing genomic regions, where each region i (i = 1, . . . , r) involves vi
probe sets, and in total w =
∑r
i=1 vi probe sets reflect true underlying copy number
variability. Thus, the subset of probe sets
{s1, . . . , sw} ⊂ {1, . . . , p} with w =
r∑
i=1
vi < p,
which are informative for association testing, is given by the condition that
|{z | (z ≤ n) ∧ ( individual z has a CNV at probe set sj)}|
n
> , (5.1)
for all sj (j = 1, . . . , w), where  > 0 is a pre-specified threshold for the assumed
minimal copy number variability of each CNV region. To check which of the p array
probe sets satisfy condition (5.1), either a sample-wide CNV calling may be applied
or alternatively  may be estimated from publicly available databases.
Finally, the global null hypothesis
H0 : no association between any {sj | sj satisfying condition (5.1) } with disease
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is tested against the alternative hypothesis
HA : at least one {sj | sj satisfying condition (5.1) } is associated with disease,
where the form of the single test statistic depends on the specific sample design.
Hence, for rejecting any single null hypothesis at the probe level multiple testing
procedures, which control the family-wise error rate (FWER) with respect to the
set of null hypotheses determined above, have to be considered.
5.1.1 Case-Control Designs
For CNV analyses, we assume to have pre-processed hybridization signal intensity
values available for a total of p probe sets in a sample comprising n individuals. In a
case-control design, intensity signals of na affected cases and nu healthy controls are
compared at each probe set in order to detect genomic regions that are associated
with disease. Let
xi = (xi1, . . . , xip) with i = 1, . . . , n
denote the n = na+nu vectors of observed individual pre-processed probe hybridiza-
tion intensity signals.
5.1.1.1 The Logistic Regression Model for Raw CNV Data
For a case-control CNV association study, the objective is to compare the presence
of certain CNVs between cases and controls in order to find association between
the respective CNV and the disease or trait of interest. When association testing
is based on pre-processed hybridization signal intensity values, counting and com-
paring the different types of CNVs between both groups is not feasible. Instead,
the relationship between the indirect CNV measurement of hybridization intensities
and individual disease affection status is most frequently explored in the context of
a logistic regression model.
Suppose that two mutually exclusive disease groups are defined and let the devel-
opment of the disease during a defined accession period be described by a Bernoulli
random variable with values of 0 (= unaffected) and 1 (= affected). Suppose that
the probability of developing the disease or trait of interest is specific to each in-
dividual and largely dependent on the individual’s genetic information. This is in
concordance with a case-control sample that was especially designed to describe the
relationship between the binary affection status and explanatory genetic variants.
In this special genetic case-control design all recruited individuals are either healthy
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or sick, and in particular they are all genetically unrelated, that is any relatives are
excluded in order to explore the influence of genetic variants on the disease status.
Concerning raw CNV data, before grouping CNV probe sets in the CNV calling
step into subsets, which make up CNVs or CNV regions, each available array probe
set is initially assumed to independently contribute to the individuals’ phenotypes.
Consequently, a separate logistic regression model is developed for each available CN
probe set. Hence, for each probe set k = 1, . . . , p, the disease affection status of the
n independent individuals of the above described case-control sample can formally
be described as a vector of n independent Bernoulli random variables
Y = (Y1, . . . , Yn) with Yi ∼ B(1,piik) for i = 1, . . . , n.
That is, each random variable Yi can either have values of 1 or 0, which stands
for the presence or absence of the disease, with probabilities of piik and 1 − piik,
respectively.
In a prospective study in which initially healthy individuals are followed through-
out the accession period to observe disease incidence, the probability for the i-th
individual of having developed the trait of interest with respect to the underlying
intensity information for the k-th probe set would equal P(Yi = 1|xik) = piik. For
each available probe set k = 1, . . . , p, the expected value of the individual affection
status, E(Yi|xik) = piik, would then be assumed to depend on the observed intensity
signal xik in the following form
E(Yi|xik) = F (β0k + β1kxik) with β0k, β1k ∈ R, (5.2)
where F (.) denotes the logistic distribution function of the presumed Logit model
F (z) =
ez
1 + ez
.
In other words, a generalized linear model (GLM) given by equation (5.2) with
logit link function F−1(z) = logit(z) = ln( z
1−z ) is assumed. Then, the odds of
being affected with respect to observed intensities at probe set k = 1, . . . , p can
equivalently be expressed as
P(Yi = 1|xik)
1− P(Yi = 1|xik) = e
β0k+β1kxik .
Consequently,
P(Yi = 1|xik)
P(Yi = 0|xik)
/
P(Yi = 1|xik0)
P(Yi = 0|xik0)
= eβ1k(xik−xik0 ). (5.3)
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equals the odds ratio for being affected (Yi = 1) for an individual with genetic
characteristic xik, relative to that for an individual with some standard genetic
regression variable xik0 .
Contrarily, a case-control study involves direct sampling from P(xik|Yi). Since
P(xik|Yi) does not completely determine P(Yi|xik), the full prospective model cannot
be estimated from case-control data alone. However, under the assumption that the
selection of cases and controls is independent of covariate values and with regard to
the Bayes’ theorem
P(Yi|xik) = P(xik|Yi)P(Yi)P(xik) ,
the odds ratios (5.3) can equivalently be written as
eβ1k(xik−xik0 ) =
P(xik|Yi = 1)
P(xik0|Yi = 1)
/
P(xik|Yi = 0)
P(xik0|Yi = 0)
.
It follows that the odds ratio (5.3) can be estimated from case-control data. Pren-
tice and Pyke (1979) have shown that through assuming a prospective logistic model
(5.2), maximum likelihood estimates from all regression coefficients except for the
constant term can be obtained by ignoring the case-control scheme, i.e. the case-
control problem can be treated as a prospective one. Thus, although logistic model-
ing is likewise applicable to retrospective case-control studies, there is one important
limitation. For case-control studies, the fitted logistic model cannot be used to pre-
dict risk for an individual with specified independent variables.
For a case-control CNV association study based on raw hybridization signal inten-
sity values, the logistic regression coefficients β1k are separately estimated for each
probe set k = 1, . . . , p. Subsequently, the hypotheses
H0 : β1k = 0 versus HA : β1k 6= 0 for k = 1, . . . , p
are tested. Prentice and Pyke (1979) have shown that maximum likelihood estimates
(MLEs) obtained by pretending that the case-control data resulted from a prospec-
tive study have the usual properties associated with MLEs. Specifically, they are
asymptotically normally distributed for large sample sizes, and thus the Wald test is
frequently applied in the testing step. Alternatively, two asymptotically equivalent
tests can be applied to the total model: the likelihood ratio test or the score test,
which is presented for the family-based design in chapter 5.1.2. However, the lat-
ter likelihood ratio techniques are not technically correct in the underlying situation
since the likelihood function is based on an incorrect model, i.e. a prospective model
for an retrospective sampling scheme.
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5.1.1.2 Multi-Marker Logistic Regression CNV Models
For the univariate model presented above, the complex logistic regression framework
would not necessarily be needed. The comparison of one continuously distributed
explanatory variable between the two differently exposed groups could be performed
in a more simple way by use of the unpaired t-test given that normality holds or
otherwise by use of the non-parametric Mann-Whitney test. However, the logistic
regression model offers the advantage that modifications and extensions can flexibly
be implemented. For example, the impact of several additional explanatory covari-
ates like age or sex, denoted by a = (ai, . . . , an) and b = (b1, . . . , bn), can easily be
incorporated in the following way
ln
(
P(Yi = 1|(xik, ai, bi))
1− P(Yi = 1|(xik, ai, bi))
)
= β0k + β1kxik + β2kai + β3kbi for k = 1, . . . , p.
Alternatively, multivariate logistic regression can be used to fit multi-marker models
in which several adjacent probe sets, cj = {cj1, . . . , cjlj} ⊂ {1, . . . , p} with j < p,
are assumed to collectively have an influence on the probability for an individual to
be affected with the disease or trait of interest
ln
(
P(Yi = 1|(xicj1 , . . . , xicjlj ))
1− P(Yi = 1|(xicj1 , . . . , xicjlj ))
)
= βj0 + βj1xicj1 + · · ·+ βjljxicjlj with j < p.
Finally, each mentioned approach for association testing in case-control data can be
traced back to a comparison of the two distributions derived from intensity obser-
vations in cases and controls. As such, multiple confounding factors such as batch
effects and noisy data as well as the known confounders of genotyping array data
such as the effective amount of DNA hybridized, background fluorescence and hy-
bridization quality can bias association test results (Chai et al., 2010). Furthermore,
different genotyping procedures or platforms can lead to group differences that are
impossible to be distinguished from association effects without pre-processing of the
data. The risk of confounding bias, which may result from the described variation
between arrays of non-biological origin, can for instance be reduced by a careful data
normalization procedure prior to any association testing (Bolstad et al., 2003).
5.1.1.3 Marker Selection for Case-Control Association Testing
In a case-control sample, only those probe sets
{s1, . . . , sw} ⊂ {1, . . . , p} with w < p
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with minimal copy number variability of  > 0 referred to the controls group,
|{u | (u ≤ nu) ∧ ( control u has a CNV at probe set sj)}|
nu
>  for j = 1, . . . , w,
are tested for an association with disease. The estimated frequency of CNVs in the
controls is not influenced by the trait of interest and should therefore represent an
unbiased estimate of the underlying CNV frequency.
5.1.2 Family-Based Trio Designs
For simplicity and with regard to the following application to data, we will limit
all considerations for the family-based design to parent-offspring trio samples. That
is, the focus will be on samples, which exclusively consist of nt nuclear families,
each comprising exactly one affected child and both biological parents. However,
all concepts can directly be adapted to larger families comprising more than one
affected or healthy child.
5.1.2.1 FBAT for Trio Designs and Raw CNV Data
We assume to have pre-processed hybridization signal intensity data on p probe
sets for nt independent trios, each comprising one affected child and both biological
parents. Let
Xji = (Xji1, . . . , Xjip) with j ∈ {o,m, f} and i = 1, . . . , nt
denote the vector of random variables for probe set intensities of either the offspring
(j = o), the mother (j = m) or the father (j = f) of the i-th trio, respectively.
Let furthermore xji denote the vector of observations for the corresponding random
variable Xji.
As proposed by Ionita-Laza et al. (2008), to test each marker probe set k = 1, . . . , p
for a CNV - phenotype association the following generalized family-based association
test (FBAT) scores can be used
Sk =
nt∑
i=1
xoik − E0(Xoik|xmik, xfik) for k = 1, . . . , p,
where E0(Xoik|xmik, xfik) denotes the expected value of the offspring’s hybridization
intensity given the two observed parental intensities and computed under the null
hypothesis of no association. We assume that both parental intensity data are
57
5.1 Strategy PS1
observed and available for association testing analyses for each of the p available
probe sets.
In order to specify the conditional null distribution of the offspring’s marker inten-
sity data, the exact null hypothesis needs to be specified. In general, genetic family-
based association tests have composite null and alternative hypotheses that account
for the marker’s state of (1): linkage with a hypothetical disease-susceptibility lo-
cus (DSL) and (2): association with the disease causing mutant allele of the DSL
or direct association with the respective phenotypic trait in case that the tested
marker is the true causal variant. Thus, tested null hypotheses may either be (Laird
and Lange, 2006): ’no association and no linkage’, ’no association in the presence
of linkage’ or ’no linkage in the presence of association’. In follow-up studies, in
which statistically significant results from previous case-control association studies
are re-analysed in further samples, the null hypothesis of ’no linkage in the pres-
ence of association’ is tested. Furthermore, the null hypothesis of ’no association in
the presence of linkage’ is used for follow-up studies that account for statistically
significant results of previous linkage studies when analysing additional samples.
Contrarily, for genome-wide association studies the null hypothesis of
H0: ’no association and no linkage’
is tested against the only testable alternative hypothesis (Ott, 1989) of
HA: ’linkage and association’ between the marker and a DSL
at each available marker probe set. Since both linkage and in particular association
between the marker and a DSL affecting the trait have to be present in order to
reject the null hypothesis in family-based association testing (Ott, 1989), the FBAT
can especially be seen as a test for association. The precise null hypothesis of the
FBAT is of particular interest when data of more than one offspring per family
is incorporated in the test statistic. In more detail, transmissions from the same
parents to multiple offspring are correlated in the presence of linkage (Laird and
Lange, 2006).
According to Mendel’s laws, each parent is equally likely to transmit his or her
genotypes and parental transmissions are independent under the null hypothesis of
neither association nor linkage. Consequently, conditional on the sufficient statistic
of the parental within-family information, the offspring’s expected intensity can
under the null hypothesis be calculated as (Rabinowitz and Laird, 2000)
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E0(Xoik|xmik, xfik) = 1
2
(xmik + xfik) for k = 1, . . . , p.
Thus, the offspring’s intensities are treated as being random, whereas parental in-
tensities are assumed to be fixed. Then, by conditioning on the sufficient statistic,
Tik = (xmik, xfik), for the true unobserved xoik for all trios i = 1, . . . , nt, the distri-
bution of Sk is the same in all null hypotheses for each genetic model, each sampling
plan and potential population admixture. Hence, the computations of p-values for
Sk conditionally given the sufficient test statistics are the same for all models in the
null hypothesis. That is, any p-value will result in rejecting the null hypothesis with
a correct type 1 error rate, irrespective of which model is true in the null hypothesis.
Finally, Sk is standardized to a large sample normal or χ
2 approximation. By
construction, since E0(Xoik|xmik, xfik) is centred around the true xoik and under the
assumption that the nt trios are stochastically independent, Sk has an expected
value of 0 under the null hypothesis for all tested marker k = 1, . . . , p. Due to
technological limitations, such as potential noisy data from a variety of genotyping
platforms, Ionita-Laza et al. (2008) proposed to use the empirical variance estimator
ofXoik, conditional on the parental intensity information, for standardization instead
of the theoretical variance under the null hypothesis. Thus, the final FBAT statistic
is obtained as
FBATk =
{∑nti=1 xoik − E0(Xoik|xmik, xfik)}2∑nt
i=1[xoik − E0(Xoik|xmik, xfik)]2
∼ χ21, (5.4)
which is under the null hypothesis asymptotically (for nt →∞) distributed accord-
ing to a chi-squared distribution with one degree of freedom.
Of note, the FBAT approach presented in equation (5.4) is invariant under linear
transformation of the hybridization intensity signals. Consequently, neither a marker
specific normalization procedure (see chapter 3.2) nor a transformation of intensity
measurements into raw copy number measurements, as described in chapter 6.1.1,
have an impact on probe-wise FBAT results. As a consequence, the FBAT can like-
wise be applied to raw hybridization intensity values as well as to raw copy number
values and moreover to any outcome of each intermediate data pre-processing step
that is based on the idea of linear intensity transformations.
More generally, the FBAT statistic presented in equation (5.4) can also be derived
as Rao’s score test statistic of a prospective GLM for the offspring’s phenotype
(Lunetta et al., 2000), which is defined by
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µik = E(Yi|xoik) = g−1(β0k + β1kxoik) with k = 1, . . . , p and β0k, β1k ∈ R,
where Y = (Y1, . . . , Ynt) denotes the vector of random variables for the children’s
disease status with some appropriate link function g(.) and where the distribution
of Yi (i = 1, . . . , nt) is assumed to be a member of the canonical exponential family.
Thus, the joint probability density function (p.d.f.) for Y at probe set k = 1, . . . , p
is of the form
f(Y1 = y1, . . . , Ynt = ynt , θ1, . . . , θnt) = exp
[
nt∑
i=1
yiθik + η(θik)
h(φ)
+ ξ(yi, φ)
]
,
with parameters β0k, β1k such that g(µik) = θik = β0k + β1kxoik. Moreover, for each
canonical GLM it is known that the first two moments of Yi are E(Yi) = η′(θik)
and Var(Yi) = η
′′(θik)h(φ). For a dichotomous phenotype, f(yi, θik) is from the
Bernoulli distribution and g(·) is the natural logit link function as presented for the
case-control design in chapter 5.1.1.1. Contrarily, f(yi, θik) is normal and g(·) is the
identity for continuous phenotypes in form of a quantitative trait. With L(y, β1k)
denoting the log likelihood of Y, the score S for β1k of probe set k = 1, . . . , p,
S(β1k) =
∂L(y, β1k)
∂β1k
=
∂
∂β1k
[
nt∑
i=1
yiθik(β1k)− η(θik(β1k))
h(φ)
]
=
nt∑
i=1
[yi − E(Yi)]xoik
h(φ)
,
and the Fisher information I for β1k,
I(β1k) = E
[
∂2L(y, β1k)
∂β21k
]
=
nt∑
i=1
E[Var(Yi)x2oik]
h(φ)2
=
∑
[yi − E(Yi)]2 x2oik
h(φ)2
,
the score test statistic to test the null hypothesis of no association is given by
R =
S(β1k = 0)
2
I(β1k = 0) =
[
∑nt
i=1(yi − µk)xoik]2∑nt
i=1(yi − µk)2 x2oik
.
In case of a trio design only affected offspring are considered, which implies that
yi = 1 for all families i = 1, . . . , nt. Thus, the term (yi − µk) = (1 − µk) vanishes
from the score statistic R since it acts as a multiplicative constant for the trio
design. The score statistic R then equals the FBAT statistic of equation (5.4) after
application of one additional assumption: The offspring’s genotypic intensities xoik
are assumed to consist of two orthogonal components
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xoik = bik + wik for k = 1, . . . , p,
where bik denotes the between-family component and wik the within-family compo-
nent, which is not sensitive to population structures and is statistically significant
only in the presence of linkage (Lange et al., 2002). Here, bik represents the average
within-family genotypic intensity level and is set to bik = E0(Xoik|xmik, xfik) (Lange
et al., 2002). Hence, testing the null hypothesis H0 : βwk = 0 in the derived model
E(Yi|xoik) = g−1(β0k + βbkbik + βwkwik) for k = 1, . . . , p
yields the FBAT statistic presented in equation (5.4).
Although the trio design is no prospective study design with respect to the indi-
vidual’s affection status but instead involves sampling from P(xoik|Yi), the FBAT
statistic was above developed as a score test statistic by modeling P(Yi|xoik). How-
ever, as stated by Lunetta et al. (2000), these two approaches are equivalent and,
in case of the trio design, result in the same tests. Advantages of the derivation of
FBATk as a score statistic is that additional covariates, such as other known risk
factors, can easily be incorporated and that effect size estimates are indirectly given.
5.1.2.2 Multi-Marker CNV FBATs
CNVs typically span more than one array probe set. Referring to this, Ionita-Laza
et al. (2008) additionally proposed a multivariate extension of the above FBAT,
which incorporates information on multiple adjacent probe sets. As the single-
marker FBAT, the multi-marker FBAT is a conditional score test that conditions
upon the within-family information of parental intensity data. The score for the
z-variate score test is given by
S[z] =
nt∑
i=1

xoi1 − E0(Xoik|xmi1, xfi1)
:
xoiz − E0(Xoik|xmiz, xfiz)
 with z < p.
The z-variate FBAT statistic, including information on z adjacent marker, has the
form
FBAT[z] = S
t
[z]Vˆ
−1S[z] ∼ χ2z,
where Vˆ denotes the empirical variance-covariance matrix with rank z.
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5.1.2.3 Marker Selection for Family-Based Association Testing
In order to guarantee at least minimal variability in copy number, say  > 0, for the
tested probe sets, only those probe sets
{s1, . . . , sw} ⊂ {1, . . . , p} with w < p
for which
|{p | (p ≤ 2nt) ∧ ( parent p has a CNV at probe set sj)}|
2nt
>  for j = 1, . . . , w
are tested for an association with disease. The lower limit for copy number variability
of each tested probe set is referred to the parents only, because a sample-based
approach might overestimate the true CNV-variability in regions where CNVs are
preferentially transmitted to the affected offspring.
5.2 Application of Strategy PS1 to the Phenotype
Obesity
Application of strategy S1 to genome-wide raw CNV data of a family-based obesity
sample comprising 424 obesity trios revealed no evidence for any association between
CNVs and the trait obesity. In this chapter, results of applying the proposed analysis
strategy PS1 to exactly the same data set will be presented. Parts of the genetic
results of this chapter have been published in Jarick et al. (2011).
5.2.1 Data Set
The family-based obesity sample comprised 424 nuclear families with one extremely
obese child or adolescent and both biological parents (for details see chapter 3.5.1 and
Jarick et al. (2011), Supplementary Table S1). For statistically significant findings
from the family-based obesity sample, follow-up analyses were performed in a case-
control sample of 453 extremely obese children and adolescents (cases) and 435
normal-weight or lean adult control subjects (controls) (for details see chapter 3.5.1
and Jarick et al. (2011), Supplementary Table S1). Finally, additional follow-up
analyses for most promising findings were performed in an independent sample of
365 obesity trios, which was recruited similarly as the family-based discovery sample
(for details see Jarick et al. (2011), Supplementary Table S1).
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5.2.2 Methods
Data pre-processing.
For each individual of the family-based as well as of the case-control sample geno-
typing was performed on the Affymetrix 6.0 chip by the ATLAS Biolabs GmbH
(Berlin, Germany). Afterwards, raw hybridization intensity signals of the ∼ 890 000
autosomal CN probe sets were extracted from the individual ’.CEL’ files by use of
the R-package ’affxparser’ (Bengtsson et al., 2008a). Prior to association testing, the
raw intensity signals of the case-control sample were quantile normalized (Bolstad
et al., 2003) to account for potential plate effects, whereas, raw fluorescence intensity
signals of the family-based samples were directly incorporated into statistical tests
since the family-based design and the family-wise assignment to genotyping plates
allows for a control of the inter-individual variability.
CNV calling.
As secondary analyses in both samples, CNVs were estimated at a genome-wide
level by use of the Affymetrix Genotyping Console (GTC) 3.0 (Korn et al., 2008;
McCarroll et al., 2008). As described in chapter 3.5.2, the HMM algorithm of the
GTC software is based on comparing individual signal intensity levels against those
of a reference sample. The reference sample size was limited to 106 parental pairs
due to computational constraints. As explained previously, two differently composed
reference samples were used for CNV frequency estimation to address potential
reference group effects on CNV calls. In more detail, one randomly designed set and
a second set of those 106 parental pairs with minimal mean BMI standard deviation
scores were considered as reference groups (for details see chapter 3.5.2 and Jarick
et al. (2011), Supplementary Table S1). Only CNV calls that were consistently
assigned via both approaches were investigated subsequently.
Marker selection for association testing.
The first essential step of strategy PS1, the selection of probe sets for association
testing, was performed on the basis of a lower frequency threshold for estimated
CNVs per probe set. In more detail, only CN probe sets in estimated CNV regions
(CNVRs) with at least five percent copy number variability were tested for an as-
sociation with obesity. Being defined as a region of overlapping CNVs, a CNVR
was claimed to consist of at least three consecutive CN probe sets. Moreover, CNV
frequencies were separately considered in offspring and parents of the family-based
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discovery sample as well as in cases and controls of the case-control sample, and the
lower CNV frequency limit of five percent was applied to each of the four sub-groups
separately.
Association testing.
Afterwards, the CNV FBAT approach was initially applied in the family-based
GWAS discovery sample of 424 obesity trios to each previously selected CN probe
set. Subsequently, significant probe sets were identified with regard to the lfdr
method by use of the central matching estimation method implemented in the R-
package ’locfdr’ (Efron et al., 2011), which was described in detail in chapter 3.5.2.
Follow-up analyses were performed in the case-control sample for each probe set
within CNVRs with lfdr significant CNV FBAT results by applying logistic regres-
sion with predictors normalized intensities, sex and age. In the follow-up analyses,
significance of probe sets was again determined by use of the lfdr method. The
number of probe sets that was analysed for follow-up in the case-control sample was
relative low. Consequently, the ’locfdr’ function of the R-package ’locfdr’ was applied
with non-default parameters ’bre’, ’df’ and ’type’, which were selected to minimize
the differences between maximum likelihood and central matching estimation.
For fine-scale analyses, multi-marker FBATs as described in chapter 5.1.2.1 were
applied in the family-based discovery sample to each CNVR with lfdr significant
results in the family-based discovery sample as well as in the case-control follow-up
sample. For each such selected CNVR, any subset of consecutive CN probe sets was
incorporated into multi-marker FBATs. In order to allow a comparison to single
marker FBAT results, multi-marker z-values were derived in application of an inverse
standard normal transformation on p-values.
Moreover, linkage disequilibrium (LD) in form of the squared pairwise Pearson’s
correlation coefficients of parental intensities from the family-based discovery sample
was calculated for all probe sets in CNVRs with lfdr significance in the family-
based discovery sample as well as in the case-control follow-up sample. Finally,
recombination rates are reported with respect to data of the 1000 Genomes project
(www.1000genomes.org).
CNV validation and replication.
In order to ensure reliability of chip-based association test results and to additionally
specify precise individual copy number states, the most promising newly identified
CNV region at chr 11q11 with evidence for an association with the binary trait obe-
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sity was on the one hand technically validated in the family-based discovery sample
by use of the qPCR technology. On the other hand, this region was furthermore
followed-up in a second family-based obesity sample of 365 independent obesity trios,
which was likewise analysed by use of qPCR. For both trio samples, qPCR derived
copy number number states were tested for an association with obesity in applica-
tion of the FBAT approach by assuming an additive genetic effect model. More
precisely, the coding for the three observed CN marker genotypes was specified as
0, 1, 2 in concordance with the determined total number of DNA copies.
5.2.3 Results
Genome-wide CNV analyses
A total of 244 autosomal CNVRs comprising 8 051 CN probe sets were detected
and tested for an association with obesity. The majority of CNVRs (n = 240) was
listed in the DGV (http://projects.tcag.ca/variation). Details on location, size and
marker distribution of the CNVRs can be found in Jarick et al. (2011) (Table 1).
Genome-wide association testing of the 8 051 selected CN probe sets in the family-
based GWAS discovery sample of 424 obesity trios revealed eight probe sets with lfdr
below 0.20, which is a sensible threshold as proposed by Efron (2004) (Figure 5.2 and
Figure 5.3). The eight lfdr significant probe sets are located in seven CNVRs (Table
5.1). The only lfdr significant CNVR that contained more than one lfdr significant
probe set, at chr 11q11, also harboured the probe set with minimal FBAT p-value
(CN 063559, p-value = 0.0074).
A total of 291 probe sets in those seven CNVRs with lfdr significant FBAT re-
sults were analysed for follow-up in an independent case-control sample. Logistic
regression analyses of the 291 probe sets yielded eight significant probe sets with
lfdr values below 0.2 in a total of four CNVRs (Figure 5.4, Table 5.2). Only for
one of these four CNVRs, at chr 11q11, the lfdr significant negative effect direction
observed in the trio sample was consistently re-observed with lfdr significance in
the case-control sample. The remaining three CNVRs showed contradictory lfdr
significant effects in the two analysed samples.
For a low number of simultaneously performed tests, the lfdr method has only
limited applicability. In order to address this limitation, follow-up analyses were
repeated in application of a more relaxed lfdr discovery threshold, which resulted
in a higher number of follow-up probe sets for the re-analyses in the case-control
sample. For a more conservative threshold of lfdr < 0.3, 26 probe sets in 14 CNVRs
showed significant FBAT results in the trio sample (Figure 5.5 and Table 5.3).
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Figure 5.2: Manhattan plot for the genome-wide CNV analysis of 424 obesity trios
accounting for 8 051 CN probe sets in 244 CNVRs. For all probe sets,
the − log10 transformed CNV FBAT p-values are shown relative to their
chromosomal position. 26 (eight) FBAT results with lfdr < 0.3 (< 0.2)
are circled (twice).
Figure 5.3: Histogram and lfdr curve of CNV FBAT z-values for the genome-wide
analysis of 424 obesity trios at 8 051 CN probe sets in 244 CNVRs.
Panel A: Histogram. The red dashed curve depicts the standard nor-
mal distribution, the dashed blue line is pˆ0fˆ0, the empirical null density,
N (−0.172, 0.6022), and the green line is the empirically estimated mix-
ture density. The small pink bars represent estimated non-null counts.
Panel B: Lfdr curve, derived from empirical estimates of f0, f and p0
(Panel A). Observed CNV FBAT z-values are illustrated as ticks on the
horizontal lines, those with lfdr < 0.2 (< 0.3) are printed in red (blue).
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Table 5.1: Results for 26 (8) probe sets with lfdr < 0.3 (0.2) across 8 051 CNV FBATs in 424 obesity trios. (in chromosomal order)
CN probe
set ID
Chr: Position
(hg18)
Cytoband
[hg18]
FBAT
z-value
FBAT
p-value lfdr
in known
CNV (DGV) in CNVR [chr: bp, hg18]
# probe sets
in CNVR
CN 020771 1 : 25 484 027..25 484 052 p36.11 −2.458 0.0140 0.034 YES 1 : 25 468 522− 25 534 812 29
CN 517829 1 : 72 543 719..72 543 744 p31.1 −2.212 0.0269 0.245 YES 1 : 72 541 074− 72 583 749 47
CN 517834 1 : 72 547 710..72 547 735 p31.1 −2.101 0.0356 0.290 YES 1 : 72 541 074− 72 583 749 47
CN 517839 1 : 72 551 683..72 551 708 p31.1 −2.392 0.0168 0.181 YES 1 : 72 541 074− 72 583 749 47
CN 519935 1 : 72 581 295..72 581 320 p31.1 −2.179 0.0293 0.258 YES 1 : 72 541 074− 72 583 749 47
CN 519936 1 : 72 581 948..72 581 973 p31.1 −2.082 0.0373 0.299 YES 1 : 72 541 074− 72 583 749 47
CN 519938 1 : 72 582 418..72 582 443 p31.1 −2.101 0.0356 0.290 YES 1 : 72 541 074− 72 583 749 47
CN 519939 1 : 72 583 514..72 583 539 p31.1 −2.177 0.0295 0.259 YES 1 : 72 541 074− 72 583 749 47
CN 818148 2 : 184 502 773..184 502 798 q32.1 −2.268 0.0234 0.224 YES 2 : 184 502 747− 184 510 699 16
CN 978208 3 : 131 275 089..131 275 114 q21.3 −2.343 0.0191 0.197 YES 3 : 131 245 537− 131 290 979 56
CN 993322 3 : 133 475 914..133 475 939 q22.1 −2.240 0.0251 0.234 YES 3 : 133 475 451− 133 478 387 3
CN 1034271 4 : 108 291 065..108 291 090 q25 −2.336 0.0195 0.200 YES 4 : 108 285 188− 108 293 270 25
CN 1063738 4 : 161 286 278..161 286 303 q32.1 −2.595 0.0095 0.121 YES 4 : 161 282 532− 161 289 730 13
CN 1139749 5 : 70 290 649..70 290 674 q13.2 −2.240 0.0251 0.234 YES 5 : 68 903 038− 70 343 313 22
CN 1175510 6 : 32 638 110..32 638 135 p21.32 −2.251 0.0244 0.230 YES 6 : 32 560 895− 32 638 289 25
CN 524300 10 : 46 478 786..46 478 811 q11.22 −2.080 0.0375 0.300 YES 10 : 46 338 178− 46 812 351 161
CN 548211 10 : 58 195 507..58 195 532 q21.1 −2.119 0.0341 0.283 YES 10 : 58 186 369− 58 196 856 40
CN 548214 10 : 58 195 736..58 195 761 q21.1 −2.128 0.0334 0.279 YES 10 : 58 186 369− 58 196 856 40
CN 587558 11 : 55 130 612..55 130 637 q11 −2.502 0.0123 0.147 YES 11 : 55 130 596− 55 210 165 58
CN 587579 11 : 55 153 205..55 153 230 q11 −2.307 0.0211 0.210 YES 11 : 55 130 596− 55 210 165 58
CN 589638 11 : 55 196 554..55 196 579 q11 −2.308 0.0210 0.209 YES 11 : 55 130 596− 55 210 165 58
CN 589644 11 : 55 203 896..55 203 921 q11 −2.191 0.0284 0.253 YES 11 : 55 130 596− 55 210 165 58
CN 063559 11 : 55 204 029..55 204 054 q11 −2.679 0.0074 0.106 YES 11 : 55 130 596− 55 210 165 58
CN 685264 15 : 28 339 425..28 339 450 q13.2 −2.228 0.0259 0.239 YES 15 : 28 280 641− 28 609 063 103
CN 119211 15 : 28 595 222..28 595 247 q13.2 −2.103 0.0355 0.290 YES 15 : 28 280 641− 28 609 063 103
CN 721778 16 : 14 897 328..14 897 353 p13.11 −2.430 0.0151 0.037 YES 16 : 14 796 084− 14 987 969 6367
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Figure 5.4: Histogram and lfdr curve for logistic regression z-values of 291 CN
probe sets at seven CNVRs in a case-control follow-up sample. Panel
A: Histogram. The red dashed curve depicts the standard normal
distribution, the dashed blue line is pˆ0fˆ0, the empirical null density,
N (−0.409, 1.1472), and the green line is the empirically estimated mix-
ture density. The small pink bars represent estimated non-null counts.
Panel B: Lfdr curve, derived from empirical estimates of f0, f and p0
(Panel A). Observed logistic regression z-values are illustrated as ticks
on the horizontal lines, those with lfdr < 0.2 are printed in red.
Table 5.2: Results for eight probe sets with lfdr < 0.2 across 291 logistic regression
tests in 453 obesity cases and 435 lean controls. (in chromosomal or-
der) Probe sets with directionally consistent, lfdr significant effect in the
family-based sample are highlighted in red. Each probe represents 25 bp.
CN probe
set ID
Chr: Position
[hg18]
FBAT
z-value
FBAT
p-value
lfdr
in CNVR
[chr: bp, hg18]
CN 484327 1 : 25 500 952+ −3.750 1.77× 10−4 0.168 1 : 25 468 522−
1 ::25 534 812
CN 980258 3 : 131 275 502+ −3.915 9.03× 10−5 0.110 3 : 131 245 537−
1 ::131 290 979
CN 980259 3 : 131 276 124+ −3.896 9.78× 10−5 0.116 3 : 131 245 537−
1 ::131 290 979
CN 980277 3 : 131 289 676+ −3.506 5.55× 10−4 0.046 3 : 131 245 537−
1 ::131 290 979
CN 587564 11 : 55 132 844+ −4.162 3.16× 10−5 0.064 11 : 55 130 596−
11 ::55 210 165
CN 721771 16 : 14 844 813+ −3.898 9.69× 10−5 0.115 16 : 14 796 084−
16 ::14 987 969
CN 721784 16 : 14 956 349+ −3.425 6.16× 10−4 0.046 16 : 14 796 084−
16 ::14 987 969
CN 723869 16 : 14 968 128+ −4.518 6.24× 10−6 0.046 16 : 14 796 084−
14 ::14 987 969
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Figure 5.5: Histogram and lfdr curve for logistic regression z-values of 661 CN probe
sets at 14 CNVRs in a case-control follow-up sample. Panel A: His-
togram. See Figure 5.4 for a detailed description. The empirical null
density is N (−0.458, 1.3692). Panel B: Lfdr curve, derived from empir-
ical estimates of f0, f and p0 (Panel A). Observed logistic regression
z-values are illustrated as ticks on the horizontal lines, those with lfdr
< 0.2 are printed in red.
Table 5.3: Results for 20 probe sets with lfdr < 0.2 across 661 logistic regression tests
in 453 obesity cases and 435 lean controls. (in chromosomal order) Probe
sets with directionally consistent, lfdr significant effect in the family-based
sample are highlighted in red. Each probe represents 25 bp.
CN probe
set ID
Chr: Position
[hg18]
FBAT
z-value
FBAT
p-value lfdr in CNVR [chr: bp, hg18]
CN 303769 5 : 69 269 171+ −4.243 2.20× 10−5 0.138 5 : 68 903 038− 70 343 313
CN 558684 10 : 46 376 766+ −4.487 7.21× 10−6 0.097 10 : 46 338 178− 46 812 351
CN 524300 10 : 46 478 786+ −4.498 6.87× 10−6 0.096 10 : 46 338 178− 46 812 351
CN 558758 10 : 46 478 929+ −4.135 3.54× 10−5 0.173 10 : 46 338 178− 46 812 351
CN 558759 10 : 46 478 952+ −4.437 9.12× 10−6 0.103 10 : 46 338 178− 46 812 351
CN 524302 10 : 46 479 180+ −4.754 2.00× 10−6 0.091 10 : 46 338 178− 46 812 351
CN 524305 10 : 46 479 195+ −4.658 3.20× 10−6 0.090 10 : 46 338 178− 46 812 351
CN 524306 10 : 46 479 220+ −4.382 1.18× 10−5 0.110 10 : 46 338 178− 46 812 351
CN 524301 10 : 46 479 382+ −4.585 4.54× 10−6 0.091 10 : 46 338 178− 46 812 351
CN 524303 10 : 46 479 399+ −4.145 3.40× 10−5 0.169 10 : 46 338 178− 46 812 351
CN 524304 10 : 46 479 414+ −4.651 3.31× 10−6 0.090 10 : 46 338 178− 46 812 351
CN 524310 10 : 46 479 759+ −4.363 1.28× 10−5 0.113 10 : 46 338 178− 46 812 351
CN 524312 10 : 46 479 800+ −4.073 4.65× 10−5 0.198 10 : 46 338 178− 46 812 351
CN 524320 10 : 46 487 406+ −4.135 3.54× 10−5 0.173 10 : 46 338 178− 46 812 351
CN 524343 10 : 46 522 903+ −4.141 3.46× 10−5 0.171 10 : 46 338 178− 46 812 351
CN 587564 11 : 55 132 844+ −4.162 3.16× 10−5 0.163 11 : 55 130 596− 55 210 165
CN 685275 15 : 28 377 334+ −3.914 9.09× 10−5 0.152 15 : 28 280 641− 28 609 063
CN 685278 15 : 28 383 727+ −4.870 1.12× 10−6 0.093 15 : 28 280 641− 28 609 063
CN 685298 15 : 28 439 410+ −4.095 4.22× 10−5 0.082 15 : 28 280 641− 28 609 063
CN 723869 16 : 14 968 128+ −4.518 6.24× 10−6 0.095 16 : 14 796 084− 14 987 969
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Compared to a more stringent lfdr discovery threshold of 0.3, probe sets in seven
additional CNVRs where incorporated into repeated case-control follow-up analyses,
which resulted in a total of 661 probe sets that were again tested in a logistic re-
gression context. Concerning these follow-up investigations, application of the lfdr
method identified 20 probe sets in five CNVRs to be significant in the follow-up
case-control sample. For three CNVRs, at chr 5q13.2, chr 10q11.22 and chr 11q11,
significant follow-up effects are directionally consistent with negative discovery ef-
fects previously observed the family-based sample.
Results of the CNVR at chr 11q11, which was the only CNVR that was initially
detected to be associated with obesity in the family-based discovery sample and
directionally consistent re-found in follow-up analyses of the case-control sample
in application of a stringent lfdr discovery threshold of 0.2, remained stable after
inclusion of a larger set of follow-up probe sets when applying a more relaxed lfdr
discovery threshold of 0.3 (Table 5.3).
Additionally, follow-up analyses in the case-control sample accounting for a re-
laxed lfdr discovery threshold of 0.3 yielded two more CNVRs (at chr 5q13.2 and at
chr 10q11.22) with lfdr significant follow-up results that reflect directionally consis-
tent effects relative to those observed in the family-based discovery sample (Table
5.3). One of these two additional CNVRs, at chr 10q11.22, was previously reported
to be the only CNV that was associated with BMI in a genome-wide CNV associa-
tion study for a sample of 597 elderly Chinese Han subjects (Sha et al., 2009).
Exploration of statistically significant CNVRs
Details on association test results as well as on the correlation structure of a total
of those seven CNVRs with lfdr significant probe sets in the family-based GWAS
discovery sample and with additional lfdr significant follow-up results with respect
to a lfdr discovery threshold of either 0.2 or 0.3 are presented in Figures 5.6 - 5.12.
There is an enrichment of low p-values with negative effect direction near the most
significant follow-up probe set at CNVR chr 10q11.22 (Figure 5.9). This enrichment
is regionally limited by two recombination peaks. Multi-marker FBAT results in
this LD-block are considerably more significant than single marker tests with effects
that are likewise of negative direction. In sum, these results suggest that deletions
in this region at CNVR chr 10q11.22 seem to be associated with obesity, which is
in concordance with results of a previous report (Sha et al., 2009).
The second CNVR that showed multi-marker FBAT results with remarkably lower
p-values compared to single-marker tests is the CNVR at chr 11q11 (Figure 5.10). Of
note, multi-marker and single-marker FBATs as well as significant logistic regression
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tests have almost exclusively negative effect directions in this region. Thus, deletions
at CNVR chr 11q11 are suggested to be associated with obesity.
Similarly, results indicated that deletions at CNVR chr 5q13.2 might be associated
with obesity (Figure 5.8). Although, this conclusion has to be constrained by large
marker gaps of up to ten kb and a low correlation structure across probe sets in the
respective region.
For the remaining four CNVRs, at chr 1p36.11, 3q21.3, 15q13.2 and 16p13.11,
there is neither a regional enrichment of low p-values nor are multi-marker FBAT p-
values lower than single-marker FBAT p-values. In addition, there is no concordance
in the effect direction of probe sets with significant test results between the discovery
and the follow-up analyses (Figures 5.6, 5.7, 5.11 and 5.12). Thus, an association of
CNVs at these four regions with obesity does not seem to be plausible.
Figure 5.6: Association test results for CNVR chr 1p36.11. Panel A: Z-values of
CNV FBATs (logistic regression tests) are depicted in red (blue). Lfdr
significant results are circled. Panel B: P-values of CNV FBATs (logistic
regression tests) are shown in red (blue) in the upper part of the panel.
Lfdr significant results are circled. Recombination rates and pairwise
linkage disequilibrium values relative to the probe set with minimal p-
value are presented in the lower part of the panel.
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Figure 5.7: Association test results for CNVR chr 3q21.3. (details at Figure 5.6)
Figure 5.8: Association test results for CNVR chr 5q13.2. (details at Figure 5.6)
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Figure 5.9: Association test results for CNVR chr 10q11.22. (details at Figure 5.6)
Figure 5.10: Association test results for CNVR chr 11q11. (details at Figure 5.6)
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Figure 5.11: Association test results for CNVR chr 15q13.2. (details at Figure 5.6)
Figure 5.12: Association test results for CNVR chr 16p13.11. (details at Figure 5.6)
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Validation and replication of CNVR chr 11q11
Among those seven CNVRs with statistically significant results in the family-based
discovery as well as in the case-control follow-up sample, the CNVR at chr 11q11
showed the lowest p-value (p = 0.0074) in the family-based discovery sample. Thus,
this region represents the most promising newly identified CNVR with association
to obesity. Consequently, this region at chr 11q11 was further analysed by use of
the qPCR technique.
The observed effect direction of deletions at CNVR chr 11q11 being associated
with obesity could be validated in the family-based discovery sample by qPCR anal-
yses. With regard to qPCR findings, this region could be identified as a bi-allelic
deletion region. In more detail, 7.71% (9.72%) homozygotes and 40.35% (40.03%)
heterozygotes for the deletion were observed among the parents (offspring) of the
424 discovery trios. Here, the slight increase of homozygous deletions in children
compared to parents is consistent with the initially observed transmission disequi-
librium. Association testing of the qPCR derived copy number states indicated a
trend towards a preferable transmission of the deletion allele to the obese children
(OR = 1.171, 95% confidence interval = 0.947− 1.448, one-sided p-value = 0.066).
Similarly, qPCR-based analyses in the family-based follow-up sample of 365 in-
dependent obesity trios revealed a directionally consistent trend (OR = 1.214, 95%
confidence interval = 0.959 − 1.537, one-sided p-value = 0.066). Finally, all 789
obesity trios (discovery and follow-up sample), for which qPCR-derived CNV states
were available, were jointly analysed to increase the precision of the effect size esti-
mator, resulting in an OR of 1.190 for the deletion allele (95% confidence interval
= 1.016− 1.394, one-sided p-value = 0.015).
5.2.4 Discussion
In application of the proposed analyses strategy PS1, a genome-wide CNV associ-
ation study for the phenotype obesity was performed in a family-based discovery
sample and a case-control follow-up sample. Association tests were restrictedly ap-
plied to 8 051 pre-selected probe sets in 244 estimated CNVRs. Significance was
assessed via the lfdr method by Ionita-Laza et al. (2008). Deletions in two CNVRs,
at chr 10q11.22 and at chr 11q11, were identified to be associated with obesity. One
of these two findings, the CNVR at chr 10q11.22, was concordantly reported with
an association effect on BMI in a previous genome-wide CNV study of 597 elderly
Chinese Han subjects (Sha et al., 2009).
The application of strategy S1 resulted in no statistically significant finding of
any CNV - obesity association at all (see chapter 3.5). Contrarily, the only previous
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report concerning associations between common CNVs and obesity on a CNV at
chr 10q11.22 to be associated with BMI (Sha et al., 2009) could be strengthened in
use of the proposed strategy PS1. Moreover, the results allow additional support
for a newly identified association of deletions at another region, at chr 11q11, with
obesity.
Consequently, the proposed analyses strategy PS1 yielded more useful results
and is therefore clearly to be favored over strategy S1 in the underlying situation.
However, it has to be kept in mind that such real data applications do not allow
any general conclusions regarding power or type 1 error levels.
Being aware of testing CNV signals exclusively in known CNV regions may be an
useful approach to explicitly alleviate the multiple testing issue (Ionita-Laza et al.,
2008), to our knowledge, this has not been investigated systematically previously.
Here, at least a data-driven investigation of this approach is provided. In particular,
the previous straightforwad application of the well established genome-wide CNV
analysis strategy S1 (Ionita-Laza et al., 2008) to the phenotype obesity (see chapter
3.5) allows a comparison of both strategies, S1 and PS1.
Besides relaxing the multiple testing issue, a further advantage of strategy PS1
over strategy S1 is that CNV probe sets can be assigned to different CNVs or CNVRs
based on estimated CNV population frequency estimates, which are available from
strategy PS1’s marker selection step. Thus, follow-up analyses have no longer to
be restricted to exactly the same probe sets, which were initially discovered to be
statistically significantly associated with the trait of interest. Instead, each probe set
that is covered by a CNV with detected significance in the discovery sample at any
involved probe set was incorporated in follow-up analyses of the case-control sample.
However, due to this procedure special care is needed with regard to the precise
correlation structure of the respective CNVs. In order to ensure that statistically
significant discovery and follow-up signals come from exactly the same CNV loci,
recombination rates were considered across the entire CNV regions.
In the presented exemplary analysis, strategy PS1 involved considerably more
expensive computing efforts in identifying those probe sets that represent common
CNVs. Although the actual individual CNV genotype does not need to be collected
since these are not involved in association testing, at the very least, sample-specific
realistic CNV frequencies have to be provided for the marker selection step. Here,
this was realized in calling CNVs in the very same sample that was later on tested
for CNV-trait associations. Thus, the leading motivation for the specific design of
strategy S1, which is to overcome the inaccuracy in CNV detection from SNP geno-
typing array data, is to some extend returned back into the proposed strategy PS1.
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With regard to current suggestions (Winchester et al., 2009) and aiming to mini-
mize the risk of false CNV classifications, CNV calling was repeatedly implemented
based on two differently composed reference groups, whereas only the overlap of
both calling results was considered to be informative enough to reflect appropriate
CNV frequencies. However, it is imaginable that this rudimentary CNV calling step
may be completely skipped in future, when the quality and information content
of public databases has become increasingly better and when these catalogs truly
reflect the human CNV map stratified by racial and ethnic origin as well as by the
individual state of health.
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6 Strategy PS2: Estimation of CNVs
by Use of Sophisticated Reference
Models
The second proposed CNV analysis strategy, which is closely related to the most
widespread genome-wide CNV analysis strategy S2, will be introduced and examined
in detail in this chapter. After having motivated the importance of reference models
in array-based CNV detection, one particular approach that fits probe-wise intensity
signals to a Gaussian mixture model will be suggested. This aspect of estimating
probe-specific copy number neutral hybridization intensity values on array-derived
CNV data prior to the application of standard CNV detection pipelines forms the
major modification of strategy PS2 relative to strategy S2. Consequently, the im-
pact of alternative reference values compared to commonly used median reference
intensity values is investigated in detail by examining stability, reproducibility and
reliability of CNV calls in publicly available Affymetrix 6.0 data of the HapMap
sample (http://hapmap.ncbi.nlm.nih.gov/) as well as on replicate data being pre-
viously analysed in several CNV mapping studies (e.g. Tuzun et al. (2005); Redon
et al. (2006)). Finally, application of the whole genome-wide CNV analysis strategy
PS2 is examplarily presented for the phenotype obesity. It will be demonstrated
that applying strategy PS2 instead of strategy S2 will dramatically change genetic
association results.
6.1 Strategy PS2
The outline of our proposed CNV analysis strategy PS2 is diagrammed in Figure
6.1. Compared to the standard CNV analysis strategy S2, which is described in
detail in chapters 3.3.1 ff., the use of a set of sophisticated global reference values
for CNV detection instead of the most widely used probe-wise median reference
intensities forms the major extension in strategy PS2. In more detail, we propose to
separately fit a finite Gaussian mixture model to the samples’ intensity data of each
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Figure 6.1: Schematic representation of the proposed CNV analyses strategy PS2.
available array probe set, and to subsequently chose the mean of each probe set’s
copy number neutral cluster for the application as the probe-wise reference intensity
value in the following log2 intensity ratio calculation.
Several authors presented CNV genotype calling algorithms (CNVtools: Barnes
et al. (2008), CNVassoc: Subirana et al. (2011), CNVmix: Marioni et al. (2007),
etc.) that are based on modelling probe-wise sample-wide log2 ratios using a finite
Gaussian mixture model. However, these models suffer from the risk of misclassified
cluster locations due to imprecise reference intensity estimation. Consequently, we
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propose to improve the precision in the estimation of the global reference valuess
prior to the application of one of the various available CNV calling software tools.
6.1.1 Motivation for a Sophisticated Reference Model
Estimating raw copy number states from hybridization intensities
The general approach for the estimation of copy number states is derived from the
definition of a CNV as ”a segment of DNA that is one kb or larger and is present
at a variable copy number in comparison with a reference genome” (Levy et al.
(2007), cf. chapter 2). Thus, the individual copy number state Cind of a certain
DNA segment is estimated relative to the same DNA segment’s copy number Cref
of a single reference sample
Cind = τ Cref ,
where τ denotes the relative difference between the two integer-valued copy number
states. Usually, the reference sample is selected to be of copy number neutral, so
called normal, state and thus harbours an absolute number of two copies of the
respective DNA segment, one on each of the two homologous chromosomes. With
this assumption of Cref = 2, values of τ =
Cind
Cref
below or above one can intuitively
be interpreted as copy number losses or gains, respectively.
Fluorescence intensities from the hybridization step of microarray experiments
are assumed to be linearly indicative for the amount of DNA transcripts labeled to
the probes on the array. Consequently, for an array probe set that represents the
respective DNA segment, τ can equivalently be expressed in terms of hybridization
intensities, Xind and Xref , of the test and the reference sample
Cind = 2
Xind
Xref
.
Although the presented intensity ratios Xind
Xref
provide an intuitive measure of copy
number changes, they have the disadvantage of treating losses and gains differently.
Duplications with a relatively doubled absolute copy number of four have an in-
tensity ratio of two, whereas hemizygous deletions with half of the copies from the
reference sample have an intensity ratio of 1
2
. To induce symmetry and to facili-
tate interpretation, it is convenient to apply log2 transformations on the microarray
intensity data
log2
(
Cind
2
)
= log2
(
Xind
Xref
)
. (6.1)
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With this most widely used transformation, the log2 intensity ratio on the right
side of equation (6.1) is symmetric around zero, which means that reciprocal copy
number changes have symmetric log2 intensity ratios: log2(2) = 1 and log2
(
1
2
)
= −1
and so on. Additional advantages of the log2 transformation are that linearity,
additivity and normality, which is of special interest for statistical analyses, are
achieved. Biological plausibility of the identity (6.1) has empirically been shown in
X-chromosome dosage response experiments including several replicates of samples
with one to five copies of the X chromosome (Huang et al., 2004).
Estimating copy number states for Affymetrix 6.0 data
Similar to most genotyping arrays, the Affymetrix 6.0 technology is characterized
by the use of several short oligonucleotide (25-mers) probe sets to characterize the
structure of genomic DNA regions. That is, CNVs that typically make up at least
one kb of DNA cannot be represented by hybridization intensities of only one single
probe set. Instead, a set of intensity signals from several adjacent SNP and CN probe
sets covering the CNV is needed for individual copy number estimation. Exemplarily,
probe-wise intensity ratios, log2 intensity ratios and corresponding raw copy number
values are depicted in Figure 6.2 for a hemizygous deletion and a duplication on
chromosome 6 of a hypothetical individual. Several algorithms have been proposed
to detect individual CNVs on the basis of individual raw copy number values. All
these software tools rely on the fundamental characteristic that a CNV is a relatively
long DNA sequence with a constant number of copies in each individual human being
(cf. chapter 3.2).
As already stated in chapter 3.1.1, the SNP array technology, such as the Affy-
metrix 6.0 genotyping arrays, does not use a specific control or reference sample.
Alternatively, reference values need to be artificially provided for each probe set
separately on the basis of intensity information for a group of collectively processed
individuals. The most widely used assumption for the determination of global ref-
erence intensity values is that the majority of randomly selected individuals is free
of specific CNVs. Consequently, in most currently available software tools for CNV
discovery, such as Birdsuite, CNAT, CNVPartition 1.2.1, dChip SNP, GADA, ITAL-
ICS, PennCNV or QuantiSNP (cf. chapter 3.2), probe-wise reference intensities are
defined to equal the sample mean or a robust sample average. For instance, the sam-
ple median or the trimmed sample mean are robust sample averages in the sense
that they are only marginally influenced by outliers.
The basic assumption for the statistical estimation of individual copy number
states from intensities of high density oligonucleotide SNP arrays is that intensity
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Figure 6.2: Exemplary probe-wise intensity ratios, log2 intensity ratios and raw
copy numbers of an individual (hypothetical) are presented for each
Affymetrix 6.0 probe set covering the depicted region on chromosome 6.
Intensity ratios, Xind
Xref
, and log2 intensity ratios, log2
(
Xind
Xref
)
, are displayed
in the middle and upper part of the panel. Transformed individual raw
copy numbers Cind = 2 · 2
log2
(
Xind
Xref
)
, referred to the upper log2 intensity
ratios, are shown in the lower part of the panel.
levels across individuals are comparable to each other. On the one hand, signal
intensities can be influences by experimental noise, which can be modeled as an ad-
ditive zero-mean Gaussian error term component. On the other hand, hybridization
intensity levels can be biased between samples due to low-quality measurements and
plate- or batch-effects, which may arise when laboratory conditions have changed
in the meantime of processing different plates or batches of plates. To separate dif-
ference of biological origin from those of non-biological origin and in order to allow
meaningful biological comparisons, a transformation at the sample level, referred
to as normalization, is typically applied to SNP array data before any statistical
estimation is done (Quackenbush, 2002). Several methods were proposed to give
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each array the same distribution, among which quantile normalization has proven
to perform favorably (Bolstad et al., 2003).
Median reference intensity values
As already noted by several authors, such as Komura et al. (2006), Bengtsson et al.
(2008b), Pique-Regi et al. (2009) or Zhang et al. (2011), the application of median
values as reference intensities is appropriate for most CNVs but can be problematic
under specific conditions. Median reference values may especially be inappropri-
ate for probe sets in genomic regions that contain common CNVs. In genomic
regions with common CNVs, the sample’s major CNV state does no longer equal
the assumed normal CNV state of two copies. By definition, a biased estimation of
reference hybridization intensity values potentially implicates a misclassification of
raw continuous copy numbers at the single locus level. Slightly erroneous continuous
raw copy numbers may nonetheless result in a correct classification into discrete raw
copy numbers at the single locus level. However, accumulated misclassified raw copy
numbers for adjacent single probe sets may on the one hand result in completely
missing to detect specific CNVs. On the other hand, especially complex CNVs may
be wrongly identified in the course of the CNV discovery step, when one of the
currently available CNV genotype calling tools is directly applied to the raw copy
number measurements.
The above described concern about median reference values is illustrated in Figure
6.3, which displays the Affymetrix 6.0 median based log2 intensity ratio profile of
replicate 4 on sample NA15510 (see section 6.2.1 for details), who was shown to
harbour a small deletion on chromosome 1 (Korbel et al., 2007). Indeed, the depicted
chromosomal region was later on shown to harbour two deletion alleles, one ten kb
deletion with low population frequency at chr 1 : 72 528−72 536 kb and another 45 kb
deletion with considerably greater population frequency at chr 1 : 72 540−72 585 kb
(Willer et al., 2009; McCarroll et al., 2008; McCarroll, 2010). Of note, exclusively
the occurrence of deletions and hence the absence of duplications was validated
for the 45 kb deletion region on chromosome 1 by use of independent validation
technologies, such as sequencing methods (McCarroll, 2010).
In the upper part of Figure 6.3, the intensity histograms of two Affymetrix 6.0
CN probe sets, CN 517821 and CN 517842, are shown. Each probe set is selected to
exemplarily represent one of the two above described CNVs and thus reflects the true
underlying CNVs’ frequency in a sample comprising approximately 300 individuals
of European origin (270 HapMap samples and 25 replicate data sets, for details see
section 6.2.1). As depicted in the lower part of Figure 6.3, median reference values
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Figure 6.3: Median based log2 intensity ratios for replicate 4 of sample NA15510,
carrying a small deletion at chr 1 : 72 528 701−72 535 958, are presented
in the lower part of the panel. Histograms of pre-processed hybridiza-
tion intensity values of a sample comprising ∼ 300 individuals are de-
picted in the upper part of the panel for two selected probe sets. In
both histograms, sample intensity medians are represented by a dashed
colored line, the intensity levels of replicate 4 on sample NA15510 are
presented by a solid colored line and intensities of replicates 1,2,3,5 of
sample NA15510 are shown as colored points. Corresponding log2 inten-
sity ratios of NA15510’s replicate 4 for the two probe sets CN 517821
and CN 517842 are highlighted in red and green in the lower part of the
panel, respectively.
are useful to identify the small infrequent deletion of sample NA15510. Contrarily,
the application of median reference intensities would falsely induce to conclude that
the same individual additionally carries a larger duplication upstream of the small
deletion. As represented in the intensity histogram for probe set CN 517842, the
sample median intensity is clearly shifted towards an intensity level below those
intensity value, which represents an individual exhibiting two copies of the respective
DNA segment. Thus, since almost half of the presented sample harbours a deletion
at probe set CN 517842, and even though the intensity of sample NA15510 can
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visually be unambiguously assigned to those intensity cluster representing two DNA
copies, the log2 intensity ratio value of 0.863 hints to a duplication. This wrong
conclusion about the presence of a duplication at chr 1 : 72 543 731 − 72 583 736
in the sample NA15510 is strengthened by several adjacent probe sets with sample
intensity profiles that are similar to this of CN 517842.
Alternative reference intensity values
Oldridge et al. (2010) presented three correction methods to account for the inaccu-
racy of median reference models for common CNVs. The first method is based on
the observation that misclassified reference values lead to an unusual high number of
CNV carriers in the analysed sample. Thus, CNVs with predicted sample frequency
above a certain threshold (e.g. ≥ 66%) were supposed to be discarded. In the sec-
ond approach, a trimmed sample intensity median, accounting for only mid-valued
intensities, is proposed for the use as reference. Thirdly, one and the same pre-
specified single reference individual was suggested to be used for log2 intensity ratio
calculation at each single probe set. After the determination of log2 intensity ratios
by any of the three correction methods, three commonly used segmentation algo-
rithms (GLAD, DNAcopy, APT) were applied to call CNV genotypes. With regard
to false positive and false negative rates, being with respect to CNVs determined by
use of the aCGH technology, the third correction method clearly outperformed the
two other presented methods.
Taking into account the above described results of Oldridge et al. (2010), we
suggest the application of a sophisticated reference model for raw copy number
calculation prior to CNV genotype calling. Empirically, it was demonstrated by
Oldridge et al. (2010) that a biologically plausible global reference system, such
as reference intensities that are genome-wide taken from one and the same single
sample, perform favorably in comparison to standard median-based reference in-
tensity determination approaches. The single reference sample design however still
implicates erroneous CNV genotype calling at CNV regions in which the reference
individual itself harbours a deletion or a duplication. For example, a deletion in the
reference individual would imply overestimated sample-wide log2 ratios and would
thereby result in the detection of duplications in biologically copy number neutral
individuals. Optimally, a global reference model would be piece-wise composed of
intensity values from several single samples that are all free of any CNV in the re-
spective chromosomal region. That is, intensity values of probe sets in chromosomal
order are taken from one single reference sample as long as this individual is not
deleted or duplicated at the respective probe set, and otherwise intensities of another
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reference individual that is free of any CNV at the respective DNA region are used.
However, since CNV states for none of the analysed samples are a priori known, this
procedure for the estimation of an optimal reference model is impossibly applicable
to Affymetrix 6.0 data. Instead, we propose to predict the theoretically optimal
reference model by estimating the expected intensity values for the presence of 2
DNA copies by separately fitting a finite Gaussian mixture model at each available
probe set.
6.1.2 Sophisticated Reference Models for CNV genotype Calling
A Gaussian mixture model for sample hybridization intensities
Assume to have pre-processed hybridization intensity data from SNP genotyping
microarrays, such as the Affymetrix 6.0 or the Illumina 1M platform. For a total
of n genotyped individuals, let intensity data for p probe sets, spanning the whole
genome, be available from chip experiments. For simplicity, all probes are assumed
to be non-polymorphic probes, so called CN probes (see section 3.1.2 for details).
Hybridization intensity signals for the A and the B allele of SNP probe sets may be
additively summarized into one single intensity measure reflecting the total amount
of DNA labeled to the respective probe set (Peiffer et al., 2006). With this proce-
dure CN and SNP probe sets do not necessarily need to be distinguished throughout
statistical analyses. However, for SNP probe sets it might be appropriate to calcu-
late the reference intensities conditional on the predicted individual SNP genotypes
(either AA, AB or BB) (Peiffer et al., 2006).
For each probe set, k = 1, . . . , p, the vector of observed individual pre-processed
hybridization intensity signals x[k] = (x1k, . . . , xnk) is assumed to be a realization of
a vector of independent and identically distributed (i.i.d.) random variables
X[k] = (X1k, . . . , Xnk) for k = 1, . . . , p.
Each random variable Xik is assumed to follow a mixture of several Gaussian dis-
tributions, which are called components. More precisely, for each k = 1, . . . , p and
i = 1, . . . , n the random variable Xik is assumed to have the following mixture
probability density function (p.d.f.)
fθk(xik) =
c∑
j=1
λkj φkj(xik),
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with parameters θk = (λk,φk) = (λk1, . . . , λkc, φk1, . . . , φkc). In particular, the mix-
ing proportion parameters are non-negative, λkj ≥ 0, and sum to unity,
∑c
j=1 λkj = 1
for each k = 1, . . . , p. The total number of components c equals the assumed
underlying number of CNV states with biological plausibility, whereas in general
c = 5 = |{0, 1, 2, 3, 4}|. Moreover, the functions φkj are assumed to be drawn from
the family of univariate Gaussian densities, that is each φkj is the p.d.f. of some
normal distribution N (µkj, σ2kj) with parameters µkj, σ2kj ∈ R,
φkj(xik) =
1
σkj
√
2pi
e
− 1
2
(
xik−µkj
σkj
)
.
Thus, model parameters θk reduce to θk = (λk, (µk1, σ
2
k1), . . . , (µkc, σ
2
kc)).
As an example of probe-wise pre-processed hybridization intensity data from a
mixture model, the sample distribution of intensities for probe set CN 517842 is
Figure 6.4: Intensity data of probe set CN 517842 for a sample comprising approx-
imately 300 individuals with highlighted median and MCMR reference
intensity values. In the lower row, densities for the two estimated mix-
ture components are included in pink. Additionally, median and MCMR
reference intensity values are highlighted in green and red in the right
part of the panel, respectively.
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depicted in Figure 6.4. For the presented intensities of a sample comprising approx-
imately 300 individuals (270 HapMap samples and 25 replicate data sets, for details
see section 6.2.1), a two-component mixture model is a reasonable with regard to
the bi-modality of the histogram. The presented model component densities were
estimated by use of the R-package ’mclust’ (Fraley et al., 2012).
MCMR reference intensity values
The choice of a sophisticated reference intensity value, called MCMR, is illustrated
for probe set CN 517842 in Figure 6.4. From a biological point of view, the most
plausible intensity reference value might be the expected value of those component
of the estimated Gaussian mixture model, which represents individuals with two
copies of the respective DNA segment. In general, the component that each indi-
vidual comes from is unobserved and for each individual it is modeled as a vector
of Bernoulli random variables Dik = (Dik1, . . . , Dikc) with Dikj ∈ {0, 1}. Since for
each k = 1, . . . , p, each single observation Xik comes from exactly one component,
the random variables Dikj sum to unity for each i = 1, . . . , n:
∑c
j=1Dikj = 1.
Additionally,
P(Dikj = 1) = λkj and (Xik|Dikj) ∼ φkj,
for j = 1, . . . , c and k = 1, . . . , p. Theoretically, the samples mean most probably
follows the copy number neutral component. Consequently, sophisticated reference
values are proposed to equal the mean of those component that the samples mean,
mk = X¯[k] =
1
n
∑n
i=1Xik, is most probably underlying. This reference value will be
called Mean Component Mean Reference, it is abbreviated as MCMR, and for each
probe set k = 1, . . . , p it is formally defined as
MCMRk = µkz
with
z = argmax
j∈{1,...,c}
P(Dikj = 1|mk)
= argmax
j∈{1,...,c}
P(Dikj = 1) φkj(mk)∑c
κ=1 P(Dikκ = 1) φkκ(mk)
= argmax
j∈{1,...,c}
λkj φkj(mk)∑c
κ=1 λkκ φkκ(mk)
.
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6.2 Comparison of Partially Applied Strategy S2 and
strategy PS2 to HapMap and Replicate Data
In the following, the applicability and performance of alternative MCMR reference
values will be presented by means of examples containing real data of alive individ-
uals. CNVs will be analysed in two different data sets. The main focus will be on
strengths and weaknesses of MCMR reference intensity values for CNV detection
compared to median (Default) reference intensity values.
By using real data examples, there is no need to artificially simulate raw data
of CNVs accounting for different models of CNV probe occurrences. In contrast
to genetic phenomena that affect only one specific chromosomal base pair position
(e.g. SNPs), a CNV requires a much more complicated simulation setting due to
the variety of involved microarray probe sets. In such a simulation, apart from
characteristics of the particular underlying genotyping technology, the number of
CNV affected probe sets and their probe-wise intensity level should be considered
in dependence of their distance and correlation structure as well as the CNV’s type,
chromosomal location and its population frequency. Real data examples provide
the possibility of comparing different reference models for CNV detection without
potential bias due to misclassified simulation models.
Publicly available Affymetrix 6.0 microarray data was analysed. On the one
hand, this public data set comprises the so-called HapMap individuals and on the
other hand it includes replicate microarrays for several individuals. The HapMap
data set is of special interest as the very same individuals were precisely analysed
in a variety of previous studies by application of several genotyping technologies.
The latter fact offers the possibility of calculating estimates for false positive and
false negative rates without the necessity of additionally collecting validation data.
Moreover, CNV calling results of replicate experiment’s data can be compared across
individuals with regard to stability and reproducibility rates.
6.2.1 Data Sets
CNVs were called genome-wide in a publicly available data set (www.affymetrix.
com/support/technical/sample data/genomewide snp6 data.affx) of Affymetrix 6.0
data for 270 samples from the International HapMap Project (www.hapmap.org)
and for an additional collection of five replicates on five single samples. Thus, a
total of 295 Affymetrix 6.0 microarray data sets were analysed.
The 270 HapMap samples are comprised of 30 Utah residents trios with ancestry
from northern and western Europe (abbreviation: CEPH), 30 Yoruban trios from
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Ibadan in Nigeria (abbreviation: YRI), 45 unrelated Han Chinese samples from
Beijing in China (abbreviation: CHB) and 45 unrelated Japanese samples from
Tokyo in Japan (abbreviation: JPT). CNVs of the full set of HapMap samples or
of a subset of all 270 HapMap samples, respectively, have been extensively analysed
by several previous studies, such as Conrad et al. (2006), Redon et al. (2006), Kidd
et al. (2008), Perry et al. (2008), McCarroll et al. (2008), Shaikh et al. (2009),
Conrad et al. (2010), Park et al. (2010).
Of special interest for the exploration of CNVs are the five sets of five Affymetrix
6.0 microarrays, each being processed for the same out of five individuals (NA10851,
NA15510, NA04626, NA01416, NA06061). Each of the five single samples has a
different number of copies of the X chromosome, varying from one to five. Sample
NA10851 is a normal male with one copy of the X chromosome, sample NA15510 is a
normal female with two copies and the other three samples have abnormal numbers
of X chromosome copies of three, four, and five, respectively. The female sample has
been extensively studied by fosmid paired end sequencing by Tuzun et al. (2005).
Additionally, Korbel et al. (2007) applied paired-end mapping to map structural
variations in the genomes of the male and the female sample. Moreover, Redon
et al. (2006) used the male and the female sample to train threshold parameters for
the analysis of the HapMap samples based on SNP genotyping arrays. Finally, Kidd
et al. (2008) mapped and sequenced structural variation from eight human genomes
with regard to NA15510 as a reference sample.
6.2.2 Methods
Reference models
The CNV detection performance of the proposed global MCMR reference model
was compared to the most widespread median reference model. In the course of the
data pre-processing step, the set of all 295 Affymetrix 6.0 microarray data sets of 295
’.CEL’ files was quantile normalized and median polished by use of the Affymetrix
Power Tools (APT) standard protocols. Subsequently, probe-wise median reference
values were determined by use of the PennCNV software (Wang et al., 2007). For
the calculation of global MCMR reference values, a Gaussian mixture model was
first fitted to the probe-wise pre-processed sample-wide intensities by use of the
R-package ’mclust’ (Fraley et al., 2012). In use of the function ’mclust()’, the pa-
rameters of the Gaussian mixture model are estimated via the EM algorithm and
the optimal model is selected according to the Bayesian information criterion (BIC).
The corresponding R-function that was used to specify probe-wise MCMR reference
intensity values is given in the Appendix.
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CNV detection
Detection of CNVs was performed in application of the PennCNV software (Wang
et al., 2007) by use of both, median and MCMR reference intensity values, respec-
tively. With regard to false positive, false negative and Mendelian inconsistency
rates of CNV calling, called CNVs were subsequently compared to published CNVs
of Tuzun et al. (2005), Korbel et al. (2007), Redon et al. (2006), Kidd et al. (2008),
Conrad et al. (2006), Perry et al. (2008), McCarroll et al. (2008), Shaikh et al.
(2009), Conrad et al. (2010) and Park et al. (2010), respectively. Additionally,
CNVs of those 5 individuals with available replicate data sets were compared across
replicates with respect to stability and reproducibility rates of CNV calls.
6.2.3 Results
6.2.3.1 Stability Rates of CNVs
To evaluate the CNV detection performance of median (Default) and MCMR ref-
erence values, the concordance of PennCNV’s CNV calls was investigated across
replicate sets of Affymetrix 6.0 data, each consisting of five chip experiments ac-
counting for the same individual. Such replicate data were available for a total of
five individuals. Thus, genome-wide CNV calls for 25 microarrays were compared at
the segment level. Respective results are summarized in Figure 6.6 and Table 6.1.
Comparisons of CNV call’s stability were performed pairwise at the segment level.
In more detail, a total of 5× 10 pairs of sets made-up of individual CNV calls were
checked against each other for chromosomal segments with concordant CNV calling
results. As shown in Figure 6.5, overlapping CNV calls across replicates of identical
type, i.e. duplications or deletions, were summed up into one so-called CNV segment.
In these considerations, only duplications and deletions were discriminated, whereas
copy number differences within duplications or deletions were not taken into account.
Figure 6.5: Schematic representation of a CNV segment defined by three overlapping
CNV calls from two replicate data sets for the same individual.
Copy number segments whose reciprocal overlap was above a certain threshold
were regarded as concordant segments. For the calculation of individual pairwise
stability rates, overlap thresholds of > 0%, > 50%, > 80% and 100% were applied.
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Individual pairwise stability rates were defined to equal the pairwise concordance
rates of CNV segments being detected in use of median (Default) and MCMR ref-
erence intensity values. Results for overlap threshold of > 50% and > 80% were
similar. Consequently, in Table 6.1 mean and median values of individual stability
rates are only presented for overlap thresholds of > 0%, > 50% and 100%.
Moreover, summarized stability rates are given for different CNV detection thresh-
olds, that is stratified by the minimal number of involved array probe sets (Figure
6.6, Table 6.1). For both, Default and MCMR reference intensity values, highest
stability rates were observed for CNV calls with more than 20 probe sets and with
regard to any pairwise overlap between replicate calls.
Individual CNV’s stability rates were statistically significantly higher with MCMR
reference intensity values compared to Default reference values, when incorporating
CNV calls with > 3, > 5 or > 10 probe sets and accounting for any pairwise overlap
between replicates. Additionally, throughout almost any overlap threshold as well as
for almost any CNV detection threshold, stability rates were at least slightly higher
with MCMR than with Default intensity reference values.
Figure 6.6: Stability rate (= pairwise concordance rates) of CNV calls using repli-
cate’s data sets on same individuals (n = 5). p: probe sets per CNV
call, D: Default calling, M: MCMR calling
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Table 6.1: Stability rates (= pairwise concordance rates) of CNV calls using five replicate’s data sets on same individuals (n = 5).
claimed #
of probe
sets per
CNV call
median number of
CNV calls
minimal
pairwise
concordance
(overlap)
median pairwise
concordance rates
mean pairwise
concordance rates
sd* of pairwise
concordance rates
p-value,
two-sided
paired
t-test
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
> 3 62 61
any 84.50% 85.83% 84.28% 85.55% 3.00% 3.40% 4.17× 10−4
> 50% 79.30% 80.35% 79.11% 80.19% 4.20% 5.04% 0.0145
100% 48.24% 48.65% 47.81% 48.21% 6.31% 6.74% 0.5200
> 5 61 60
any 85.15% 86.48% 84.91% 86.00% 3.16% 3.18% 0.0041
> 50% 80.15% 80.70% 79.73% 80.59% 4.33% 4.83% 0.0564
100% 48.12% 48.61% 47.88% 48.25% 6.17% 6.53% 0.5498
> 10 53 53
any 86.27% 87.50% 86.28% 87.26% 2.68% 3.19% 0.0100
> 50% 80.77% 81.84% 80.72% 81.42% 4.67% 5.15% 0.1467
100% 48.04% 47.67% 47.53% 47.23% 7.17% 7.04% 0.6759
> 15 47 46
any 87.36% 87.70% 87.68% 87.79% 3.10% 3.52% 0.7428
> 50% 82.14% 82.61% 82.75% 82.93% 4.75% 5.34% 0.7471
100% 46.79% 47.46% 47.06% 46.52% 7.06% 7.38% 0.4821
> 20 40 38
any 89.51% 89.97% 89.44% 89.84% 3.08% 3.11% 0.2350
> 50% 84.93% 84.93% 84.41% 84.79% 4.81% 4.61% 0.4652
100% 46.33% 46.48% 46.23% 45.82% 8.43% 7.50% 0.5873
> 25 33 32
any 89.26% 89.57% 89.55% 89.51% 3.24% 3.01% 0.9116
> 50% 85.90% 85.29% 85.69% 85.37% 4.81% 4.67% 0.5975
100% 45.66% 45.90% 45.70% 45.03% 7.73% 7.70% 0.4145
* sd = standard deviation.
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6.2.3.2 Reproducibility Rates of CNVs
CNV calls of the above described replicate data for five individuals have also been
investigated with regard to their reproducibility across five replicate experiments.
Individual reproducibility rates were determined for each genomic interval with iden-
tical replicate-wise CNV configuration (Figure 6.8, Table 6.2).
For this purpose, overlapping CNVs of each individual’s five replicates were at
first merged into one CNV region (CNVR). The breakpoints of the maximum in-
terval covered by any overlapping CNV were chosen as the CNVR’s boundaries.
Afterwards, individual complex CNVRs including replicate CNVs with discordant
estimated boundaries but overlapping segments, were subdivided into several sub-
CNVRs as depicted in Figure 6.7. Thus, each sub-CNVR was defined to contain
only one specific replicate CNV and not to harbour two different copy number states
per replicate. Consequently, the sub-CNVR’s boundaries were exactly given by the
set of CNV’s breakpoints. Briefly, a CNVR represents a union of overlapping CNVs
and the sub-CNVRs precisely describe the exact structure of the CNVR.
Figure 6.7: Schematic representation of a CNV region (CNVR) containing six sub-
CNVRs, being defined by overlapping CNV calls of five replicates for the
same individual, with reproducibility rates ranging from 0 to 100%.
With regard to the number of available replicate experiment data sets per indi-
vidual (n = 5), reproducibility rates were calculated with respect to 2/5 %, 3/5 %,
4/5 %, and 100 % concordance across CNV calls at the sub-CNVR level. In more
detail, the x% reproducibility rate was defined to equal the proportion of individual
sub-CNVRs with consistent CNV calling results in at least x% of the replicates.
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Neither the stability rate nor the reproducibility rate directly predict the CNV
calling performance of Default or MCMR reference intensity values; however, they
both indicate the stability and reproducibility of CNV detection performance. Table
6.2 shows that CNV calls based on MCMR reference intensity values have higher
average estimated reproducibility compared with Default reference intensity values.
The difference in reproducibility rates decreases when the minimal number of in-
formative array probe sets per CNV call increases, that is with an increased CNV
detection threshold. Reproducibility rates are statistically significantly higher in
application of MCMR reference intensity values in comparison to Default reference
intensity values, when CNV calls where claimed to harbour more than three, five or
ten probe sets and when then a complete reproducibility of 100% is considered.
Similarly to the stability rates, reproducibility rates were at the highest level for
a CNV detection threshold of 20 probe sets per CNV call, and this was consistently
observed across each reproducibility value as well as for both, MCMR and Default
reference intensity values. Thus, this threshold for CNV detection of > 20 probe sets
per CNV call will be applied throughout the following considerations if not stated
otherwise.
Figure 6.8: Reproducibility of CNV calls from five replicate’s data sets for a total of
five individuals. D: Default calling, M: MCMR calling
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Table 6.2: Reproducibility rates of CNV calls using five replicate’s data sets on same
individuals (n = 5).
claimed
# of
probe
sets per
CNV
call
mean
number
of sub-
CNVRs
with
Default
[MCMR]
reference
repro-
ducibi-
lity
mean of sdb of p-
value,
two-
sided
paired
t-test
reproducibility
ratesa
reproducibility
ratesa
Default
Default
Calling
Default
Default
Default
MCMR
Calling
Default
Default
Default
Default
Calling
Default
Default
Default
MCMR
Calling
Default
Default
> 3
235.2
[230.4]
≥ 40% 74.93% 78.23% 5.03% 3.70% 0.0675
≥ 60% 57.05% 61.63% 7.04% 4.87% 0.1441
≥ 80% 45.28% 47.72% 7.57% 5.82% 0.1304
100% 29.77% 32.00% 3.68% 4.03% 0.0088
> 5
229.2
[225.6]
≥ 40% 75.68% 78.62% 5.10% 3.75% 0.1265
≥ 60% 58.01% 62.36% 6.50% 4.76% 0.1742
≥ 80% 45.94% 48.15% 7.36% 5.62% 0.1888
100% 30.21% 32.49% 3.75% 3.95% 0.0122
> 10
202.0
[199.2]
≥ 40% 75.46% 78.36% 5.76% 4.23% 0.1463
≥ 60% 57.86% 61.51% 8.12% 5.81% 0.2524
≥ 80% 45.67% 46.79% 8.61% 6.01% 0.4715
100% 30.84% 32.73% 4.58% 5.00% 0.0357
> 15
171.6
[168.0]
≥ 40% 75.42% 77.93% 6.35% 5.62% 0.1482
≥ 60% 58.88% 61.58% 9.07% 6.28% 0.2909
≥ 80% 46.83% 46.67% 8.17% 7.38% 0.8683
100% 31.32% 32.82% 4.02% 5.33% 0.1167
> 20
144.8
[141.2]
≥ 40% 77.58% 79.80% 7.52% 6.00% 0.2720
≥ 60% 60.95% 65.07% 9.93% 6.34% 0.1677
≥ 80% 48.59% 49.57% 7.77% 5.97% 0.3683
100% 31.72% 33.54% 4.33% 5.62% 0.1634
> 25
113.2
[112.0]
≥ 40% 77.29% 78.10% 4.48% 2.65% 0.6109
≥ 60% 60.64% 61.98% 7.67% 6.37% 0.4285
≥ 80% 46.18% 46.64% 6.94% 5.90% 0.7506
100% 30.99% 32.20% 4.21% 4.52% 0.4212
a The x% reproducibility rate equals the proportion of individual sub-CNVRs with consistent
CNV calling results in at least x% of the individual’s replicates.
b sd = standard deviation.
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6.2.3.3 False Positives and Negatives for CNVs of NA15510
Individual NA15510 has previously been investigated using various technical and
algorithmic approaches, as for instance by Tuzun et al. (2005), Korbel et al. (2007),
Redon et al. (2006) and Kidd et al. (2008). In all these four reports, CNV results
were followed up by at least one alternative experimental method. CNVs that could
be validated in this way were considered in the following investigations of false
positive and false negative CNV calls of NA15510’s five replicates.
A comparison of previous results is summarized in Table 6.3 and in Figure 6.9.
Apart from results of Tuzun et al. (2005) and Kidd et al. (2008), the overlap of CNVs
across the studies is in general low. Out of a total of 681 CNV segments, only four
segments were consistently reported in all four publications. The majority of CNVs
(67.40%) was exclusively detected in one study. Due to this inconsistency in CNV
results across various designs, quality assessment for CNV detection algorithms is
complicated. Here, false positve and false negative rates for replicates of NA15510
are likewise given with respect to each previous study.
Table 6.3: Overlap between CNVs for NA15510 reported by four publications.
All reported CNV calls
overlap in %* Kidd Korbel Redon Tuzun
Kidd (n = 248) - 22.18% 5.65% 77.82%
Korbel (n = 340) 16.18% - 8.24% 14.71%
Redon (n = 160) 8.75% 17.50% - 7.50%
Tuzun (n = 218) 88.53% 22.94% 5.50% -
.
Validated reported CNV calls
overlap in %* Kidd Korbel Redon Tuzun
Kidd (n = 198) - 17.17% 7.07% 41.41%
Korbel (n = 114) 28.95% - 5.26% 13.16%
Redon (n = 125) 11.20% 4.80% - 4.80%
Tuzun (n = 95) 86.32% 15.79% 6.32% -
* CNV overlap has been calculated at the CNV segment level (see Figure 6.5), that is several
overlapping CNV calls of the same type were combined into one CNV segment.
Concerning previous reports, there seems to be a trend of longer CNVs being
more concordantly detected by use of different technical and methodical approaches
(Figure 6.9). However, this trend is not statistically significant (Kruskal-Wallis rank
sum test; all CNVs: p-value = 0.32, validated CNVs only: p-value = 0.17).
97
6.2 Comparison of Partially Applied Strategy S2 and strategy PS2 to HapMap
and Replicate Data
Figure 6.9: Similarity of CNVs for NA15510 reported by four publications.
A variety of false negative CNV reports in several studies is potentially caused
by technological limitations coupled with restricted genomic resolution. As shown
in Figure 6.10, the distributions of CNV lengths across studies are statistically sig-
nificantly different depending on the applied experimental method (Kruskal-Wallis
rank sum test p-value < 2.2× 10−16).
Although gains and losses < 1 kb were in fact primarily not regarded as a CNV,
this definition increasingly broke down with the ability of sequencing technologies
to detect much smaller variants with varying copy number in a population. Thus,
currently listed CNVs in the Database of Genomic variants (DGV) additionally
encompass such small deletions and insertions of less than 1 kb. Consequently, all
gain or loss data were considered as CNVs here. In contrast to the application of
sequencing techniques (Tuzun et al. (2005), Korbel et al. (2007) and Kidd et al.
(2008)), the use of former SNP arrays limited CNV detection to the identification of
larger variants due to their sparse probe density on the genome (Redon et al. (2006)).
However, since the genomic probe coverage of currently available SNP genotyping
arrays, such as the Affymetrix 6.0 array, is doubled relative to those SNP arrays
used by Redon et al. (2006), CNVs of almost the complete size spectrum became
detectable without sequencing approaches (see results for PennCNV in Figure 6.10).
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Figure 6.10: Distribution of CNV length for NA15510 in four publications and in
application of PennCNV with Default and MCMR reference values.
Sources for CNV calls: 0 = Kidd et al. (2008), 1 = only validated
CNVs from Kidd et al. (2008), 2 = Korbel et al. (2007), 3 = only
validated CNVs from Korbel et al. (2007), 4 = Redon et al. (2006), 5 =
only validated CNVs from Redon et al. (2006), 6 = Tuzun et al. (2005),
7 = only validated CNVs from Tuzun et al. (2005), 8 = PennCNV with
MCMR reference intensity values, 9 = PennCNV with Default reference
intensity values.
CNV calls for the sample NA15510 were estimated in application of the PennCNV
software in consideration of median (Default) and MCMR reference intensity val-
ues, respectively. The percentage of false positive and false negative findings was
evaluated with respect to results of the four previous publications (Table 6.4). In
more detail, results of each single study, the respective validated CNV results as well
as the combined set of all reported or all validated CNVs were considered as gold
standard for sensitivity and specificity analyses. Thus, a total of ten different gold
standard test settings were investigated in order to address the above mentioned dif-
ficulty in finding an appropriate global CNV reference set. Apart from false negative
estimates, results for Redon et al. (2006) were identical to those for only validated
CNVs of Redon et al. (2006). As expected, false negative estimates were lower with
respect to validated CNVs. However, this was consistently observed for both, De-
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fault and MCMR reference values, whereas the respective specificity estimates were
identical. Thus, false positive and false negative estimates are only presented once
for Redon et al. (2006) in Table 6.4.
Both, false positive and false negative estimates were calculated at the CNV seg-
ment level (see Figure 6.5). For each replicate, the percentage of false positive
CNV calls was defined to equal the number of called but not confirmed CNV seg-
ments among the total number of called CNV segments. Contrarily, the percentage
of false negative CNV calls was calculated as the percentage of non-called CNVs
among the set of gold standard CNVs. Estimates for false positive and negative
rates were determined in application of the CNV detection thresholds of more than
3, 5, 10, 15, 20 and 25 probe sets per CNV call and for confirmation thresholds of
more than 0%, 50%, 80% and exactly 100% overlap between PennCNV’s and gold
standard CNV calls. In order to allow a fair comparison, CNV detection thresholds
were likewise applied to gold standard CNVs.
Differences for Default and MCMR based CNV calls showed comparable direc-
tional trends across CNV detection and confirmation thresholds. Since the inclusion
of CNVs that involved more than 20 array probe sets yielded the highest stability
and reproducibility rates (see Table 6.1 and Table 6.2), only results for this CNV
detection threshold of > 20 array probe sets per CNV are presented in Table 6.4.
Moreover, results for confirmation thresholds of more than 80% and exactly 100%
overlap were similar, whereas false positive and false negative estimates were lowest
when any overlap between PennCNV’s CNV calls and gold standard CNVs was
considered as a confirmation of CNV calls. Consequently, results are only given
with respect to a confirmation threshold of more than 0% overlap in Table 6.4.
On the one hand, the number of called CNVs is lower in application of MCMR
reference intensity values (n=43) compared to Default reference intensity values
(n=49). On the other hand, the percentage of false positive CNV calls was for almost
all gold standards, with the exception of one (Korbel et al. (2007)), reduced by ap-
plication of alternative MCMR reference intensity values. For most gold standards,
the false positive rate was even statistically significantly reduced by on average 2.1%
and especially by up to 4% with respect to the set of validated reference CNVs from
all four publications. Moreover, the percentage of false negative CNVs was overall
comparable between Default and MCMR based CNV calls with an average increase
of 0.6% false negatives for alternative MCMR reference intensity values. However,
there was no difference at all for half of the considered gold standard CNV sets,
and with respect to the set of all validated reported CNVs an increase of 0.3% false
negatives was observed for MCMR based CNVs realative to Default CNV calls.
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Table 6.4: Genome-wide false positive and false negative estimates for CNV calls of five replicates for NA15510. Genome-wide
gold
Gold
Standard
confirmeda non-confirmedb total % false positivesc % false negativesd
replicate
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Korbel
replicate 1 25 23 17 16 42 39 40.48% 41.03% 66.22% 68.49%
replicate 2 21 20 18 17 39 37 46.15% 45.95% 71.62% 72.60%
replicate 3 22 21 16 15 38 36 42.11% 41.67% 70.27% 71.23%
replicate 4 22 20 15 14 37 34 40.54% 41.18% 70.27% 72.60%
replicate 5 22 20 15 15 37 35 40.54% 42.86% 70.27% 72.60%
average
[total, unique]
22.4
[28]
20.8
[25]
16.2
[21]
15.4
[18]
38.6
[49]
36.2
[43]
41.96% 42.54% 69.73% 71.50%
p-valuee,
two-sided
paired t-test
- - - 0.3011 0.0057
Korbel -
validated
replicate 1 12 11 30 28 42 39 71.43% 71.79% 55.56% 59.26%
replicate 2 10 10 29 27 39 37 74.36% 72.97% 62.96% 62.96%
replicate 3 10 10 28 26 38 36 73.68% 72.22% 62.96% 62.96%
replicate 4 10 9 27 25 37 34 72.97% 73.53% 62.96% 66.67%
replicate 5 11 10 26 25 37 35 70.27% 71.43% 59.26% 62.96%
average
[total, unique]
10.6
[14]
10
[12]
28
[35]
26.2
[31]
38.6
[49]
36.2
[43]
72.54% 72.39% 60.74% 62.96%
p-valuee,
two-sided
paired t-test
- - - 0.3693 0.0705
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Table 6.4: continued. continued continued continued continued continued continued continued continued continued continued con
gold
Gold
Standard
confirmeda non-confirmedb total % false positivesc % false negativesd
replicate
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Kidd
replicate 1 22 21 20 18 42 39 47.62% 45.15% 86.00% 86.67%
replicate 2 21 21 18 16 39 37 46.15% 43.24% 86.67% 86.67%
replicate 3 20 20 18 16 38 36 47.37% 44.44% 88.00% 88.00%
replicate 4 19 19 18 15 37 34 48.65% 44.12% 88.00% 88.00%
replicate 5 18 19 19 16 37 35 51.35% 45.71% 88.00% 87.33%
average
[total, unique]
20
[24]
20
[23]
18.6
[26]
16.2
[21]
38.6
[49]
36.2
[43]
48.23% 44.73% 87.33% 87.33%
p-valuee,
two-sided
paired t-test
- - - 0.0084 1.0000
Kidd -
validated
replicate 1 20 19 22 20 42 39 52.38% 51.28% 83.19% 84.03%
replicate 2 19 19 20 18 39 37 51.28% 48.65% 84.03% 84.03%
replicate 3 18 18 20 18 38 36 52.63% 50.00% 85.71% 85.71%
replicate 4 17 17 20 17 37 34 54.05% 50.00% 85.71% 85.71%
replicate 5 17 18 20 17 37 35 54.05% 48.57% 85.71% 84.87%
average
[total, unique]
18.2
[22]
18.2
[21]
20.4
[27]
18
[22]
38.6
[49]
36.2
[43]
52.88% 49.70% 84.87% 84.87%
p-valuee,
two-sided
paired t-test
- - - 0.0128 1.0000
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Table 6.4: continued. continued continued continued continued continued continued continued continued continued continued con
gold
Gold
Standard
confirmeda non-confirmedb total % false positivesc % false negativesd
replicate
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Tuzun
replicate 1 19 18 23 21 42 39 54.76% 53.85% 85.27% 86.05%
replicate 2 18 18 21 19 39 37 53.85% 51.85% 86.05% 86.05%
replicate 3 17 17 21 19 38 36 55.26% 52.78% 87.60% 87.60%
replicate 4 16 16 21 18 37 34 56.76% 52.94% 87.60% 87.60%
replicate 5 16 17 21 18 37 35 56.76% 51.43% 87.60% 86.82%
average
[total, unique]
17.2
[21]
17.2
[20]
21.2
[28]
19
[23]
38.6
[49]
36.2
[43]
55.48% 54.47% 86.82% 86.82%
p-valuee,
two-sided
paired t-test
- - - 0.0154 1.0000
Tuzun -
validated
replicate 1 8 7 34 32 42 39 80.95% 82.05% 87.10% 88.71%
replicate 2 7 7 32 30 39 37 82.05% 81.08% 88.71% 88.71%
replicate 3 8 8 30 28 38 36 78.95% 77.78% 88.71% 88.71%
replicate 4 7 7 30 27 37 34 81.08% 79.41% 88.71% 88.71%
replicate 5 7 7 30 28 37 35 81.08% 80.00% 88.71% 88.71%
average
[total, unique]
7.4
[9]
7.2
[8]
31.2
[40]
29
[35]
38.6
[49]
36.2
[43]
80.82% 80.06% 88.39% 88.71%
p-valuee,
two-sided
paired t-test
- - - 0.1892 0.3739
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Table 6.4: continued. continued continued continued continued continued continued continued continued continued continued con
gold
Gold
Standard
confirmeda non-confirmedb total % false positivesc % false negativesd
replicate
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Redon
replicate 1 20 20 22 19 42 39 52.38% 48.72% 86.67% 86.67%
replicate 2 18 18 21 19 39 37 53.85% 51.35% 88.00% 88.00%
replicate 3 18 18 20 18 38 36 52.63% 50.00% 88.00% 88.00%
replicate 4 18 18 19 16 37 34 51.35% 47.06% 88.00% 88.00%
replicate 5 18 18 19 17 37 35 51.35% 48.57% 88.00% 88.00%
average
[total, unique]
18.4
[20]
18.4
[20]
20.2
[29]
17.8
[23]
38.6
[49]
36.2
[43]
52.31% 49.14% 87.73% 87.73%
p-valuee,
two-sided
paired t-test
- - - 7.82E− 04 1.0000
Korbel,
Kidd,
Tuzun &
Redon
replicate 1 38 35 4 4 42 39 9.52% 10.26% 86.71% 87.72%
replicate 2 34 33 5 4 39 37 12.82% 10.81% 88.11% 88.42%
replicate 3 34 33 4 3 38 36 10.53% 8.33% 88.11% 88.42%
replicate 4 33 31 4 3 37 34 10.81% 8.82% 88.46% 89.12%
replicate 5 34 33 3 2 37 35 8.11% 5.71% 88.11% 88.42%
average
[total, unique]
34.6
[42]
33
[38]
4
[7]
3.2
[5]
38.6
[49]
36.2
[43]
10.36% 8.79% 87.90% 88.42%
p-valuee,
two-sided
paired t-test
- - - 0.0542 0.0206
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Table 6.4: continued. continued continued continued continued continued continued continued continued continued continued con
gold
Gold
Standard
confirmeda non-confirmedb total % false positivesc % false negativesd
replicate
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Default
Calling
MCMR
Calling
Korbel,
Kidd,
Tuzun &
Redon -
validated
replicate 1 36 34 6 5 42 39 14.29% 12.82% 84.62% 85.47%
replicate 2 32 32 7 5 39 37 17.95% 13.51% 86.32% 86.32%
replicate 3 32 32 6 4 38 36 15.79% 11.11% 86.75% 86.75%
replicate 4 31 30 6 4 37 34 16.22% 11.76% 86.75% 87.18%
replicate 5 32 32 5 3 37 35 13.51% 8.57% 86.32% 86.32%
average
[total, unique]
32.6
[40]
32
[37]
6
[9]
4.2
[6]
38.6
[49]
36.2
[43]
15.55% 11.55% 86.15% 86.41%
p-valuee,
two-sided
paired t-test
- - - 0.0033 0.2071
Both, PennCNV’s CNV calls (Default and MCMR) as well as gold standard CNVs were claimed to harbour more than 20 informative Affymetrix 6.0
probe sets.
a Confirmed CNV calls are those that were likewise reported in the gold standard study.
b Non-confirmed CNV calls are those that were called but not reported otherwise.
c The percentage of false positives was calculated as the cardinal number of the overlap between PennCNV’s CNV calls and gold standard CNVs divided
by the total number of PennCNV’s CNV calls.
d The percentage of false negatives was calculated as the number of gold standard CNVs that were not called with PennCNV divided by the total
number of gold standard CNVs.
e P-values < 0.05 with an effect direction indicating a superiority (inferiority) of MCMR reference intensity values over Default reference intensity values
are printed in red (green).
d 2-sided p-values of paired t-tests
d 2-sided p-values of paired t-tests
d 2-sided p-values of paired t-tests
d 2-sided p-values of paired t-tests
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6.2 Comparison of Partially Applied Strategy S2 and strategy PS2 to HapMap
and Replicate Data
6.2.3.4 False Positives and Negatives for HapMap CNVs
Results of eight previous publications, namely Kidd et al. (2008), Park et al. (2010),
Perry et al. (2008), Conrad et al. (2006), Shaikh et al. (2009), Conrad et al. (2010),
McCarroll et al. (2008) and Redon et al. (2006), for CNVs of up to 270 HapMap
individuals were used to estimate the percentage of false positive and false negative
CNV calls derived from PennCNV in application of Default and MCMR reference
intensity values.
At first, previously reported CNV results were compared against each other with
regard to an overall concordance. Since not all studies investigated CNVs on all
270 HapMap samples, only CNVs of those individuals that were analysed in both of
any pair of two publications were checked for consistency at the CNV segment level
(see Figure 6.5 for details). As presented in Table 6.5, the pairwise overall overlap
between any two previous reports on HapMap CNVs is low, it ranges from 0.62%
to 67.8% (mean = 24.03%, median = 16.73%).
Table 6.5: Pair-wise overall between HapMap CNVs reported by eight publications.
overlap
in %
[# of
samples]*
K
id
d
P
ar
k
P
er
ry
C
on
ra
d
(M
en
d
el
)
S
h
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h
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on
ra
d
(T
il
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g)
M
cC
ar
ro
ll
R
ed
on
Kidd - - 9.0 [2]
0.6
[3]
1.7 [3]
10.8
[8]
6.1
[8]
1.7 [8]
Park - -
16.8
[5]
- 2.7 [8]
45.9
[20]
14.4
[20]
4.3
[20]
Perry
10.0
[2]
21.1
[5]
-
1.2
[12]
3.1
[11]
18.0
[30]
12.3
[30]
10.4
[30]
Conrad
(Mendel)
44.0
[3]
-
45.0
[12]
-
28.6
[27]
54.4
[60]
46.8
[60]
19.4
[60]
Shaikh
40.6
[3]
67.8
[8]
49.1
[11]
12.8
[27]
-
54.5
[111]
48.0
[111]
26.7
[111]
Conrad
(Tiling)
16.6
[8]
46.7
[20]
13.1
[30]
1.1
[60]
2.3
[111]
-
13.1
[270]
3.1
[270]
McCarroll
43.1
[8]
62.9
[20]
40.6
[30]
4.2
[60]
8.9
[111]
58.3
[270]
-
13.1
[270]
Redon
25.1
[8]
39.1
[20]
66.1
[30]
3.2
[60]
9.3
[111]
26.4
[270]
25.1
[270]
-
* CNV overlap has been calculated at the CNV segment level (see Figure 6.5 for details). The
presented percentaged overlap equals the proportion of CNVs reported by the publication
in row that were also reported by the publication in column.
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6.2 Comparison of Partially Applied Strategy S2 and strategy PS2 to HapMap
and Replicate Data
Furthermore, the concordance of results from those three studies (Conrad et al.,
2010; McCarroll et al., 2008; Redon et al., 2006) that investigated CNVs on all
270 HapMap samples is depicted in Figure 6.11. In all these publications, CNVs
were derived from data of SNP genotyping arrays of different type and resolution.
Only 1.66% of all reported CNVs can be consistently found in all three publications,
and 11.44% are consistent throughout exactly two publications. Thus, the majority
(86.90%) of previously published HapMap CNVs was only stated once. Conse-
quently, false positive and false negative estimates being calculated with respect to
previous results, can only be seen as a rough potentially biased estimate.
Figure 6.11: Venn diagram for CNVs of 270 HapMap individuals from three studies
(Conrad et al. (2010), McCarroll et al. (2008) and Redon et al. (2006)).
The percentage of false positive and false negative PennCNV’s CNV calls was
calculated for CNV detection thresholds of more than 3, 5, 10, 15, 20 and 25 probe
sets per PennCNV and gold standard CNVs. Moreover, confirmation thresholds of
more than 0%, 50%, 80% and exactly 100% reciprocal overlap were considered with
respect to each as well as to all previous publications as gold standard. Differences
for Default and MCMR calling were directionally consistent across different CNV
detection and confirmation thresholds. With regard to results of previous chapters
(see Table 6.1 and Table 6.2), comparative results on false positive and false negative
estimates are presented in Table 6.6 and Figure 6.12 for a CNV detection threshold
of more than 20 probe sets per CNV call and for a confirmation threshold that
implicates any overlap between experiment (PennCNV) and gold standard as a
confirmation event.
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Table 6.6: Genome-wide false positive and false negative estimates for CNV calls of up to 270 HapMap individuals. Genome-wide
Gold
Standard
[# of
samplesa]
# of CNV calls % of false positivesb % false negativesc
Calling
Calling
total
sample’s
median
[mean]
p-valued total
sample’s
median
[mean]
p-valued total
sample’s
median
[mean]
p-valued
Kidd
[8]
Gold 3 917 470.5 [489.62] - - - [-] - - - [-] -
Default 338 41.5 [42.25]
0.1090
53.85 56.32 [54.27]
0.1028
94.64 92.12 [88.80]
0.6758
MCMR 325 39.5 [40.62] 51.69 49.89 [52.01] 94.59 92.12 [89.02]
Kidd -
validated
[8]
Gold 1 077 152.5 [134.62] - - - [-] - - - [-] -
Default 338 41.5 [42.25]
0.1090
55.92 57.27 [56.37]
0.1064
81.24 81.77 [78.48]
0.8687
MCMR 325 39.5 [40.62] 53.85 51.33 [54.13] 81.06 80.47 [78.59]
Park [20]
Gold 1 734 71.5 [86.70] - - - [-] - - - [-] -
Default 773 40 [38.65]
0.8180
28.59 26.38 [28.36]
0.1450
67.24 58.75 [63.16]
0.9258
MCMR 771 40.5 [38.55] 27.37 26.28 [27.04] 67.19 57.73 [63.11]
Perry [30]
Gold 2 598 86 [86.60] - - - [-] - - - [-] -
Default 1 231 43 [41.03]
0.1364
30.22 30.5 [29.95]
0.0041
67.51 67.60 [67.32]
0.2689
MCMR 1 215 40.5 [40.50] 28.97 29.8 [28.70] 67.90 67.07 [67.68]
Conrad
(Mendel)
[60]
Gold 618 10 [10.47] - - - [-] - - - [-] -
Default 1 642 28 [27.83]
0.3842
84.10 84.85 [83.69]
0.0883
47.25 50 [44.84]
0.5208
MCMR 1 649 28 [27.95] 84.29 84.85 [83.98] 47.41 50 [45.30]
Shaikh
[112]
Gold 919 8 [8.28] - - - [-] - - - [-] -
Default 4 777 43 [43.04]
1.21E-08
76.43 76.47 [76.19]
2.09E-05
7.18 0 [6.53]
0.9040
MCMR 4 635 41 [41.76] 75.71 75.68 [75.53] 7.18 0 [6.57]
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Table 6.6: continued. continued continued continued continued continued continued continued continued continued continued con
Gold
Standard
[# of
samplesa]
# of CNV calls % of false positivesb % false negativesc
Calling total
sample’s
median
[mean]
p-valued total
sample’s
median
[mean]
p-valued total
sample’s
median
[mean]
p-valued
Shaikh -
validated
[112]
Gold 867 7 [7.81] - - - [-] - - - [-] -
Default 4 777 43 [43.04]
1.21E-08
77.35 76.92 [77.03]
5.76E-05
2.08 0 [1.81]
0.1999
MCMR 4 635 41 [41.76] 76.68 77.08 [76.43] 2.42 0 [2.17]
Conrad
(Tiling)
[270]
Gold 21 529 80 [80.33] - - - [-] - - - [-] -
Default 12 330 43 [46.01]
4.99E-12
53.50 49.94 [49.57]
0.0024
70.73 71.16 [70.89]
6.55E-26
MCMR 12 017 41 [44.84] 53.84 50 [50.02] 71.95 72.22 [72.11]
McCarroll
[270]
Gold 14 922 55 [55.47] - - - [-] - - - [-] -
Default 12 357 43 [45.94]
6.03E-12
43.13 37.93 [38.49]
9.56E-19
52.20 51.72 [52.35]
0.1571
MCMR 12 045 41 [44.78] 41.70 36.54 [36.94] 52.41 52.17 [52.57]
Redon
[270]
Gold 17 302 63 [64.32] - - - [-] - - - [-] -
Default 12 357 43 [45.94]
6.03E-12
61.23 57.69 [57.83]
2.38E-06
82.77 82.50 [81.81]
0.0285
MCMR 12 045 41 [44.78] 60.50 56.86 [57.15] 82.87 82.81 [81.99]
any
[270]
Gold 66 696 225 [247.94] - - - [-] - - - [-] -
Default 12 357 43 [45.94]
6.03E-12
24.36 17.31 [18.19]
5.97E-05
67.07 65.52 [65.77]
1.99E-09
MCMR 12 045 41 [44.78] 23.76 16.67 [17.64] 67.53 65.96 [66.29]
a Only CNV calls of samples that were analysed in the gold standard study were considered in the comparison of Default and MCMR calling.
b CNV calls with any overlap between gold standard and Default or MCMR calling were considered as being recovered, respectively.
c CNV calls with no overlap between gold standard and Default or MCMR calling were considered as being unrecovered, respectively.
d Two-sided p-values of paired t-tests are reported. P-values < 0.05 with a superior (inferior) effect of MCMR references relative to Default ones
are printed red (green).
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6.2 Comparison of Partially Applied Strategy S2 and strategy PS2 to HapMap
and Replicate Data
Figure 6.12: Number, false positive and negative rates of Default and MCMR based
CNV calls of up to 270 HapMap individuals.
Regarding the number of individual CNV calls, an MCMR based CNV detection
yields statistically significantly less CNV calls compared to the Default approach.
On average, the mean number of CNV calls per individual was reduced by 0.998 calls
(2.26%) when applying alternative MCMR reference intensity values. Moreover, the
percentage of false positive MCMR CNV calls was reduced with respect to almost
all considered gold standards. With increasing sample size, statistical significance
for a reduction of the false positive rate was increasingly observable. In particular,
for all studies that incorporated more than 100 individuals, the percentage of false
positives was statistically significantly reduced. With MCMR calling, a 0.94% lower
mean false positive rate was reached on average. Mean false negative rates tend to
be higher with MCMR reference intensity values by on average 0.33%.
6.2.3.5 Mendelian Inconsistency Rates for HapMap CNVs
Another measure for comparing the accuracy of CNV detection algorithms is the rate
of Mendelian inconsistent CNV calls in family data. Previous results of McCarroll
et al. (2008) and Redon et al. (2006) demonstrate that more than 99% of all CNV
events are derived from inheritance rather than from new mutations. Thus, observed
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Mendelian discordance across estimated familial CNVs is most likely caused by a
misclassification of CNVs rather than by de novo events at these loci.
For a total of 60 HapMap trios (30 CEPH & 30 YRI), Mendelian inconsistency
rates were investigated for CNV calls based either on Default or MCMR reference
intensity values. For each trio, the proportion of those offspring’s CNVs was deter-
mined that were not estimated to be derived from parental CNVs in a Mendelian
mode of inheritance. As shown in Table 6.7, there was no statistically significant
difference in Mendelian inconsistency rates across 60 HapMap trios between those
CNVs that were derived from the Default or from the alternative (MCMR) approach,
respectively.
Table 6.7: Mendelian Inconsistency Rates in offspring’s CNVs of 60 HapMap trios.
number of
CNV calls in
offspring
mean
Default Calling 46.33
MCMR Calling 45.47
median
Default Calling 45.0
MCMR Calling 44.0
Mendelian
inconsistency
rate* [%]
mean
Default Calling 17.2
MCMR Calling 17.6
median
Default Calling 15.9
MCMR Calling 17.1
p-value, two-sided paired t-test 0.4253
* The Mendelian inconsistency rate was calculated as the proportion of offspring’s CNVs that
are not estimated to be derived from Mendelian inheritance.
6.2.4 Discussion
Validity of CNV calls is an essential component of association studies of CNVs with
disease. Modification of strategy S2 into the proposed analysis strategy PS2 was mo-
tivated by the desire to improve CNV genotyping accuracy and thereby improving
the meaningfulness of subsequent association test results. Consequently, the sepa-
rate investigation of the isolated CNV calling step of both strategies was considered
to be appropriate prior to the presentation of the whole strategy’s implementation,
which is given in the following chapter. In our evaluation of the two involved in-
tensity reference models for CNV identification, we found considerable variation
among the reference models in terms of the number of CNVs called, their stability
and reproducibility rates as well as false positive and false negative estimates.
For stability rates of replicate CNVs detected by use of MCMR and Default refer-
ence values, alternative reference intensity values were overall superior to the most
111
6.2 Comparison of Partially Applied Strategy S2 and strategy PS2 to HapMap
and Replicate Data
widely used median ones. The differences declined when the number of minimal
probe sets per CNV call increased. However, stability rates for both references were
poor when an absolute identity between individual replicate CNV calls was consid-
ered as a pairwise concordance event. For CNVs containing more than 20 probe
sets and any pairwise overlap being considered as a stable calling event, MCMR
and Default references showed highest median stability rates of 89.97% and 89.51%.
To some extent, the comparability between stability rates of MCMR and Default
is limited by the small number of available replicate data sets, which was only five
replicates for each of five individuals.
Consistently, MCMR calling showed higher mean reproducibility rates compared
to Default calling. As with stability rates, the superiority of MCMR calling de-
creased with increasing CNV detection threshold, i.e. with higher minimal number
of involved array probe sets. In case of Default calling, mean reproducibility rates
were lowest for the maximal set of all called CNVs throughout all concordance lev-
els (40%, 60%, 80% and 100%). For MCMR calling, no connection was observed
between lowest reproducibility rates and CNV detection thresholds. Highest repro-
ducibility rates were, however, concordantly found when including only CNV calls
with more than 20 probe sets for both calling approaches (Default: 77.6%, MCMR:
79.8%). At least for the five individuals with available replicate data, the num-
ber of MCMR and Default CNV calls and subCNVRs reached comparable levels.
Thus, higher stability and reproducibility of MCMR calling may indeed indicate its
improved reliablity over Default calling. However, generality of this ovservation is
limited by the small number of available replicate data (n = 5).
Concerning sample NA15510, MCMR calling produced six fewer calls relative
to the 49 standard derived CNVs. Being confronted with a variety of differently
composed CNV gold standards, MCMR calls were continuously assessed to include
a lower percentage of false positives with simultaneously unchanged false negative
rates in comparison to Default calling. Relatively poor consistence was found be-
tween the four considered gold standards. Investigation of CNV call’s false rates is
limited by this lack of a gold standard, since some type of CNVs might be over- or
under-represented in recent reports. It is challenging to assess whether both call-
ing approaches are likewise affected by these inadequacies. Future next-generation
sequencing might overcome this concern in providing an ultimate gold standard.
Observations from the investigation of sample NA15510 could be strengthened by
respective evaluation of false CNV rates for up to 270 HapMap samples. Again, the
number of CNV calls tended to be lower with MCMR calling. Moreover, false posi-
tive rates were reduced compared to standard calling for almost all considered gold
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standards. However, false negative rates tend to be higher by alternative MCMR
reference values. Thus, the reduced number of CNV calls might end up with loosing
true CNV findings when switching from standard to MCMR calling.
Finally, an absence of any difference in genome-wide Mendelian inconsistency
rates was observed across 60 HapMap trios. This underlines that applying MCMR
calling instead of Default calling, which was shown to offer the potential to improve
validity of CNV calls, might overall lead to no more than moderately positive effects.
However, on the one hand the number of available HapMap trios was limited to a
relatively small number, which might cause a lack of statistical power to detect true
underlying quality differences between Default and MCMR calling. On the other, it
is quite conceivable that the correct classification of only one causal CNV loci might
suffice to detect CNV association effects on disease status.
6.3 Application of Strategy PS2 to the Phenotype
Obesity
The previous chapter focused on one particular aspect of the proposed analysis
strategy PS2, namely the effect of a sophisticated intensity reference model on the
quality of CNV calls. Contrarily, this chapter attempts to assess advantages and
disadvantages of the whole strategy PS2. Due to their similar nature, a comparison
of strategy PS2 with strategy S2 will be of particular interest. Aiming to asses
potential consequences of the choice of the CNV analyses strategy on genetic results,
the genome-wide data set of raw CNV data for 424 obesity trios was re-analysed in
application of strategy PS2.
6.3.1 Data Set
The family-based sample was made up of 424 obesity trios, each comprising one
extremely obese child or adolescent and both biological parents. Details on recruit-
ment and phenotypical characteristics are given in chapter 3.5.1 and in Jarick et al.
(2011) (Supplementary Table S1). Moreover, follow-up association analyses were
additionally performed in a second family-based obesity sample of further 281 inde-
pendent obesity trios that were similarly recruited and composed as the first sample
(for details see Jarick et al. (2011), Supplementary Table S1). For both samples
genotyping was performed on the Affymetrix 6.0 chip by the ATLAS Biolabs GmbH
(Berlin, Germany) (for details see chapter 3.5.2).
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6.3.2 Methods
For each individual of both trio samples, CNVs were detected by use of the PennCNV
software (Wang et al., 2007) in application of MCMR reference intensity values (see
chapter 6.2.2 for details). In the previous chapter, CNV calls based on Affymetrix
6.0 data with more than 20 consecutive informative probe sets were shown to be
most reliable with regard to stability and recovery rates. Consequently, each CNV
call that covered less than 21 consecutive informative probe sets was discarded from
subsequent association tests.
As secondary analyses, Mendelian inconsistency rates were determined for each
trio of both samples as the proportion of offspring’s CNVs that were not called to be
derived from parental CNVs. As primary analyses, estimated CNVs were tested for
an association with the binary trait obesity in application of the FBAT approach
by assuming an additive genetic effect model. In more detail, the coding for the
different marker genotypes was specified to 0, 1, 2, 3, 4 in condordance with the
estimated total unphased number of DNA segment copies. As described previously
in detail, exclusively the set of unique CNV’s start and end sites in 244 pre-specified
genomic regions with a minimal copy number variability of five percent were tested
for an association in order to avoid redundancies and to ensure a minimal number
of informative families across FBATs (see chapter 3.6.1). Moreover, significance
was assessed by use of the lfdr method, which accounts for the fact that multiple
hypotheses were tested simultaneously (Efron et al. (2001), see chapter 3.5.2).
The most promising CNV region on chr 11q11 was technically validated by use of
qPCR (Applied Biosystems, TaqMan assay Hs03802074 cn at chr 11: 55 203 791±50
bp) by the Department of Child and Adolescent Psychiatry of the University of
Duisburg-Essen. Validity was assessed in comparing array-based and qPCR-based
results. Finally, CNV FBATs were re-calculated for all sites of this region with
respect to qPCR derived CNV genotypes on all 705 obesity trios of both family-
based samples.
6.3.3 Results
Genome-wide CNV calling in 424 obesity trios
A total of 47 825 CNVs were detected in the 1 272 individuals of the first family-
based sample of 424 obesity trios, out of which 15 820 CNVs were observed in the
offspring and 32 005 in the parents. Among those CNVs, 40 050 were located in the
244 pre-specified CNVRs with previously observed minimal copy number variability
of five percent (offspring: n = 13 427, parents: n = 26 623).
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Table 6.8: Mendelian Inconsistency Rates for CNVs of 705 Obesity Trios with De-
fault and MCMR calling, respectively.
in 424
obesity
trios
in 281
obesity
trios
in 705
obesity
trios
number
of CNV
calls in
offspring
mean
Default Calling 37.4 39.2 38.1
MCMR Calling 37.3 39.8 38.3
median
Default Calling 36.0 39.0 37.0
MCMR Calling 36.0 39.0 38.0
Mende-
lian
inconsi-
stency
rate* [%]
mean
Default Calling 24.8 19.0 22.4
MCMR Calling 23.0 17.8 20.9
median
Default Calling 23.1 18.6 21.1
MCMR Calling 21.6 17.1 20.0
p-value, two-sided paired t-test 4.06E-09 2.58E-05 5.41E-13
* The Mendelian inconsistency rate was calculated as the proportion of offspring’s CNVs that
were not estimated to be derived from Mendelian inheritance.
Figure 6.13: Number (Panel A) and Mendelian inconsistency rates (Panel B) of CNV
calls from 705 obesity trios with Default and MCMR calling, respec-
tively.
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Compared to CNVs that were called in application of default parameters and
Default median reference intensity values (see chapter 3.6 for details), the mean
number of identified MCMR-based CNVs was similar in the group of 424 offspring.
However, MCMR-based CNVs showed statistically significantly reduced Mendelian
inconsistency rates in comparison to CNVs from a standard procedure (p = 4.06×
10−9, see Table 6.8 and Figure 6.13).
Genome-wide association testing in 424 obesity trios
In the first family-based sample of 424 obesity trios, FBATs were performed for a
total of 3 199 unique CNV’s start and end sites at 244 CNVRs in the association
testing step (Figure 6.14). 49 sites, reflecting 32 sub-CNVRs in seven CNVRs,
yielded lfdr values below 0.2, which is a threshold to be sensible as proposed by
Efron (2004) (see Figure 6.14 and Table 6.9).
Figure 6.14: Histogram and lfdr curve of CNV FBAT z-values for the genome-wide
analysis of 424 obesity trios at 3 199 unique CNV’s start and end sites
in 244 CNVRs.
Panel A: Histogram. The red dashed curve depicts the standard nor-
mal distribution, the dashed blue line is pˆ0fˆ0, the empirical null density,
N (0.332, 0.8512), and the green line is the empirically estimated mix-
ture density. The small pink bars represent the estimated non-null
counts.
Panel B: Lfdr curve as derived from empirical estimates of f0, f and
p0 (Panel A). Observed CNV FBAT z-values are illustrated as ticks on
the horizontal lines, those with lfdr < 0.2 are printed in red.
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Table 6.9: Results for 32 sub-CNVRs reflecting 49 CNV’s start and end sites with
lfdr< 0.2 across 3 199 FBATs in 424 obesity trios at a total of 244 CNVRs.
(in chromosomal order)
Chr: Position
[hg18]
FBAT
z-value
FBAT
p-value lfdr
in CNVR
[chr: bp, hg18]
2: 41 091 947 - 41 099 391 −2.385 0.0171 0.124 2: 41 091 935 - 41 099 404
3: 131 245 549 - 131 246 387 −2.283 0.0224 0.145 3: 131 245 537 - 131 290 979
3: 131 269 711 - 131 269 888 −2.160 0.0308 0.176 3: 131 245 537 - 131 290 979
3: 131 269 889 - 131 271 914 −2.279 0.0227 0.146 3: 131 245 537 - 131 290 979
3: 131 271 915 - 131 273 779 −2.332 0.0197 0.134 3: 131 245 537 - 131 290 979
3: 131 273 780 - 131 274 037 −2.337 0.0194 0.134 3: 131 245 537 - 131 290 979
3: 131 274 038 - 131 274 200 −2.259 0.0239 0.150 3: 131 245 537 - 131 290 979
3: 131 274 201 - 131 274 319 −2.197 0.0280 0.166 3: 131 245 537 - 131 290 979
3: 131 274 320 - 131 276 344 −2.239 0.0252 0.155 3: 131 245 537 - 131 290 979
3: 131 276 345 - 131 276 696 −2.193 0.0283 0.167 3: 131 245 537 - 131 290 979
3: 131 276 697 - 131 277 782 −2.143 0.0321 0.181 3: 131 245 537 - 131 290 979
3: 131 277 783 - 131 281 471 −2.455 0.0141 0.112 3: 131 245 537 - 131 290 979
3: 131 281 472 - 131 282 357 −2.360 0.0183 0.129 3: 131 245 537 - 131 290 979
3: 131 282 358 - 131 288 741 −3.111 0.0019 0.039 3: 131 245 537 - 131 290 979
3: 131 288 742 - 131 288 926 −3.155 0.0016 0.038 3: 131 245 537 - 131 290 979
3: 131 289 689 - 131 291 500 −2.137 0.0326 0.182 3: 131 245 537 - 131 290 979
3: 196 868 323 - 196 875 860 −2.341 0.0192 0.133 3: 196 868 311 - 196 946 380
3: 196 875 861 - 196 884 255 −2.333 0.0197 0.134 3: 196 868 311 - 196 946 380
3: 196 884 256 - 196 895 126 −2.355 0.0185 0.130 3: 196 868 311 - 196 946 380
3: 196 895 127 - 196 901 833 −2.621 0.0088 0.088 3: 196 868 311 - 196 946 380
3: 196 901 834 - 196 907 468 −2.949 0.0032 0.052 3: 196 868 311 - 196 946 380
3: 196 907 469 - 196 914 787 −2.120 0.0340 0.187 3: 196 868 311 - 196 946 380
3: 196 914 788 - 196 928 237 −2.176 0.0296 0.171 3: 196 868 311 - 196 946 380
3: 196 928 238 - 196 928 253 −2.226 0.0260 0.158 3: 196 868 311 - 196 946 380
7: 133 446 382 - 133 448 649 −3.032 0.0024 0.045 7: 133 435 705 - 133 449 750
7: 133 448 650 - 133 449 098 −2.620 0.0088 0.088 7: 133 435 705 - 133 449 750
10: 58 186 381 - 58 191 255 −2.656 0.0079 0.083 10: 58 186 369 - 58 196 856
10: 58 191 256 - 58 196 843 −2.524 0.0116 0.101 10: 58 186 369 - 58 196 856
11: 55 209 586 - 55 210 152 −2.134 0.0329 0.183 11: 55 130 596 - 55 210 165
12: 9 529 176 - 9 542 559 −2.597 0.0094 0.091 12: 9 525 125 - 9 604 954
12: 9 542 560 - 9 604 941 −2.469 0.0136 0.110 12: 9 525 125 - 9 604 954
12: 9 604 942 - 9 606 831 −2.508 0.0121 0.104 12: 9 525 125 - 9 604 954
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Genome-wide CNV calling in further 281 obesity trios
Statistically significant findings from the first family-based GWAS discovery sample
of 424 obesity trios were followed up by investigating a second independent family-
based sample of further 281 obesity trios: Concerning this second sample, a total of
33 372 CNVs were identified in the 843 individuals (offspring: n = 11 177, parents:
n = 22 195). A subset of 29 112 CNVs were located in the 244 pre-specified CNVRs
(offspring: n = 9 774, parents: n = 19 338).
As has been observed for the initially considered sample, Mendelian inconsistency
rates for MCMR-based CNVs of the second sample were statistically significantly
lower than for CNVs being estimated by use of the Default procedure (p = 2.58 ×
10−5, Table 6.8). The reduced Mendelian inconsistency rates across MCMR-based
CNVs become even more evident when both samples were considered in a combined
manner (p = 5.41× 10−13, Table 6.8).
Genome-wide association testing in further 281 obesity trios
In the genome-wide association testing step of the second sample, a total of 3 718
FBATs were performed at all unique CNV’s start and end sites in the 244 pre-
specified CNVRs. 381 sites, reflecting 47 CNVRs, showed significance with lfdr
values below 0.2 (Figure 6.15).
Figure 6.15: Histogram and lfdr curve of CNV FBAT z-values for the genome-wide
analysis of 281 obesity trios at 3 718 unique CNVs start and end sites in
244 CNVRs. See Figure 6.14 for a detailed description. The empirical
null density is N (0.042, 0.6102).
Three of the seven CNVRs with significance in 424 obesity trios also indicated
evidence for an association with obesity in the additional 281 obesity trios (Table
6.10). Of note, only one CNVR (at chr 11: 55 130 596 - 55 210 165) showed sta-
tistically significant and continuously directionally consistent effects in both trio
samples.
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Table 6.10: Results for eleven sub-CNVRs reflecting 25 CNV’s start and end sites at
three CNVRs with lfdr values < 0.2 in genome-wide FBATs accounting
for 281 as well as for further 424 obesity trios. (in chromosomal order)
Chr: Position [hg18]
FBAT
z-value
FBAT
p-value lfdr in CNVR [chr: bp, hg18]
3: 131 288 927 - 131 289 688 −2.266 0.0234 0.026 3: 131 245 537 - 131 290 979
10: 58 186 381 - 58 186 526 −2.263 0.0237 0.026 10: 58 186 369 - 58 196 856
10: 58 186 527 - 58 196 843 −2.380 0.0173 0.017 10: 58 186 369 - 58 196 856
11: 55 133 074 - 55 134 453 −1.871 0.0614 0.085 11: 55 130 596 - 55 210 165
11: 55 134 454 - 55 142 243 −1.824 0.0681 0.094 11: 55 130 596 - 55 210 165
11: 55 142 244 - 55 142 244 −1.674 0.0941 0.131 11: 55 130 596 - 55 210 165
11: 55 142 245 - 55 143 361 −1.729 0.0837 0.116 11: 55 130 596 - 55 210 165
11: 55 149 884 - 55 178 915 −1.611 0.1072 0.152 11: 55 130 596 - 55 210 165
11: 55 178 916 - 55 187 640 −1.737 0.0824 0.114 11: 55 1305 96 - 55 210 165
11: 55 209 586 - 55 210 152 −1.742 0.0816 0.127 11: 55 1305 96 - 55 210 165
11: 55 210 153 - 55 217 258 −2.000 0.0455 0.059 11: 55 1305 96 - 55 210 165
Figure 6.16: CNV FBAT z-values (Panel A), p-values and CNV calls (Panel B) for
two obesity trio samples at CNVR on chr 11q11. blue: 424 trios, red:
281 trios, green: all 705 trios. CNV calls of all 705 trios are presented
as vertical bars and the bar thickness reflects the CNV frequency. gray:
homozygous deletion, blue: heterozygous deletion, purple: duplication.
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This CNVR at chr 11q11 was already identified to be associated with the trait
obesity in application of strategy PS1 (see chapter 5.2). Details on FBAT z-values,
p-values and CNV calls in this most promising CNVR at chr 11q11 are presented in
Figure 6.16 for both obesity trio samples as well as for the combined sample of all
705 nuclear families.
CNV validation
Finally, the array-based observation of deletions in the described CNVR at chr 11q11
being associated with obesity in both family-based obesity samples was technically
validated by qPCR analyses (see Table 6.11). The array-derived association effect
was consistently re-observed for qPCR-based CNVs (FBAT p-value = 0.023). More-
over, the majority of MCMR-based copy number states could by validated as true
findings (false positives = 0.35%, false negatives = 11.55%).
Table 6.11: Locus-specific false positive and false negative estimates for CNV calls
of 705 obesity trios at chromosome 11 : 55 130 596− 55 210 165 (hg18).
qPCR
vali-
dated
CNVs
CNV calls
of MCMR
callinga
CNV calls
of Default
callinga
# of homozygous deletions (cn=0) 169 169 [168] 169 [168]
# of heterozygous deletions (cn=1) 830 687 [687] 342 [342]
# of copy number neutrals (cn=2) 1 077 1 211 [1 072] 1 098 [614]
# of heterozygous duplications (cn=3) 0 3 [0] 461 [0]
# of complex CNVs - 6 6
# of CNVs failed to be assigned 39 39 39
% of false positive CNV callsb - 0.35% 47.48%
% of false negative CNV callsc - 11.55% 44.13%
p-value, FBAT, two-sided −0.0231 −0.0295 −0.5114
z-value, FBAT two-sided −2.2711 −2.1772 −0.6566
a The number of CNV calls with identical individual called copy number state (cn) and qPCR
result is given in brackets.
b False positives: the percentage of individuals who were called to have a CNV, but were
confirmed to be copy number neutral by qPCR analyses.
c False negatives: the percentage of individuals who were called to be copy number neutral, but
were confirmed to be copy number variable by qPCR analyses.
Contrarily, the association effect at chr 11q11 would not have been detected, if a
Default calling procedure was applied, that is if median reference intensity values
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were used (Default FBAT p-value = 0.5114 in 705 obesity trios). The main reason
for this fundamental weakness of strategy S2 might be the high rates of misclassified
CNV calls (false positives = 47.48%, false negatives = 44.13%).
6.3.4 Discussion
In this chapter, the data of two family-based samples for genome-wide association
studies (GWASs) on early-onset extreme obesity were analysed in application of
strategy PS2. Directionally consistent and genome-wide statistically significant as-
sociation was exclusively observed for deletions in a region on chromosome 11q11.
This association effect could be strengthened by validation data of qPCR experi-
ments. In chapter 3.6, the analogous application of strategy S2 to the same data
example did not reveal evidence for an association of any CNV with the trait obesity.
It was demonstrated that high false positive and false negative rates of CNV calls
identified in use of strategy S2 caused invalid association test results especially for
the CNVR at chr 11q11. Consequently, a superiority of strategy PS2 over strategy
S2 could be shown for the analysed obesity data example. As mentioned previously,
due to the complexity of any genetic genome-wide data set, this observation does
not allow a general evaluative conclusion regarding power or type 1 error levels of
strategy S2 and strategy PS2.
QPCR experiments were only performed for the most promising CNV region on
chr 11q11, which probably reflects a realistic procedure for practical use with regard
to monetary cost considerations. Thus, the genome-wide effect of using MCMR
instead of Default median reference intensity values for CNV calling cannot com-
prehensively be assessed at a genome-wide level. However, the respective qPCR
validation data impressively demonstrate how the choice of the global intensity ref-
erence set may dramatically influence association test results for common CNVs at a
locus-specific level. In addition to that, estimates on genome-wide Mendelian incon-
sistency rates were consulted to evaluate the validity of MCMR and median-based
CNV calls at a genome-wide level. With regard to previous reports, most CNV
events are rather derived from inheritance than from new mutation events (McCar-
roll et al., 2008; Redon et al., 2006). As a consequence, low Mendelian inconsistency
rates indicate a high quality of CNV calling. For the two obesity data sets, genome-
wide Mendelian inconsistency rates of CNV calls were statistically significantly re-
duced in use of MCMR instead of median reference intensity values. Consequently,
for the presented data example CNV calling validity was improved in use of strategy
PS2 relative to strategy S2. Of note, Mendelian inconsistency rates are likewise far
from the optimal zero value for MCMR based CNVs, which potentially reflects the
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limited effect of sophisticated reference models, such as the proposed MCMR model,
on validity of CNV calling. This limitation might be caused by several other biases,
such as raw data quality and robustness, which are not addressed by the choice of
the intensity reference model.
In sum, strategy PS2 turned to be out to be more useful as strategy S2 for the
genome-wide CNV analysis of the obesity data set. However, this result should
not be overestimated because it is based on only one observation. Additionally,
the moderate reduction of genome-wide Mendelian inconsistency rates relative to
strategy S2 rather suggests that a limited number of CNV calls is actually affected
by a more precise genotype assignment. Contrarily, this small number may suffice
to enormously change genome-wide results. Indeed, any single truly associated and
correctly genotyped CNV region offers the potential to end up with genome-wide
significance. For later practical use and with regard to a reduction of computation
time, it might be particularly appropriate to follow selected genomic regions up in
application of more than one reference CNV calling model. In particular, visual
inspection of raw intensity data may be useful to identify those respective regions.
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In this thesis I explored several whole genome-wide analysis strategies for raw CNV
data using the two most widespread methods from recent research as well as two
modified techniques that aim to overcome weaknesses of currently used procedures.
Initially, I presented the two main existing approaches for CNV association analy-
ses based on genome-wide SNP genotyping data that primarily differ in the extent
to which individual CNV genotypes are assessed prior to genome-wide association
testing. In application of the existing strategy, which completely skips CNV call-
ing while instead focussing on raw continuous intensity CNV measurements in the
association testing step, I studied the role of common CNVs in severe early-onset
obesity. In use of this strategy, no CNVs could be identified as being causal for that
phenotype. Using the other existing strategy, which bases association testing on
discrete CNV genotypes being obtained from previous application of CNV calling
software tools, I investigated the role of both, common CNVs in severe early-onset
obesity and rare CNVs in childhood ADHD. Again, no evidence for any association
between CNVs and the trait obesity were detected. Contrarily, this second stan-
dard CNV analysis strategy turned out to be useful to discover rare CNVs at the
PARK2 locus as being statistically genome-wide significantly associated with ADHD
in children. Secondly, I presented two modified approaches for genome-wide CNV
association analyses, which are both motivated by previous concerns with regard
to the two above mentioned commonly applied strategies (Ionita-Laza et al., 2008;
Zhang et al., 2011). On the one hand, Ionita-Laza et al. (2008) proposed that a re-
finement on the marker selection before the association testing of raw hybridization
intensity CNV measurements might be useful to alleviate the multiple testing issue,
and thus to simplify the detection of underlying CNV association effects. Here, this
proposal was taken up and the corresponding re-analysis of potential CNV - obesity
association effects led to the identification of CNVs at chromosome 10q11.22 and
at chromosome 11q11 being positively associated with early-onset obesity. One of
these two findings is strengthened by a previous study, which concordantly reports
on CNVs at chromosome 10q11.22 being associated with BMI in a sample of 597
elderly Chinese Han subjects (Sha et al., 2009). The other finding related to CNVs
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at chromosome 11q11 remains to be proven in large-scale meta-analyses. On the
other hand, several authors, such as Zhang et al. (2011), realized that especially
array-based CNV calling of common CNVs is greatly influenced and to some extent
distorted by the use of log2 ratios that were calculated with respect to the sample’s
mean or median hybridization intensity values, which is common practice in most
currently available CNV calling software suites. Alternatively, I propose to esti-
mate copy number neutral reference hybridization intensity values for each probe
set in a Gaussian mixture model framework prior to the determination of log2 ratios
and subsequent CNV calling and association testing. In an isolated application to
CNV calling, this approach showed slightly better quality of CNV calls compared to
standard derived CNV genotypes. As a demonstration and to allow a comparison
across all presented strategical approaches, I applied the lastly suggested strategy
to re-re-analyse associations of CNVs on obesity. Not only were again CNVs at
chromosome 11q11 found to be statistically genome-wide significantly associated
with obesity, but also it became apparent how the misclassification of eventually
only one single CNV region can dramatically change genome-wide association test
results. The latter aspect was demonstrated with respect to qPCR experiment data
for the chromosome 11q11 region, which was nearly consistent with MCMR based
CNV calls but substantially differed from respective standard derived CNVs. To
my knowledge, this is the first time that such a variety of alternative whole genome
CNV analysis strategies has been investigated and comparably been applied to real
data examples.
Genome-wide CNV analyses strategies based on raw genotyping array data are
complex procedures including several partial steps, such as data pre-processing,
CNV identification, association testing and validation experiments. It is worth con-
sidering overall limitations of the conclusions towards advantages and disadvantages
across the presented strategies, which have already been discussed in a comparative
sense at the end of each data example chapter. In order to judgmentally embrace
the entire spectrum of different CNV analyses strategies, a much larger variety of
different approaches addressing each single aspect of the whole analyses pipeline is
needed. Here, I explicitly concentrated on two characteristics, the marker selection
for testing raw CNV measurements and improving CNV calling quality by alternate
reference models, which leaves a lot of room for investigating further facets. Many
of the remaining aspects have already been evaluated in an isolated way, that is
in picking out and concentrating on a certain sub-step of the whole genome-wide
CNV analysis. For instance, the effect of different normalization methods in data
pre-processing (Bolstad et al., 2003) or the optimal choice of an appropriate soft-
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ware algorithm for CNV detection (Winchester et al., 2009; Koike et al., 2011; Zhang
et al., 2011; Dellinger et al., 2010) were investigated in much detail. When separately
evaluating selected sub-steps of a whole genome-wide CNV analysis strategy, the ac-
tual effects on genome-wide association test results are left to speculation. However,
any improvement on each single pipeline part offers the potential to substantially
increase validity of the whole analysis. Contrarily, completely implemented pipelines
focussing on the modification of single aspects are presented here.
Due to its availability, all analyses were restricted to one selected type of raw CNV
data, namely to those being collected from the Affymetrix 6.0 SNP genotyping
arrays. As outlined in chapter 3, each presented strategy can with slight array-
specific adaptations likewise be applied to alternatively derived raw CNV data.
However, especially the observed superior performance of strategy PS2 over strategy
S2 might in parts be affected by the characteristics of Affymetrix 6.0 data, which is
known to require much more robust algorithms than those of Illumina SNP arrays
or CGH arrays (Koike et al., 2011).
Moreover, practical investigations of strategies S2 and PS2 were limited to the
use of the PennCNV software for calling CNVs with standard and MCMR reference
intensity values. Apart from the consequence of suffering from a restricted trans-
ferability to other CNV calling software, this design guarantees a valid comparison
between both approaches. Of note, most commonly used CNV detection software
tools start their estimating calculations with log2 ratios, and can thus likewise be
applied in use of several alternate reference intensity models.
Finally, the evaluation of the four presented CNV analysis strategies was per-
formed in application to real data examples for seemingly healthy HapMap and
replicate samples as well as for the phenotypes obesity and ADHD. Although the
investigation of HapMap and replicate CNV calls and additionally the repeated
whole genome-wide analyses of one and the same obesity data set admitted mean-
ingful statements concerning the superiority of the proposed strategies over standard
strategies, these results have to be handled with caution and cannot be understood
as general conclusions or recommendations. Below the line, it has been shown that
targeted modification of standard CNV analyses approaches may reveal useful asso-
ciation results. In this respect, it is important to remember that in particular the
proposed strategy PS1 did not only end up with a new CNV - obesity association
finding at chromosome 11q11, which still has to prove its validity in future large
scale-meta analyses. Most importantly, the previous finding of a CNV - BMI asso-
ciation at chromosome 10q11.22 was re-identified (Sha et al., 2009). However, all
this does not allow any general conclusion regarding power or type 1 error levels
125
7 General Discussion
for which, as already mentioned in each single previous discussion, target-orientated
and informative simulation studies have to be conducted. Nevertheless, since an
appropriate simulation design might realistically only account for selected aspects
of a whole genome-wide CNV analysis, a broad range of such simulation studies is
needed to allow recommendations for a genome-wide analyses that starts with the
extraction of raw hybridization intensities and ends up with association p-values.
Last but not least, the determination of false positive and false negative rates for
HapMap and replicate CNV calls in chapter 6.2 has provided an insight into the
difficulties and complexity in finding an appropriate gold standard CNV set. For
example, out of a total of 681 CNV segments that were reported in at least one of
four publications (Tuzun et al., 2005; Korbel et al., 2007; Redon et al., 2006; Kidd
et al., 2008) for sample NA15510, only four CNVs (= 0.59%) were consistently found
in all four reports. These and other CNV-specific challenges, such as the complex
correlation structure of involved CNV markers, the lack of full knowledge on causes
for CNV occurrence, their inheritance mechanism or their genome-wide interrela-
tionship, were the reasons to restrict strategy comparisons to real data applications.
With regard to recent advances in next-generation sequencing techniques that will
provide highly reliable CNV information for thousands of individuals at moderate fee
and time, many of the addressed difficulties of SNP array based CNV association
analyses will be eliminated in future. Until then, however, there might still be
great interest in using the variety of collected genome-wide SNP genotyping data by
the largest possible amount. Now, data from whole genome-wide SNP association
studies can be used for dual purposes, SNP and CNV analyses. Consequently, many
genome-wide SNP genotyping data sets that were so far only investigated towards
SNP associations will be remembered with respect to CNV re-analyses. Towards
an implementation of any of the presented strategies, I would recommend using a
second approach maybe only to selected genomic regions on a single data set to
generate most informative results. It is also important, to let as many CNV results
as possible be validated by independent techniques, such as qPCR experiments.
Against this background and keeping in mind that the validity of genome-wide
results are affected by the interaction of locus-specific reliability, a collection of
several validation experiments accounting for a variety of selected genomic loci on
a random basis might be an optimal approach.
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Appendix
R-function for probe-wise specification of MCMR
reference intensity values
find.MCMR.reference <- function( all.probewise.intensities ){
# The input ’all.probewise.probewise’ should equal a vector of
# sample-wide probe-wise pre-processed hybridization intensity
# values from SNP arrays.
# As output the probe-specific MCMR reference intensity value will
# be given.
# For the estimation of the underlying probe-wise Gaussian mixture
# model those vector of intensities that is free of outliers is
# used.
probewise.intensities <-
all.probewise.intensities[ !all.probewise.intensities %in%
boxplot.stats(all.probewise.intensities)$out ]
# The underlying Gaussian mixture model is estimated by use of the
# R-package ’Mclust’ which applies the EM algorithm for model
# parameter estimation and the BIC for model selection.
library( mclust )
ints.clust.est <- Mclust( probewise.intensities )
# The MCMR reference intensity value is selected to equal the mean
# of those component that the samples mean is most probably
# underlying.
sample.mean <- mean( probewise.intensities )
numb.clusts <- ints.clust.est$G
lik.mean <- c(1:numb.clusts)
post.prob.mean <- c(1:numb.clusts)
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if( numb.clusts > 1 ){
for( c in 1:numb.clusts ){
m <- ints.clust.est$parameters$mean[c]
if( ints.clust.est$parameters$variance$modelName == "E" ) {
sd <- sqrt(ints.clust.est$parameters$variance$sigmasq)
} else {
sd <- sqrt(ints.clust.est$parameters$variance$sigmasq[c])
}
prop <- ints.clust.est$parameters$pro[c]
lik.mean[c] <- dnorm( sample.mean), m, sd ) * prop
}
for( c in 1:numb.clusts ){
post.prob.mean[c] <- lik.mean[c] / sum(lik.mean)
}
mean.clust <- which.max( post.prob.mean )
MCMR.reference <- ints.clust.est$parameters$mean[mean.clust]
} else {
MCMR.reference <- ints.clust.est$parameters$mean[1]
}
return( MCMR.reference )
}
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